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ABSTRACT 
Does the inclusion of the cost and burden of adverse drug reactions associated with drug-resistant 
TB treatment affect the incremental cost-effectiveness of new treatment regimens? A case study 
from the introduction of bedaquiline in South Africa National TB Programme 
 
Kathryn Lou Bistline 
 
South Africa has one of the world’s highest burdens of TB, HIV/TB co-infection, and drug-resistant TB. Sec-
ond-line TB treatment is less effective, more expensive, and more toxic than treatment for drug-sensitive TB. 
Nearly 1 in every 5 persons who starts treatment for drug-resistant TB in South Africa will die; 1 in every 3 
persons who survives treatments experiences permanent, profound hearing loss. For decades there was lit-
tle progress in TB research, however, and so treatment with old regimens continued despite safety concerns. 
In 2012 the US and European regulatory authorities approved a new drug, bedaquiline, but only for treat-
ment in cases with no other options. In 2015, the South African Medicines Control Council approved bedaq-
uiline for drug-resistant TB, but only a limited number of doses were approved in the 2016/2017 annual 
budget and the focus, again, was only for the patients who had no other options. In order to inform policy 
makers in planning and budgeting for drug-resistant TB treatment, the aim of this thesis was to determine 
whether the simple calculation that bedaquiline was too expensive relative to standard regimens using kana-
mycin was too simple. Particularly, given the high burden of adverse drug reactions (ADR) associated with 
kanamycin, would the inclusion of the cost and burden of ADR affect the incremental cost effectiveness ratio 
of a new treatment regimen where bedaquiline replaces kanamycin? 
Analysis of the national drug-resistant TB case register showed that mortality during second-line treatment 
was early, primarily in the first 6 months of treatment, even when patients do not have extensive drug re-
sistance. HIV-positive patients not on anti-retroviral therapy (ART) at initiation of drug-resistant TB treat-
ment have the highest risk of mortality. The high early mortality is a real risk that clinicians have to balance 
when deciding to initiate ART and effective second-line TB treatment both as quickly as possible. Daily injec-
tions coupled with taking more than 10 pills each day are a heavy burden for patient compliance, but also 
pose concerns in terms of overlapping and compounding toxicities; this burden was confirmed through a 
meta-analysis of the pooled frequency of adverse events among cohorts with at least 25% of the patients 
HIV-positive. A competing risk analysis of a cohort of drug-resistant TB patients from Johannesburg – ad-
dressing the reality that patients may not have experienced an ADR because they died rather than because 
they were at lower risk – indicated that HIV-infected patients who are not yet stable on ART and second-line 
TB treatment are at the highest risk of ADR.  
A Markov model built and parameterized using the data from the South African national TB programme indi-
cates that bedaquiline for all drug-resistant TB led to a small gain in effectiveness at a cost that was under 
the costs of the drug itself, due to savings from daily injection visits. While cost-effective, it was not clear 
that South African policy makers needed to move beyond the offer of bedaquiline for patients with extensive 
drug resistance. However, the calculation, and the decision point, were different once the costs and disabil-
ity associated with ADRs was included in the analysis. Bedaquiline-based regimens offer a cost-saving and 
more effective alternative to an injection-based regimen for drug-resistant TB patients treated in the public 
sector in South Africa.  
  
iv 
DEDICATION AND ACKNOWLEDGEMENTS  
For anyone who has never visited or worked at an M/XDR-TB hospital or met a survivor of this disease, the 
passion and commitment of the patient advocates, clinicians and policy makers working in this field may 
seem unexplainable. At the end of 2017, a published review included the words and photos of patients, call-
ing out for attention and action.[1]  
“During my treatment period, I lost my hearing. It started with the right ear. Both ears were affected by 
July— just 2 months after I started treatment. I felt so lost and isolated because I couldn’t communicate with 
my family. I preferred to be alone, that way I felt like I was coping. Meanwhile I was dying inside because all 
my dreams and the fun I used to have with my loved ones were shattered.” Ntokozo Nkosi, South Africa [1] 
I dedicate this work to the women who have taught me to see, listen, and serve. When there is suffering, we 
are called to truly see it, truly listen to those who need our help, and act.  
I would like to express my sincere gratitude for the following people, organizations, and funders: 
The generous support of the American people through the United States Agency for International Develop-
ment (USAID), award to Right to Care #674-A-12-00020 which supported the work of the clinical file review 
and the initial screening process for the meta-analysis. The contents of those manuscripts are the responsi-
bility of the authors and do not necessarily reflect the views of USAID or the US government.  
My supervisor, Edina Sinanovic for her guidance and encouragement through this long process. I wouldn’t 
have made it from the first initial thoughts of trying for a PhD to this point without her straight-forward re-
sponses on what working on a PhD really means – from personal commitment, to administrative details, and 
technical learning. 
My co-supervisor, mentor, and friend, Cindy Firnhaber, for her constant encouragement and support to take 
this huge step. Her strong sense of ethical research, clinical insight and focus on the patient as she read each 
version of the protocol and each draft manuscript always pushed my analysis and interpretation further.    
My friends who also happen to be dedicated, passionate clinicians and programme leaders, Liesl Page-Shipp 
and Rebecca Berhanu. I would never have taken on this topic without having been in awe of your work. 
Thank you for your patience in explaining the clinical aspects of this disease to an economist.  
All the patients, site staff, and clinicians of Bedaquiline Clinical Access Programme for the opportunity to 
study an intervention based on learning from evidence to improve patient outcomes. Thank you to the SA 
National TB Programme staff at Civitas for the opportunity to work alongside you in budgeting and planning 
for an end to TB. 
The small but powerful team who made up the Right to Care Research Department from 2014 to 2016 and 
our collaborators in the Right to Care TB Focal Point at Themba Lethu Clinic during the same period.   
My mom, Gloria Schnippel, forever a teacher. Thank you for always being there even when I was thousands 
of miles away. And thank you for having inspired a life-long desire to keep learning and to achieve more.  
My brother, Greg Schnippel, for not letting me give up and always helping out when I needed it.  
And finally, most importantly, my two boys, Marcus and Christopher Bistline, for all the nights that I spent on 
the computer and with piles of papers. I hope to share with you the commitment to others that keeps me 
working through the night. And I pray that you will have healthy, long lives.  
v 
PREFACE 
As per general provisions 6.7 in the General Rules for the Degree of Doctor of Philosophy (PhD) of the Uni-
versity of Cape Town, and with the approval of the University Doctoral Degrees Board on 29 January 2018, 
this thesis includes the full-text of manuscripts that have been published in or submitted for publication in 
peer-reviewed journals. 
I confirm that I have been granted permission by the University of Cape Town’s Doctoral Degrees Board to 
include the following publications in my PhD thesis, and where co-authorships are involved, my co-authors 
have agreed that I may include the publications:  
1. Schnippel K, Firnhaber C, Ndjeka N, Conradie F, Page-Shipp L, Berhanu R, Sinanovic E. Persistently 
high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. 
The International Journal of Tuberculosis and Lung Disease. 2017 Oct 1;21(10):1106-11. 
2. Schnippel K, Berhanu RH, Black A, Firnhaber C, Maitisa N, Evans D, Sinanovic E. Severe adverse 
events during second-line tuberculosis treatment in the context of high HIV Co-infection in South 
Africa: a retrospective cohort study. BMC Infectious Diseases. 2016 Oct 21;16(1):593.  
3. Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Adverse drug reactions during drug-
resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. Jour-
nal of Antimicrobial Chemotherapy. 2017 Apr 16. doi: 10.1093/jac/dkx107.  
4. Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E. Incremental cost effectiveness of bedaq-
uiline for the treatment of rifampicin-resistant tuberculosis in South Africa: model-based analysis. 
Applied Health Economics and Health Policy. 4 Oct 2017. doi: 10.1007/s40258-017-0352-8. 
5. Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Direct costs of managing adverse 
drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. The International 
Journal of Tuberculosis and Lung Disease, 2018. In press. 
6. Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E. Impact of adverse drug reactions on the incre-
mental cost effectiveness of bedaquiline for drug-resistant tuberculosis. The International Journal of 
Tuberculosis and Lung Disease, 2018. In press. 
 
 
Kathryn Lou Bistline 
BSTKAT003 





ADR Adverse drug reaction 
AE Adverse event 
aHR Adjusted Hazard Ratio (aHR) 
ALT Alanine aminotransferase, a liver function laboratory test 
AM Amikacin 
ART Antiretroviral (ARV) therapy for HIV 
BCAP Bedaquiline Clinical Access Programme 
BDQ Bedaquiline 
BMI Body mass index 
CFZ Clofazimine 
CI 95% confidence interval 
CIOMS Council for International Organizations of Medical Sciences 
CM Capreomycin 
CPI Consumer Price Index 
DALY Disability adjusted life year 
DOH Department of Health 
DR-TB Drug resistant tuberculosis 
DST Drug susceptibility testing 
DW Disability weight 
E, EMB Ethambutol 
ECG Electrocardiogram (machine or test) 
EDRweb Electronic drug resistant TB case register 
EFV Efavirenz 
ETO Ethionamide 
GBD Global Burden of Disease study 
GFR Glomerular Filtration Rate, a kidney function laboratory measure 
GXP GeneXpert machine 
H, INH Isoniazid 
Hb Haemoglobin 
HIV Human Immunodeficiency Virus 
HR Hazard ratio 
IA Injectable agents for anti-TB treatment, e.g. kanamycin, capreomycin, amikacin 
ICER Incremental cost-effectiveness ratio 
inhA inhA protein (result of genotypic test for INH resistance) 
IQR Interquartile range 




LPA, PCR Line probe assay or polymerase chain reaction (e.g. HAIN Genotype MTBDR®) 
LYS Life years saved 
LZD Linezolid 
MCC South African Medicines Control Council 
vii 
MDR-TB  Multidrug-resistant tuberculosis 
MDR/RR-TB Multidrug-resistant or rifampicin-resistant tuberculosis 
MFX Moxifloxacin 
NDOH National Department of Health 
NHLS National Health Laboratory Services 
  
NTP National Tuberculosis Programme 
NVP Nevirapine 
OBR Optimized background regimen 
OFX Ofloxacin 
PAS p-aminosalicylic acid 
preXDR-TB Pre-extensively drug-resistant TB, either FLQ or SLD resistance 
QALY Quality adjusted life years 
QT Interval between start of Q wave and end of T wave 
QTcF QT interval corrected using Fridericia formula 
R, RIF Rifampicin 
RR-TB Rifampicin resistant TB 
SA South Africa, South African 
sd Standard deviation 
sHR Sub-hazard ratio 




USD, US$ United States dollar 
WHO World Health Organisation 
WTP Willingness to pay 
XDR-TB Extensively drug-resistant TB 
Xpert MTB/RIF Xpert MTB/RIF® test on GXP platform 
Z, PZA Pyrazinamide 




GLOSSARY OF TERMS 
Adverse drug reactions or adverse events that occur during treatment which are believed to be related 
to a drug or combination of drugs rather than the underlying disease can range 
in severity and may affect different systems of the body. 
 
Cost-effectiveness  analysis is used to answer questions about how much the effect (of the new pol-
icy or treatment or product) costs to adopt. The incremental cost-effectiveness 
ratio (ICER) is one measure to compare two different interventions, where the 
difference in cost and effectiveness is presented as a ratio 
 
Decision-analysis modelling is a method to represent the complex choices in a simplified form 
where expected values such as costs and outcomes can be estimated for differ-
ent options and compared. Options are often outlined as trees, with each 
branch representing the outcome of different possible paths. 
 
Disability adjusted life 
years  
is one measure used in health economics to allow for comparability across dis-
eases, injury, and interventions. DALYs are the sum of life years lost and years of 
life lived with disability. An intervention that resulted in a year more of perfect 
health than the base case would be said to avert 1 DALY. The measure is an al-
ternative approach for the same purpose of common outcome assessment as a 
quality-adjusted life year (QALY). 
 
Disability weighting is the measure used to reduce the comparable value of a year of life according 
to the extent of disability. While subjective, the intent is to measure the differ-
ence between interventions where the same number of persons survive but 
that not all persons return to (or attain) perfect health. The Global Burden of 
Disease study is a large-scale, repeated attempt to have consensus on the 
weights assigned to different disabilities.  
 
Injectable agents Second-line injectable drugs for TB treatment include the aminoglycosides  
(kanamycin, amikacin) and cyclic peptides (capreomycin). Streptomycin is a first-
line injectable anti-TB drug. 
  
Markov modelling is one type of decision-analysis modelling. For health economics, patients are 
represented as being in one health state and then have a probability of transi-
tioning to a different health state in a time step. Markov models have no his-
tory, so that each transition probability is independent of the time spent in (a) 
previous health state(s).  
 
Provider perspective for cost studies, it is important to indicate whose costs are being included in the 
equation as some decisions may involve a trade-off where an intervention is 
cheaper for one part of society but more expensive for another.  
 
ix 
Rifampicin-resistant TB or RR-TB, is TB that is at least resistant to the core first-line drug. If a patient 
with RR-TB is also resistant to isoniazid with or without any other first-line drug 
resistance, it is known as multi-drug resistant (MDR-) TB. A patient with MDR-TB 
resistant also to either (a) fluoroquinolone(s) or (a) second-line injectable(s) is 
described throughout this thesis as preXDR-TB, although this terminology is not 
used by the WHO. MDR-TB patients with resistance to both (a) fluoroquino-
lone(s) and (a) second-line injectable(s) are said to have extensively drug re-
sistant (XDR-) TB. 
 
Treatment regimens MDR/RR-TB is treated with a multi-drug regimen; no single-drug treatment is 
approved for use. In 2016, the WHO recommended a standardized short-course 
regimen of 9-12 months in addition to the standard long-course regimen of 18-
24 months recommended in 2011.  When a new drug is added to the standard 
regimens, and the other drugs in the regimen are unchanged, the standard 
drugs are sometimes referred to as background regimen. When drugs are re-
moved for intolerance or resistance or added to strengthen the regimen, it is 
said to be individualized and no longer the standard offered to all patients.  
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1 INTRODUCTION AND OVERVIEW  
1.1 INTRODUCTION 
Tuberculosis (TB) is the leading cause of infectious disease globally.[2] In 2016, there were an estimated 10.4 
million incident cases and nearly 1.7 million deaths from TB.[2] In 2014, the World Health Assembly adopted 
a 20-year strategy to end TB with a vision of zero TB deaths, disease or suffering. However, resistance to ri-
fampicin, one of the core first line treatments for TB has been growing over time and threatens progress in 
ending the TB epidemic. In 2016, there were an estimated 600,000 incident cases of multi-drug resistant or 
rifampicin-resistant TB (MDR/RR-TB) across the world and an estimated 240,000 persons with MDR/RR-TB 
died.[2] Resistance to TB drugs can be acquired during TB treatment, for example during treatment interrup-
tions or if inadequately dosed for weight or concomitant medication. TB is an airborne disease and drug-re-
sistant strains of the TB bacteria can also be transmitted. In 2016, 4.1% (95%CI: 2.8-5.3%) of new TB cases 
(no prior history of having TB) were estimated to have MDR/RR-TB as well as 19% (95%CI: 9.8-27%) of previ-
ously treated TB cases.[2]  Second-line TB treatment is complicated to administer, with potential for severe 
and permanently disabling adverse drug reactions (ADR) [1,3–5] and success rates of 52 to 62%.[2,5–8]  
“Patients with drug-resistant TB face agonising, prolonged suffering and often permanent disability while on 
second-line treatment, together with devastating economic hardship, stigma and discrimination. On top of 
the clinical toll taken by M/XDR-TB treatment, patients often face catastrophic economic repercussions, push-
ing them into extreme poverty.”[9] 
The WHO estimates that only 1 in 4 persons with MDR/RR-TB are diagnosed and 1 in 5 persons with drug-
resistant TB are initiated on appropriate treatment. Evidence from countries with repeated drug-resistance 
surveillance [2] as well as modelling shows that, because of the limited diagnosis and effectiveness of sec-
ond-line treatment that the proportion of drug-resistant TB among all TB will increase over time.[10,11] By 
2050, 2.59 million additional people are projected to die every year from MDR-TB, in excess of current 
United Nations mortality projections and MDR-TB is estimated to have a global cost of $15.7 trill from 2015 
to 2050.[11]  
Although updated modelling and analysis by the World Health Organization (WHO) presented in the 2017 
Global Tuberculosis Report shows a declining trend in TB incidence and prevalence for South Africa since 
2008, the WHO also estimates that South Africa has among the worst rates of TB incidence and prevalence 
per 100,000 population in the world, at 781 / 100,000 (95% confidence interval (CI): 543–1 060).[2] Perhaps 
of more concern is that South Africa ranks in the top 10 countries for the absolute number of RR-TB cases 
diagnosed in 2016, with 19,073.[2] For the 2014 South African cohort, only 54% of MDR/RR-TB patients were 
cured or successfully completed treatment.[2]  
Adding to the burden, an estimated 59% of TB patients in South Africa are co-infected with the human im-
munodeficiency virus (HIV).[2] TB/HIV co-infected patients, especially those not on antiretroviral therapy 
(ART), have higher mortality than HIV-negative patients.[12,13] A 2015 meta-analysis reported a pooled pro-
portion of 38% (95%CI: 28 to 48.1%) mortality for HIV co-infected adults with MDR/RR-TB.[12] In 2016, the 
WHO estimated that the mortality rate for TB/HIV was 181/100,000 population (95%CI: 120-254), 4-times 
the rate of mortality among TB excluding HIV-positive patients (41/100,000 population, 95%CI: 31-52).[2] TB, 
and particularly RR-TB, represents a major challenge to public health in South Africa. 
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RR-TB treatment models 
Currently, RR-TB requires 12-24 months of anti-TB second-line treatment.[14–17] RR-TB can be mono-RIF 
resistant TB, MDR-TB that is resistant to both RIF and isoniazid (INH),  extensively drug resistant (XDR) TB 
which is MDR-TB plus resistance to second-line drugs from the fluoroquinolone and injectable drug classes, 
or preXDR-TB which is MDR-TB plus resistance to either a fluoroquinolone or a second-line injectable 
drug.[18] The standard of care for MDR/RR-TB treatment in South Africa from 2011 through the end of 2016 
was to use a standardized regimen for all RR-TB patients until further resistance was either confirmed or 
ruled-out. The regimen consists of 6 months (intensive phase) of 5 drugs (a second-line injectable, a fluoro-
quinolone, ethionamide or ethambutol, terizidone, and pyrazinamide) followed by 12 to 18 months (continu-
ation phase) of 4 drugs, excluding the injectable. Patients with additional drug resistance were eligible for 
individualized second-line TB regimen (if preXDR-TB or XDR-TB, pre/XDR-TB) and INH may be added to the 
regimen (if mono-RIF resistant).[15,17,19] In 2016, the WHO recommended a ‘short-course’ regimen, where 
the intensive phase can be limited to 3-4 months and the continuation phase to 6-9 months for patients with 
no prior exposure to second-line anti-TB drugs or in whom resistance to second-line anti-TB drugs had been 
excluded.[14,20] The South African National TB Program (NTP) adopted these guidelines for a shorter regi-
men in 2017, after the period of analysis for this thesis.  
RR-TB treatment costs 
The STOP TB Global Plan 2016 to 2020 estimated that, at current levels, approximately US$7 billion is spent 
each year on prevention, diagnosis, and management of TB.[21] The South African TB budget for 2017 was 
reported as US$244 million.[2] Evaluations of both costs and effectiveness of interventions to manage TB are 
essential for improved planning and investment in TB control, and where possible, these need to be specific 
to the context and country in which it will be implemented.[22] However, there is insufficient evidence of 
real-world, contextualized cost and effectiveness evaluations for even the most commonly implemented TB 
interventions.[23] While drug-resistant TB treatment is more expensive than drug-sensitive TB treatment, 
globally, there is evidence that MDR/RR-TB treatment is cost-effective.[24] In South Africa, MDR/RR-TB 
treatment, including the cost of clinical care in out-patient or in-patient facilities, laboratory monitoring, and 
anti-TB drugs, is estimated to cost US$3,894 [25] to US$4,925 [26] per person adjusted to 2016 USD.[27,28] 
New treatments for RR-TB, bedaquiline 
Results of a pilot clinical trial where 8 weeks of bedaquiline (manufactured by Janssen Pharmaceuticals un-
der the name brand Sirturo) or placebo was added to the standard of care regimen in South Africa, showed a 
dramatic increase, from 9 to 48%, in the proportion of MDR-TB patients who converted to a negative sputum 
culture at 8 weeks without significant increase in the frequency or severity of adverse drug reactions 
(ADR).[29] Use of bedaquiline significantly reduced the time to culture conversion (hazard ratio(HR): 2.253, 
95%CI: 1.08 to 4.71).[29] Building on this successful pilot, a Phase 2b clinical trial of 24 weeks of bedaquiline 
or placebo in addition to the standard of care regimen, was implemented. Culture conversion on bedaquiline 
was also significantly higher (HR: 2.44; 95%CI: 1.57 to 3.80) and there was a higher rate of cure.[30] How-
ever, final treatment outcomes of the Phase 2b clinical trials were not as promising and there were more 
deaths in the bedaquiline arm.[30] The authors indicated it was a statistically significant imbalance in mortal-
ity with more deaths occurring in the patients on bedaquiline compared to placebo (12.7% and 2.5%, respec-
tively).[30]  
In 2013 the WHO issued interim guidelines which reviewed available evidence on the benefits and risks of 
bedaquiline use for the treatment of RR-TB.[31] The revised guidance indicated the Phase 2b findings had 
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potentially “very serious bias” for imprecision from the small patient numbers and also “serious bias” for in-
directness; none of the deaths in the bedaquiline arm were attributed to bedaquiline.[31] However, because 
of the statistically significant imbalance in mortality, the recommendation in both 2013 and 2017 was cau-
tious.[31,32] As per the guidelines:  
“Bedaquiline may be added to a WHO-recommended regimen in adult MDR-TB patients under the 
following conditions (conditional recommendation, very low confidence in estimates of effect, i.e. 
very low quality of evidence):  
• when an effective treatment regimen containing four second-line drugs in addition to pyra-
zinamide according to WHO recommendations cannot be designed; 
• when there is documented evidence of resistance to any fluoroquinolone in addition to multi-
drug resistance.” [31] 
The phase 2b trial for bedaquiline included South African public-sector drug-resistant TB sites; thus, some 
South African clinicians had experience with and familiarity with bedaquiline before the results of the clinical 
trial were completed. However, the clinical trial had strict inclusion and exclusion criteria, so that only 5 of 
the 66 bedaquiline patients (8%) were HIV-positive. To increase access to bedaquiline for drug-resistant TB 
patients for whom an effective treatment regimen could not be constructed, the South African Medicines 
Control Council (MCC) approved a compassionate use programme for bedaquiline in December 2012.[33] 
The Bedaquiline Clinical Access Programme (BCAP) also increased the body of evidence for use of bedaqui-
line in HIV-infected patients and the experience of clinicians in the South Africa public sector drug-resistant 
TB programme. Interim results among patients with pre/XDR-TB indicated a high rate of culture conver-
sion.[34] In October 2014, the MCC approved the use of Sirturo (bedaquiline) for treatment of MDR/RR-
TB.[19]  
An exploratory cost-effectiveness analysis of bedaquiline was used for the 2013 WHO recommendations, but 
was completed prior to final results of the Phase 2b study being available and with uncertainty around 
whether bedaquiline would increase cure by reducing loss to treatment follow-up, death or failure.[31] The 
WHO’s guideline development group’s 2016 systematic review of updated evidence on the use of bedaqui-
line prior to issuing 2017 revisions to the guidelines did not update the cost effectiveness analysis.[32] In the 
first (2013) version of the WHO guidance, one of the concerns about the cost-effectiveness analysis was the 
simplifying assumptions of the model: “While the cost-effectiveness modelling showed overall benefit, there 
were concerns about the simplifying assumptions used (e.g. no accounting for the difference in serious ad-
verse events, no accounting for effect on transmission, uncertainty about application of trial outcomes – in-
cluding deaths – to routine programmatic conditions, etc.).”[31] According to a review by Reuter et al (2017), 
these simplifying assumptions may have excluded  significant societal costs:  
“Moreover, the ongoing use of [injectable agents, (IA)] requires a significant amount of logistical support and 
likely contributes to the difficulties faced by persons who are unable to return to work, school, or perform 
other activities of normal life while on treatment. These attributes of IA treatment most certainly contribute 
to costs incurred by persons living with MDR-TB, and are not compatible with the WHO’s End TB Strategy, 
which has pledged to eliminate catastrophic costs to MDR-TB patients by 2020. The WHO has also high-
lighted the ethical duty to address all forms of suffering associated with TB, through appropriate access to 
care and to the management of adverse drug reactions.”[1] 
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1.2 AIMS AND OBJECTIVES 
This study aims to use the introduction of bedaquiline within the South African National TB Programme (SA 
NTP) as a case study to determine whether the inclusion of the cost and burden of ADR associated with 
MDR/RR-TB treatment affects the incremental cost-effectiveness ratio (ICER) of new treatment regimens. In 
order to complete this analysis, the costs and burden of ADR, in addition to the costs and effectiveness of 
MDR/RR-TB treatment in South Africa will need to be estimated.  
Objectives 
1. To describe the types, frequency, and severity of ADRs experienced during MDR/RR-TB treatment. 
2. To evaluate the provider cost of prevention, monitoring, and management of ADRs incurred during 
MDR/RR-TB treatment, including drugs, hospitalization, laboratory monitoring, and clinic visits. 
3. To estimate the ICER of bedaquiline treatment regimen compared to the long-course, standard of 
care (SOC) MDR/RR-TB treatment regimen in SA, having included the cost and burden of ADR during 
MDR/RR-TB treatment. 
Thus, the objectives of this study are listed in the order in which they were answered. Before costs of ADR 
management could be added to the cost-effectiveness model, they needed to be estimated. Before the costs 
of ADR management could be estimated, the types and frequencies of ADR experienced had to be described.  
The results of this study were intended inform comparison of new treatment regimens for MDR/RR-TB and 
assist policy makers in planning and budgeting for MDR/RR-TB treatment within the SA NTP and the HIV/TB 
programme of the South African public health sector. While use of health technology assessment is not a 
required or consistently used approach to health policy decision making within the South Africa, it does have 
a role particularly in the HIV and TB sector. The 2012-2016 and 2017-2022 South African HIV and TB national 
strategic plans (NSP) have been ‘costed’, including estimates of the cost of the proposed interven-
tions.[35,36] The 2012-2016 NSP [35] could be critiqued as mostly a presentation of the costs for the inter-
ventions selected already by policy makers, i.e. regardless of relative cost effectiveness.[37] In comparison, 
the 2017-2022 NSP was intended to have an investment approach and decisions were to have been in-
formed by the work of the investment case that combined disease modelling and cost-effectiveness analysis 
of packages of HIV and TB interventions.[36,38,39] Thus, while routine use of health technology assessment 
is still nascent in South Africa, there is a willingness and interest by the policy makers within the National De-
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1.3 OVERALL STRUCTURE AND CONCEPTUAL FRAMEWORK 
This thesis includes an introduction, background and literature review, six results chapters which are also 
manuscripts, and a discussion and conclusions chapter. Manuscripts are included word-for-word as the final 
submitted version. As per guidance on the inclusion of the manuscripts, these have been reformatted to be 
consistent with the overall formatting of the thesis. Page, table, and figure numbering as well as citation 
number and referencing style in each manuscript have been updated to be consistent with the overall thesis, 
but no other editing has been done to the final version of the manuscripts as submitted. Thus, the index of 
tables, index of figures, and the references are consistent throughout the document. Supplemental materials 
from the manuscripts and other appendices constitute the final section of the document.  
Conceptual framework 
Overall, the research presented aims to use cost-effectiveness analysis to inform policy, treatment guidelines 
and decisions as to the inclusion of bedaquiline for the treatment of RR-TB. The conceptual framework intro-
duced in therefore on how cost-effectiveness analysis can inform this particular policy. An overview of the 
framework is provided below; more detailed review of the concepts of cost-effectiveness and their applica-
tion to RR-TB treatment guidelines can be found in Chapter 2.  
Cost effectiveness ratios are a means of comparing both the costs and the effectiveness of an intervention at 
the same time, so that decision makers are not limited to the one dimension or the other.  
Figure 1-1 Cost-effectiveness ratio of bedaquiline regimens for MDR/RR-TB treatment 
 
Focusing in on only cost, for example, bedaquiline and the other drugs in the background regimen are more 
costly than the standard injection-based regimen drugs. As the Figure 1-1 shows, the costs of ADR monitor-
ing, prevention, and management will be added to the typical cost categories of MDR/RR-TB treatment, in-
cluding hospital and clinic utilization, 2nd line TB drugs, laboratory sputum monitoring and procedures such 
as chest x-ray. Similarly, the effectiveness of the bedaquiline regimens (i.e. increased cure) will be calculated 
using the end of treatment results, the final outcome of treatment. These results will be adjusted to account 
for the ADR associated with the second-line MDR/RR-TB treatment.  
Incremental cost-effectiveness analysis is based upon calculating the incremental cost, the difference be-
tween the cost of the new intervention and the SOC, and incremental effectiveness of two alternatives. The 
results are presented as a ratio of the incremental costs divided by the incremental effectiveness. Incremen-
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tal cost-effectiveness rations (ICERs) are most appropriate when there is an existing intervention that is al-
ready shown to be cost effective relative to a ‘do nothing approach’. As a result, the question for decision 
makers has shifted from ‘why should I do anything?’ to ‘what would it cost to do achieve more health?’ or 
‘could I minimize costs without losing any health?’. These are questions on the marginal, or or incremental 
cost and benefits of two alternatives. Therefore, the base case can be taken as the current standard of care 
compared to the new intervention or health technology. For this thesis study, the resulting adjusted ICERs 
from the proposed analysis will be compared to those estimated without ADR costs and disability burden to 
determine whether the increased complexity of considering ADRs affects the overall cost-effectiveness de-
termination and placement on a cost-effectiveness plane.  
Estimated ICERs and uncertainty around the ICERs can be visualized if plotted on a cost-effectiveness plane 
that is typically divided into quadrants. Interventions that are higher cost and lower effectiveness (lower 
right quadrant) than an alternative are said to be dominated – the decision to avoid high costs and low effec-
tiveness is straightforward. The converse, lower costs and higher effectiveness (upper left quadrant), simi-
larly is an easier decision if money can be saved and better outcomes obtained. Higher cost and higher effec-
tiveness (upper right quadrant) typically requires additional information to make the decision, such as af-
fordability of the higher costs and willingness (of the payer) to pay the higher costs. The lower left quadrant, 
with lower costs but also lower effectiveness, is sometimes chosen because of affordability reasons.  
Figure 1-2 Cost-effectiveness plane 
 
In addition to placement on a quadrant, cost-effectiveness acceptability curves provide information on the 
probability that an intervention either meets a certain threshold for cost-effectiveness (such as a willingness 
to pay threshold, described in Chapter 2) or is more cost-effective than the alternative intervention.[40] This 
presentation of cost-effectiveness results can assist decision makers in understanding the underlying uncer-
tainty in the results as well as whether further research is needed prior to making a decision. For example, if, 
despite a high level of uncertainty in effectiveness or cost input parameters, there is a high probability that 
the new intervention or health technology will be cost-effective, this is important to communicate to deci-
sions makers.  
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1.4 SUMMARY OF METHODS 
A mixed methods approach was used, including literature review, patient-file review, ingredients-based 
guidelines costing, and decision-analysis modelling. Methods for each of the major results are described be-
low.  
ADR experienced during MDR/RR-TB treatment. 
A retrospective, de-identified analysis of a clinical file review was used to describe the frequency, duration, 
and severity of ADR experienced during MDR/RR-TB treatment at two sites in Johannesburg, South Africa. 
Results are presented in Chapter 4.2. Additionally, a systematic review and meta-analysis describing the fre-
quency and severity of ADR during MDR/RR-TB treatment in the context of high HIV prevalence settings is 
presented as Chapter 5.2. 
Provider cost of prevention, monitoring, and management of ADRs  
The resources required for ADR prevention and monitoring, because applicable to all patients on treatment, 
are included in the standard of care and bedaquiline treatment costs in Chapter 6. ADR management costs 
based on guidelines and clinician input were estimated by extracting ingredients costs from public sector da-
tabases and literature to estimate the bottom-up provider costs for ADR including hospital and clinic utiliza-
tion, medications, and laboratory investigations. These costs were multiplied expected frequencies of each 
type of ADR and results are presented in Chapter 7.  
ICER of bedaquiline treatment regimen compared to SOC MDR/RR-TB treatment regimen in South Africa, having 
included the cost and burden of ADR during MDR/RR-TB treatment.  
In order to estimate the ICER of bedaquiline for all MDR/RR-TB compared to the injection-based regimens, a 
Markov health state model that represents MDR/RR-TB treatment in South Africa, including appropriate 
health states for HIV/TB co-infection was built. Transition probabilities for the health states, disaggregated 
by HIV and ART status were generated from the national drug-resistant TB register for South Africa. Results 
on the timing of mortality were described in . Provider costs of ingredients for MDR/RR-TB in South Africa 
are provided as input parameters. The model and results of the analysis are presented through Chapter 6.  
The model expanded on and parameterized using the frequencies of ADR estimated in Objective 1 and the 
costs of these ADR estimated in Objective 2. Thus, the costs of RR-TB treatment were increased by the ex-
pected average ADR costs (expected incidence of ADR multiplied by the unit cost of the ADR) associated with 
the regimen. The expanded model and results, including the results of probabilistic sensitivity analysis are 
presented in Chapter 8. 
It should be noted that three of the results chapters (Chapter 6, Chapter 7, and Chapter 8) are built from a 
Markov model in TreeAge. Unit costs anti-TB drugs, laboratory monitoring, and common procedures (e.g. 
audiology and ECG) for SOC and bedaquiline treatment are common throughout all three models, as are the 
monthly transition probabilities for MDR/RR-TB and XDR-TB for loss from treatment, culture conversion (the 
inverse of treatment failure), and death. However, during the analysis for the costing of ADR management, it 
was recognized that use of average costs added to the total cost per patient did not sufficiently account for 
the differences in frequencies and severity of events that had been established through the analyses in 
Chapters 4-5 and that these should be added to the model as health states. With additional health states, 
the point estimates and one-way sensitivity analysis was not sufficient for the complexity of the possible pa-
tient outcomes. More specifically, prior to the introduction of an calculated cost of moderate ADR and se-
vere ADR, the cost inputs to the model were ingredients based and therefore could be represented as point 
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estimates. However, the costs of ADR management vary according to event experienced, duration, and clini-
cal management. Further, there was likely correlation between input parameters – patients with HIV newly 
initiating on ART were more likely to die during treatment and more likely to experience costly severe ADR. 
In these cases (input parameter uncertainty or imprecision and correlation), probabilistic sensitivity analysis, 
rather than deterministic sensitivity analysis is recommended.[40–42] Thus, between Chapter 6 and Chapter 
7, unit costs and transition probabilities were converted to distributions (normal and beta, respectively) and 
the ADR management costs were added using a gamma distribution. At this point, Chapter 6 had already 
been published using the initial model and thus, there are differences in the estimate for the cost per patient 
of the SOC from Chapter 6 to Chapter 8.  
Additionally, while there have been some studies indicating the patient costs associated with TB and 
MDR/RR-TB diagnosis and treatment, similar information is not available for patient costs associated with 
ADR experienced during MDR/RR-TB treatment. Thus, in order to maintain the same perspective for the 
costs of both treatment and ADR, a provider perspective was chosen for the analysis. Patient costs of TB, in-
cluding direct costs incurred for medical expenditure (for example, seeking over the counter or private sec-
tor care prior to accessing the public health clinic), direct costs for non-medical expenditure (for example, 
transport to the clinic) and indirect costs associated with loss of income while ill or hospitalized, can be cata-
strophic to the patient and family.[43–45] In one study from South Africa, the proportion of patients who 
were employed dropped from 37% before illness to 3% during MDR/RR-TB treatment; this loss of income 
and productivity was associated with 44% of the study participants relying on social grants as their primary 
source of income during treatment.[44] Especially in contexts like South Africa where the costs of medica-
tion and clinical care is provided free of charge, the indirect costs of illness are the largest component of pa-
tient costs for TB and MDR/RR-TB.[43–45] Exclusion of patient costs by the use of a provider perspective 
therefore does not represent the societal costs and this limitation will be noted in results chapters (6-8) as 
well as in the discussion (Chapter 9).   
 
Interventions compared 
No MDR/RR-TB treatment. 
As a comparator to the standard, long-course, IA-based MDR/RR-TB treatment regimen, no MDR/RR-TB 
treatment was modelled. The situation may represent undiagnosed or undetected active TB disease, which 
does occur. The mortality rate for this intervention (no MDR/RR-TB treatment) was assumed to be the same 
as the mortality rate during early MDR/RR-TB treatment (e.g. weeks 0-12).   
MDR/RR-TB treatment without bedaquiline (injectable agent-based regimen). 
The standard of care regimen for both MDR/RR-TB treatment and XDR-TB treatment was modelled as the 
comparison scenario. However, this regimen is no longer in use in South Africa. Roll-out of bedaquiline for 
patients with additional drug-resistance began in March 2015 [19], and as of late 2016 bedaquiline was avail-
able across all provinces for patients who have additional resistance and therefore are eligible for individual-
ized treatment regimens. While not in use, this scenario was used as a base-case scenario for comparison as 
bedaquiline use within the SA NTP was adopted without cost-effectiveness analysis.[19] Additionally, this 
scenario is still in accordance with the WHO guidelines for MDR/RR-TB treatment long-course regimens, 
where bedaquiline is considered as an alternative to the core drugs.[14]   
 
Page | 9 
• MDR/RR-TB treatment consisting of 6 months of kanamycin (IA), moxifloxacin (fluoroquinolone), ter-
izidone, ethionamide, and pyrazinamide, followed by 12 months of moxifloxacin, terizidone, ethiona-
mide, and pyrazinamide. 
• XDR-TB treatment consisting of 6 months of capreomycin (IA), moxifloxacin (fluoroquinolone), ter-
izidone, ethionamide, pyrazinamide, and para-aminosalicylic acid followed by 12 months of moxi-
floxacin (fluoroquinolone), linezolid, terizidone, ethionamide, pyrazinamide, clofazimine and para-
aminosalicylic acid. 
Bedaquiline for XDR-TB only 
Another comparator was established that better represents the regimens in place in the SA NTP throughout 
2016. The model was based on standard of care, long-course IA-based regimen for MDR/RR-TB and an indi-
vidualized, bedaquiline containing regimen for patients who fail treatment and require XDR-TB treatment. 
Treatment interventions modelled here represent the guidelines issued by the SA NTP in June 2015.[19]  
• MDR/RR-TB treatment consisting of 6 months of kanamycin (IA), moxifloxacin (fluoroquinolone), ter-
izidone, ethionamide, and pyrazinamide, followed by 12 months of moxifloxacin, terizidone, ethiona-
mide, and pyrazinamide. 
• XDR-TB treatment consisting of 6 months of bedaquiline, levofloxacin (fluoroquinolone), terizidone, 
ethionamide, pyrazinamide, and para-aminosalicylic acid followed by 12 months of moxifloxacin 
(fluoroquinolone), linezolid, terizidone, ethionamide, clofazimine and pyrazinamide. 
Bedaquiline for all MDR/RR-TB  
This fourth comparison arm was built using a bedaquiline-based regimen for both MDR/RR-TB and XDR-TB. 
This proposed regimen is not currently in use in the SA NTP or reported to be in use by mid-2017. Tiberi et al 
and Caminero and Scardigli (2015) suggested a re-grouping of the WHO classification of MDR/RR-TB treat-
ment which would promote bedaquiline to be used rather than the IA; and that kanamycin would only be 
used if an insufficient number of drugs could be otherwise used.[46,47] This proposed regimen was also im-
plicitly recommended in the 2015 SA NTP guidelines for the roll-out of bedaquiline, where bedaquiline could 
be used to replace kanamycin (single-drug substitution) in the case of toxicity to kanamycin.[19]  
• MDR/RR-TB treatment consisting of 6 months of bedaquiline, levofloxacin (fluoroquinolone), ter-
izidone, ethionamide, and pyrazinamide, followed by 12 months of moxifloxacin, terizidone, ethiona-
mide, and pyrazinamide. 
• XDR/RR-TB treatment consisting of 6 months of bedaquiline, levofloxacin (fluoroquinolone), ter-
izidone, ethionamide, pyrazinamide, and para-aminosalicylic acid followed by 12 months of moxi-
floxacin (fluoroquinolone), linezolid, terizidone, ethionamide, clofazimine and pyrazinamide. 
Ethical Considerations 
The study protocol was approved by the Human Research Ethics Committee of the University of Cape Town 
(490/2015, July 2015). Portions of the study protocol were also submitted to and approved by the Human 
Research Ethics Committee of the University of Witwatersrand: #M150340, March 2015 for analysis of 
EDRweb and #M131128 in November 2013 for the ADR clinical file review.  
Outline of chapters 
Chapter 1 provides an introduction to the research, based upon the approved proposal for the PhD research. 
Chapter one also describes the aims and objectives, the overall structure of the thesis, and the conceptual 
framework.    
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Chapter 2 presents a comprehensive literature review covering the basis for using cost-effectiveness analysis 
for health policy decision making, the state of the MDR/RR-TB epidemic in South Africa, the current treat-
ment guidelines and new drug regimens, and the burden of ADR during MDR/RR-TB treatment. The chapter 
summarizes current literature and presents unanswered questions that framed the PhD research.  
Chapter 3 describes the timing of mortality during MDR/RR-TB treatment based upon analysis of the SA na-
tional electronic drug-resistant TB case register, the EDRweb. The timing and risk factors for mortality, in-
cluding the differential risks of mortality for HIV-negative, HIV-infected patients on ART, and HIV-infected 
patients not on ART, were used for the development and parameterization of the Markov health state model 
used for the analysis in Chapters 6-8.  
Chapter 4 reports on the results of a ADR-focused clinical file review of two out-patient MDR/RR-TB clinic 
cohorts in Johannesburg, South Africa. Although a retrospective review, the clinical data captured provided 
more in-depth understanding of the ADR experienced by MDR/RR-TB patients.  
Chapter 5 presents the results of a systematic review and meta-analysis on the types, frequency, and sever-
ity of ADR during MDR/RR-TB treatment in cohorts where at least 20% of the patients were HIV-infected.  
Chapter 6 is the first of three results chapters using a newly established Markov model for MDR/RR-TB treat-
ment. This model includes separate health states for initiation of MDR/RR-TB treatment, intensive phase, 
continuation phase, and completion. The model was parameterized using the cohort analysed and described 
in Chapter 3, bottom up ingredients costing from the perspective of the provider – the SA NTP – and uses 
separate transition probabilities from all health based upon HIV and ART status.  
Chapter 7 describes the direct, provider costs of managing the most frequently occurring moderate to severe 
ADR associated with the current standard of care MDR/RR-TB treatment regimen in the SA public health sec-
tor. Using guidelines for the management of ADR, resource use was extracted and multiplied by ingredient 
unit costs from South Africa; the same ingredient costs were used to parameterize the cost-effectiveness 
model in Chapter 6 and Chapter 8.  
Chapter 8 builds upon the Markov model first presented in Chapter 6 and modified in Chapter 7 to include 
the disability weighting for patients who survive and complete MDR/RR-TB treatment but who experienced 
ototoxicity associated with the use of the second-line injectable agents.  
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2 LITERATURE REVIEW 
“I have to take them [medicines and injections] daily. And I cry every day. Every day I cry for an hour … 
the place where they give the injection becomes stone hard. When I take the injection, I can't lift my 
legs, my legs hurt a lot and I am unable to walk. If you give me pills, I will eat them. As many as you 
want me to [eat]. I have no problems with that. The injections are very painful.” – Female patient, aged 
37 years [48] 
2.1 INTRODUCTION 
The aim of this chapter is to review the literature on the question of the incremental cost-effectiveness of 
bedaquiline for the treatment of MDR/RR-TB in South Africa. The chapter starts by reviewing the literature 
first to understand whether the question has been previously answered. Is the incremental cost-effective-
ness of bedaquiline in the South African context already known? Is the cost-effectiveness known for a simi-
lar-enough context that the findings can be applied and used for decision making?  
Second, the chapter starts back at the beginning – is the question itself a useful one for decision makers? 
The role of health economics and outcomes research, especially the use of decision-analytical models and 
analysis to inform decisions on the adoption of new health technologies is reviewed. Then, the chapter fol-
lows the logic of health economic evaluation and reviews existing literature to answer ‘so what?’ Next, the 
burden of MDR/RR-TB in South Africa is reviewed. Concerns around the current standard of care and poten-
tial new drugs that may be able to improve health outcomes are summarized. Measurements of effective-
ness are reviewed for appropriateness in answering the overall topic. The next part of the chapter goes into 
more detail to unintended consequences of some drugs – adverse drug reactions (ADR) – and what impact 
these ADR might have on clinical and policy level decisions to use new drugs.  
Finally, the chapter provides a summary of findings and highlights the outstanding questions that need to be 
answered for evidence-based decision making.  
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2.2 COSTS AND COST-EFFECTIVENESS OF MDR/RR-TB TREATMENT 
First, literature on the cost-effectiveness of MDR/RR-TB was reviewed to determine whether the research 
question had already been answered. A growing body of work on MDR/RR-TB captures the costs of the med-
ications that make up the treatment regimen, the clinic or hospital visits ‘consumed’ for administering and 
monitoring treatment, and the laboratory testing for monitoring treatment.[24] Measures of effectiveness 
have tracked the standard definitions now used for MDR/RR-TB: successfully treated (cured or completed), 
failed, or died. While drug-resistant TB treatment is more expensive than drug-sensitive TB treatment, glob-
ally, there is evidence that MDR/RR-TB treatment is cost-effective.[24]  
Drummond et al summarizes key factors that might affect the applicability of a cost-effectiveness analysis to 
a new setting, including population demography and disease epidemiology, variations in clinical practice, 
and relative prices and costs.[40] Because of the high rates of HIV co-infection and differences in treatment 
regimens, prevalence of second-line drug resistance, models of care, and relative costs of health care ser-
vices compared to internationally procured pharmaceuticals and diagnostics, preference was given to cost-
effectiveness evidence from South Africa. A Google Scholar search of “South Africa” AND “MDR” OR “Rifam-
picin resistant” AND “cost” identified multiple studies that described the costs of MDR/RR-TB treatment in 
South Africa.[24–26,49,50] An article published in 2001 analysing the cost-effectiveness of directly observed 
treatment in the USA and South Africa[51] was excluded from the review because of the major changes to 
HIV and MDR/RR-TB treatment guidelines since 2009 in South Africa. Analyses focusing solely on diagnosis of 
drug resistant TB, for example the roll-out of Xpert MTB/RIF, were excluded as the MDR/RR-TB costs used 
were either citing other studies or were presented with insufficient detail to evaluate. Published costs of 
MDR/RR-TB treatment which may be comparable to the current standard of care in South Africa were re-
viewed and costs extracted. As inpatient admission for MDR/RR-TB treatment was found to be a major com-
ponent of the total cost [24,50], many of the studies have been focused on the comparison of inpatient vs 
outpatient models of care. MDR/RR-TB treatment using an ambulatory (outpatient) model of care for South 
Africa is estimated range from US$3,894 [25] to US$4,925 [26] cost per patient for the 24 months of treat-
ment when adjusted to 2016 USD.[27,28]  
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Table 2-1 Literature of  costs of standard, long-course, injection-based MDR/RR-TB treatment  
Model of RR-TB treat-
ment; Cost method 
Setting,  
period 





tient) RR-TB treatment 
for all stable patients 









TB drug regimen 
Primary health care (outpatient) 
visits 
Diagnosis and TB treatment 
monitoring 
ADR monitoring: kidney func-
tion, liver function, thyroid 





2,585 – 32,506) 
[26,49] 
Inpatient treatment for 
all RR-TB patients until 
culture conversion 









TB drug regimen 
Diagnosis and treatment moni-
toring 
ADR monitoring: kidney func-
tion, liver function, thyroid 
function, and hearing 
tests/ECG? 





tient), 2011 USD: 





Outpatient per patient 
treated 





Hospital inpatient stay (if inpa-
tient) 
Hospital outpatient visit 
Clinic visits 
TB drug regimen 
Diagnostic / monitoring tests 
ADRs 










Costs and cost-effectiveness of bedaquiline 
More recently, the cost and cost effectiveness of new drugs has been the focus of economic evaluations. The 
initial WHO 2013 guidance for the use of bedaquiline included results of an exploratory cost-effectiveness 
analysis. According to the published guidance, the bedaquiline was determined to be cost-effective in many 
settings, when compared to a willingness to pay threshold (WTP) of the gross national income per capita.[31] 
Because of the much lower assumed WTP threshold for low-income countries (including for the modelled 
context of Nepal at US$540), the cost-effectiveness of bedaquiline was considered to be ‘uncertain’ or ‘am-
biguous’ in low-income settings.[31] Also, the expert group indicated that it was uncertain about the afforda-
bility of the treatment (even if cost-effective) in many high-burden MDR/RR-TB settings. Additionally, the 
expert group concluded: “While the cost-effectiveness modelling showed overall benefit, there were con-
cerns about the simplifying assumptions used (e.g. no accounting for the difference in serious adverse 
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events, no accounting for effect on transmission, uncertainty about application of trial outcomes – including 
deaths – to routine programmatic conditions, etc.).”[31]  
Evidence has been growing on the cost-effectiveness of bedaquiline in different settings. As of August 2017, 
five studies were identified that analysed the cost-effectiveness of bedaquiline [52–57], in addition to the 
original analysis included in the WHO recommendations.[31] The studies were identified using a Google 
Scholar search for “bedaquiline” AND “cost”. Review articles summarizing other studies but not presenting 
original research or articles providing only a unit cost were excluded from the analysis. All of the identified 
studies assumed that the mortality imbalance in the Phase 2b trial was an anomaly and assumed no differ-
ence in mortality for the bedaquiline regimen versus standard regimen in the base case analysis.[52–57] The 
analyses similarly made assumptions so that the concerns of the expert group about no accounting for dif-
ference in serious adverse events was not answered. Similar to the initial exploratory analysis and the Phase 
2b trial, all identified reviews considered bedaquiline added on to the standard regimen rather than replac-
ing the injection. 
Key findings of the cost-effectiveness analyses for bedaquiline were extracted from literature and summa-
rized below (Table 2.2). A previously published cost-effectiveness analysis established that bedaquiline could 
actually be cost saving compared to the standard regimens when patients who are sputum culture positive 
are hospitalized until sputum negative.[53] However, South Africa adopted ambulatory, outpatient care for 
MDR/RR-TB in 2011 and therefore was unlikely to realize this cost saving. Similarly, like the adaptation of the 
model for Italy, surgery for MDR/RR-TB patients who have failed treatment is very rare in South Africa and 
the use of bedaquiline could not avert surgical costs.[56]  
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Table 2-2 Cost effectiveness analysis of introduction of bedaquiline 
Regimens compared Setting, period Result Refer-
ence 
Standard regimen vs standard 
regimen + bedaquiline including 
XDR-TB 
Korea, 2014 ICER = 1,300 KRW/QALY over 
10 years 
[52] 
Background regimen vs back-
ground regimen + bedaquiline 
United Kingdom, 2014 ICER = -11,434 GBP/QALY over 
10 years (cost saving, domi-
nated background regimen) 
[53] 
Background regimen vs back-
ground regimen + bedaquiline 
for MDR/RR-TB and XDR-TB sep-
arately 
Germany, 2014 ICER MDR = 22,118EUR/QALY 
ICER XDR = 5,472 EUR/QALY 
over 10 years 
[54,57
] 
Background regimen vs back-
ground regimen + bedaquiline 
including transmission 
South Africa, 2013 ICER = 14,576 USD/DALY 
averted over 10 years, if be-
daquiline at ½ lowest range 
price 
[55] 
Background regimen vs back-
ground regimen + bedaquiline 
including transmission, societal  
and provider payer perspectives 
Italy, 2014 ICER = 16,639 EUR/LYG [56] 
 
The Markov model initially built for analysing the use of bedaquiline in the United Kingdom was also used to 
estimate the cost-effectiveness of bedaquiline in multiple low and middle-income countries, including South 
Africa. South Africa does benefit from a very discounted price to access bedaquiline, at ZAR 9,950 (US$675) 
for a complete course of treatment. Bedaquiline was projected to be cost effective, even at costs for bedaq-
uiline 30- to 70-times what it is priced at for South Africa.[55]  However, this finding was driven by a very low 
treatment success rate for the standard regimens and therefore a large reduction in the number of patients 
requiring XDR-TB treatment once regimens included bedaquiline [55]. Additionally, while the rates of HIV/TB 
co-infection in South Africa are among the highest in the world [58] the model did not account for the higher 
mortality of MDR/RR-TB patients with HIV co-infection [13] or the on-going costs of ART after MDR/RR-TB 
treatment completion. Thus, it is uncertain whether the modelled results would be appropriate for decision 
makers to apply in the South African context.   
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2.3 HEALTH AND OUTCOMES RESEARCH 
With the understanding that the research question remains unanswered, the next review considered the ap-
propriateness of a question of cost-effectiveness. Is it useful and appropriate for decision makers to consider 
the cost-effectiveness of new treatment regimens? Cost-effectiveness analysis (CEA) is a type of economic 
evaluation that compares both the monetary costs and the effectiveness of two different interventions. CEA 
of health care programs is a method for helping decision makers to optimize finite resources in the achieve-
ment of population health. As Drummond et al lay out in their text on economic evaluation in healthcare, 
questions around the comparative costs of two different health programs or interventions should be pre-
ceded by questions of efficacy and effectiveness.[40] If a new treatment is not efficacious in improving the 
outcome of interest in a tightly controlled setting such as a Phase 2 randomized, controlled clinical trial, no 
one would want to buy the new treatment, making questions of its cost less relevant. The efficacy from con-
trolled trials must be replicated in ‘real world’ conditions or settings with broader inclusion categories and 
less control over outside factors, such as during Phase 3 clinical trials, for the new drug to be declared effec-
tive. Similarly, there is less interest in purchasing new treatments that are known to be ineffective, and 
therefore economic evaluations such as CEA on these ineffective treatments would be less likely. As indi-
cated in Chapter 1.3 in introducing the cost-effectiveness plane, for cost minimization, at times a less effec-
tive but lower cost intervention would be the preferred option. The United Kingdom’s National Institute for 
Health Care Excellence summarizes the decision point in its guidelines.[41] Health economists are encour-
aged to recommend consideration by the guidelines development group of interventions that either 1) “in-
crease clinical effectiveness at an acceptable level of increased cost” or 2) “are less effective than current 
practice but free up a substantial amount of resources”.[41]   
There is no formal definition for what level of efficacy or effectiveness is efficacious or effective, the levels 
are often presented in relation to another value which is known. For example, new treatments are often 
compared to the natural history of disease, i.e. what was observed to have happened to patients with a dis-
ease prior to treatment options being available. New treatments might also be compared to the currently 
accepted standard of care, where the comparative effectiveness of achieving cure is more of interest than 
the absolute effectiveness relative to no treatment at all. In CEA, this is defined as the difference between an 
intervention mix constrained CEA and a generalized CEA.[42] Evaluation and decisions on the relative effi-
cacy and effectiveness of different healthcare interventions can happen at many different levels, including 
the patient choosing to go to a clinic when s/he coughs; the clinician choosing whether to order expensive 
diagnostic tests or to send the coughing patient home with cough syrup; and the government health depart-
ment choosing to launch a TB symptom screening campaign or an infant immunization campaign. Integrating 
the use of systematic review, clinical trial results, and other evidence as to the efficacy and effectiveness of 
healthcare into the clinical decision making progress is now known as evidence based medicine.[59]  
In South Africa, MDR/RR-TB is primarily treated in the public sector, at government supported facilities. All 
patients are offered services free of charge. Medical aid funds are not required to offer treatment for TB or 
drug resistant TB; the prescribed minimum benefits reference “Diagnosis and acute medical management; 
successful transfer to maintenance therapy in accordance to DOH guidelines.”[60] Thus, decisions made at 
the public health level, in terms of setting the DOH guidelines, tenders, and approach are the most relevant 
and impactful on MDR/RR-TB outcomes in South Africa. Public health decision making, as with clinical deci-
sion making, also does not start with questions of cost. Before asking about efficacy and effectiveness, for 
public health policy and budget making, the first questions are often about burden and impact. Essentially, 
the first question is ‘So what? Why should (we) care?’. Diseases or health problems that only affect a small 
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proportion of the society or that have a relatively small impact on even a large proportion of the society, sel-
dom rise to the level of priority for public health policy. Thus, for public health, the first evidence considered 
is a quantification of the mortality and morbidity from different causes. Quantification of mortality and mor-
bidity at the global or national context can help to focus policy and decision makers on the diseases and is-
sues that are having (and will have in the future) the most impact on the population.[61] For example, apply-
ing the burden of disease methodology to South Africa in the early 2000’s identified that South Africa was 
facing a quadruple ‘burden of disease’: HIV/AIDS, ‘pre-transitional diseases linked to under development’, 
non-communicable diseases, violence and injury.[62,63] Measurement of the burden of different diseases 
does not mean that public health decision makers will only or should only consider the results of a quantifi-
cation exercise. Additionally, decision makers need to consider societal values and preferences, especially 
with regards to the distribution of health across different population groups.[63,64] However, the quantifica-
tion provides a starting point for prioritization and evidence to use in the debates.   
Evidence as to effectiveness of an available intervention is still essential to public health policy making as it is 
for clinical management of individuals.[65] There is a re-enforcing loop – research needed to develop effec-
tive interventions or to build the evidence base that existing interventions are (not) effective – often only 
happens after the ‘so what?’ question has been answered.[61,65]  The World Bank 1993 report on investing 
in health established the case for why health is essential to development and then defined the major failures 
with previous investments in health: misallocation of resources (not allocating towards interventions that 
are most cost-effective), inequity, inefficiency, and ‘exploding’ costs. With this diagnosis of the problem, the 
three-pronged recommendation for investing in health was to 1) foster an environment that enables house-
holds to improve health; 2) improve government spending on health; and 3) promote diversity and competi-
tion.[66] While information on the comparative or incremental cost-effectiveness of an intervention is not 
the only evidence that is or should be considered; its importance for public health decision making is now 
well established.[40,42,64]  
DALYs and QALYs 
As we can see above, CEA starts first with measurement of effectiveness. Using a measurement common 
across multiple diseases, injuries and disabilities can assist in optimizing resource allocation for population 
health and not just optimizing treatment of any one disease. Thus, there is a need to define how (how much) 
alleviating the mortality or morbidity of a particular disease or injury contributes to the overall population 
health. The disability adjusted life years (DALYs) approach measures both years of life lost and years lived in 
a state of reduced health (disability). Life years saved are directly calculated using the deaths occurring as a 
result of the disease or injury using the age of the patient at death subtracted from the life expectancy at 
that age of that specific population.  
Quality-adjusted life years (QALYs) are an alternative outcome to DALYs which are also commonly used. 
QALYs are gained while DALYs are averted, and sometimes the two terms are used as the mathematical re-
flection of the other (e.g. 1 - disability weight = quality adjusted year). However, there are difference in the 
methodology for calculating QALYs compared to DALYs. QALYs are most commonly used for resource-rich 
settings.[67] QALYs use utility measurements, where the disutility of being in hospital or having a disease is 
considered to be less than 1(perfect utility) but greater than 0 (no utility, or death). QALYs incorporate hospi-
talization, loss of productivity, and disability as a whole [68]; this makes it challenging to disentangle one ef-
fect from the other when modelling a new treatment that potentially has a difference in one of these fac-
tors. The QALYs therefore are also specific to the setting and expectations of that setting. For example, in 
low-burden, resource-rich settings with low mortality and little drug resistance, active TB is considered to 
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have a very low disutility and therefore little incentive to avoid active TB through preventative interven-
tions.[69] There is little evidence from limited-resource settings as to the disutility of having TB, especially 
when combined with HIV infection or with additional drug resistance.[68] One of the first cost-effectiveness 
analyses for the treatment of MDR/RR-TB in Peru used a QALY of 0.58 [70] based upon a study from In-
dia.[71] This lack of evidence on the disutility of a disease or disability within limited-resource settings is not 
limited to TB; most studies measuring utility (or disutility) are from resource-rich settings, e.g. Europe, the 
USA, and Australia.[67]  
Disability weightings 
Disability weighting, in contrast to utility, is intended to have a more limited scope and measure disability 
only; loss of welfare is excluded from the measurement.[72] A disability weight is a measure between 0 and 
1 where 0 represents full health and 1 represents death; the higher the disability weight, the more DALYs 
add up. Disability weights were constructed in order to provide a way to consider non-fatality outcomes 
across multiple health conditions and interventions.[72] Disability weights are more subjective than mortal-
ity, but attempt to at least transparently describe and quantify for debate different weights. DALYs are based 
on two principles: “Principle 1. The burden calculated for like health outcomes should be the same.” and 
“Principle 2. The non-health characteristics of the individual affected by a health outcome that should be 
considered in calculating the associated burden of disease should be restricted to age and sex.”[72] The first 
principle attempts to exclude issues of stigma or temporality of the disability. The second principle attempts 
to exclude issues such as whether the person affected is a wage earner or ‘contributes to society’ in some 
way.   
In absence of a specific study from the context being analysed, the disability weights of reference are those 
from the Global Burden of Disease (GBD) study. The methodology underlying the disability weights reported 
in the GBD 2013 has evolved substantially from the origin of the DALYs in 1996. Initially, disability weights 
were assigned to classes ranked according to loss of welfare and function (Table 2.3).[73] The different 
health states were assigned a disability weighting by a group of experts from around the world met at the 
WHO (e.g. persons from the US were from the U.S. Centres for Disease Control) who were asked to weigh 
the social preference for time spent in one state versus another.[72,73] It was recognized, although left to 
future work, that there was outstanding debate over how to elicit utility or preference for one health state 
over another and whether the relative weights of disability would differ across the globe.[72,73] Newer 
states reflect not only improved statistical analysis and methodology for collecting valuation; especially for 
HIV/AIDS, the prognosis and understanding of the prognosis for a person living with HIV who is on ART has 
also changed over time. The 2004 value for an AIDS cases on ART represented a disability weight nearly 2-
times that of the value used in 2013 (0.167 compared to 0.078, respectively)[74] in part because of the addi-
tional 10-years of experience and understanding that ART is a very effective treatment.   
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Table 2-3. Definitions of disability weighting in the 1996 DALY construct [73] 
Class Description Weight 
Class 1 Limited ability to perform at least one activity in one of the following areas: recrea-
tion, education, procreation or occupation 
0.096 
Class 2 Limited ability to perform most activities in one of the following areas: recreation, 
education, procreation or occupation 
0.220 
Class 3 Limited ability to perform most activities in two or more following areas: recreation, 
education, procreation or occupation 
0.400 
Class 4 Limited ability to perform most activities in all of the following areas: recreation, ed-
ucation, procreation or occupation 
0.600 
Class 5 Needs assistance with instrumental activities of daily living such as meal prepara-
tion, shopping or housework. 
0.810 
Class 6 Needs assistance with activities of daily living such as eating, personal hygiene or toi-
let use.  
0.920 
 
In 2015, weights for 220 disabilities were published as part of the GBD 2013.[74] Each of the disabilities had 
been mapped as a sequela of a disease, e.g. hearing loss could occur as a result of congenital abnormality, 
ear infection, or meningitis.[75] As part of the GBD 2010 study, more than 40,000 persons were surveyed 
through face-to-face, telephone, or web-based questions comparing pairs of different health states. Thus, 
the weights were calculated from repeated measurements comparing one health states to another, rather 
than asking for participants to assign a score or rank the 220 conditions individually.[74]  The pairwise com-
parisons were anchored to a ranking between 0 and 1 using a public health evaluation approach – partici-
pants in the web survey were asked to choose whether to allocate resources to one disability or to a group 
of another disability to determine how many people would have to be helped for the two disabilities to be 
considered equal (e.g. whether curing 100 cancers is equivalent to 10, 100 or 1,000 TB cases).[74,75]  
Although Salomon et al concluded from the GBD 2010 study that there is a significant level of consistency 
across different contexts (e.g. Peru compared to the USA) [74], this conclusion has continued to be ques-
tioned.[75–78] A South African team replicated many of the methods from the GBD 2010 in Cape Town, 
South Africa to investigate whether the weightings would be similar in the SA context.[79] A total of 671 per-
sons, mostly younger than 50 years and 79.3% without having matriculated from secondary school were in-
terviewed.[79] The differences in weighting found is not only due to cultural differences, but may also be 
because of the anchoring done where persons were asked how many years of healthy life were equivalent to 
10 years in the disabled state (a time trade-off approach).[79] In 2013, the weights were revised again in or-
der to 1) incorporate additional sequelae; 2) revising the lay description of certain health states to improve 
consistency of wording across different levels of severity; and 3) to assess whether weighting is insensitive to 
the duration of disability.[75] 
Co-morbid conditions 
Co-morbid conditions, such as HIV and TB, are more challenging to assess. The loss of health due to TB/HIV 
co-infection was a specific trade off that interviewees were asked to consider for the GBD study. However, 
other less common co-morbidities or additional co-morbid conditions while TB/HIV co-infected do not have 
published disability weights. For example, HIV-infected patients may experience one or more ADR during 
MDR/RR-TB treatment. These patients may have a higher disability weight than those without ADR. When 
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there are co-morbid conditions that were not grouped for the ranking questions (e.g. diabetes and TB), the 
scores can be adjusted to determine the overall burden of the co-morbidity.[80–82]  
As Haagsma et al describe, when there are co-morbidities, sometimes the higher of the morbidities is used 
only (the one with the greater disability weight); sometimes the two disability weights are added; and some-
times they are multiplied.[82] Haagsma et al found that highest correlation between observed disability 
weights for certain combinations of conditions and the calculated comorbidity weight was highest for addi-
tive approach and the multiplicative approach.[82] A separate study of multiplicative approach also found 
high correlation to observed values for certain combinations of comorbidities.[80] The two or more disability 
weightings can be converted to scores (1-disability weight) and then multiplied to determine the overall bur-
den of the co-morbidity[80,83], similar to methods used for calculating the utility in a cost-utility analy-
sis.[80] Thus, a person who has TB without HIV infection (disability weight (dw) = 0.331, converted score = 
.669) who has severe hearing loss with ringing (GBD 2010 disability weight=0.065, converted 
score=0.935[74]) would have a combined score of 0.626 or equivalent disability weight of 0.374. 
1 - dwTBHIV = scoreTBHIV 1 - dwhearing = scorehearing  
1 - 0.331 = 0.669 1 - 0.065 = 0.935  
scoreTBHIV  x scorehearing = scoreTBHIV hearing  1 - scoreTBHIV hearing = dwTBHIVhearing 
0.669 x 0.935 = 0.626  1 – 0.626 = 0.374 
 
Costs 
Once (relative or incremental) effectiveness is established, the question of costs must be addressed. Again, 
the text by Drummond et al offers a useful framing, asking: ‘Which costs should be considered?’ and ‘How 
should costs be estimated?’[40] For the proposed analysis comparing two different drug regimens for the 
treatment of MDR/RR-TB, an incremental costing rather than a full costing is appropriate. Further, the costs 
can be narrowly defined to those that would likely differ between the two options. For example, the man-
agement and operations of the district health system is unlikely to differ based upon different drug regimens 
administered and therefore can safely be kept outside the scope of the incremental costing. For where pos-
sible, the bottom-up costing methods to be implemented for the study are consistent with the “Guidelines 
for cost and cost-effectiveness analysis of tuberculosis control” [84], in order to facilitate comparison to 
other studies and to non-DR tuberculosis costing control. An ingredients-based approach building up pro-
vider costs is a recommended method for costing studies [84] and has been used for the many of the eco-
nomic evaluations of MDR/RR-TB reviewed above.[26,49,50,85–87]  
Cost effectiveness thresholds  
Estimated cost effectiveness ratios and ICERs can also be compared against a theoretical threshold below 
which an intervention is considered to be cost-effective. In some countries that routinely use health technol-
ogy assessments to evaluate new interventions (e.g. the UK), WTP thresholds may be explicitly set.[41,88,89] 
Use of a WTP threshold assists decision makers in understanding whether any of the interventions being an-
alysed are worthwhile. For example, if the decision maker is willing to pay a $500 for a life saved and the 
cost of the intervention is $400 per life saved, that intervention would be considered ‘cost-effective’ (CER < 
WTP). However, in many contexts, the WTP is not an expressed; policy makers do not explicitly state that 
they are willing to pay a certain dollar amount for a life saved. Initially, the World Bank defined interventions 
that cost $50 or less per DALY in low-income settings or $150 or less per DALY in middle-income settings as 
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highly cost-effective.[66,90] In middle-income countries such as South Africa, less than $500 per DALY 
averted would be considered cost effective by this standard.[90] The WHO CHOICE project (Choosing Inter-
ventions that are Cost-Effective) set a standard based upon the per capita income for a country. Interven-
tions are considered cost effective if they cost less than three times the average per capita income per DALY 
averted; interventions are considered very cost effective if they cost less than the average per capita income 
per DALY averted.[42,91] For South Africa, with a gross national income (GNI) per capita of $3,320 in 1993 
(https://data.worldbank.org/country/south-africa), the difference between these two thresholds ($500 vs 
$9,960) is nearly 20-fold. However, there is growing recognition that while the simplicity of a global formula 
for a threshold based on per capita income and a pass/fail assessment of interventions is attractive, it pro-




Modelling is one method for extending the costs or effectiveness beyond the limitations of a particular 
study. For example, many clinical trials have interim markers or intermediate outcomes which are used to 
compare interventions while the differential effectiveness may be realized outside of the time limits of the 
study. Modelling helps to extend the expected results beyond what was demonstrated or observed in a 
study. Drummond et al explains the key objectives of economic evaluation that modelling provides: 1) struc-
ture of health states and alternate outcomes); 2) framework for analysing evidence by selection and use of 
input parameters; 3) evaluation of alternative options; 4) consideration of uncertainty and variability; and 5) 
identification of priority unanswered questions for further research.[40] Modelling is an appropriate form of 
economic evaluation when there is need to bring together various sources of evidence on costs and effec-
tiveness in order to inform decisions about health care policy [48]. Markov models are a form of health-state 
transition models. They are appropriate for closed cohorts where transitions occur at specific states. The 
more simplified decision tree models, in contrast, neither reflect time nor can they reflect time-dependent 
parameters.[92] Best practice recommendations are that cycle length should reflect clinical events.[92]  
Literature was reviewed to identify existing models for estimating the cost-effectiveness of MDR/RR-TB 
treatment. Three basic approaches were identified: 1) average cohort costs multiplied by expected out-
comes; 2) state transition model starting from TB infection; and 3) Markov health state model. A cost-effec-
tiveness model used to analyse the introduction of bedaquiline has been applied and adapted to many con-
texts. However, none of the models identified allowed for both the contextualization of high prevalence HIV 
setting and alternative MDR/RR-TB treatment strategies. HIV health states were common in state transition 
and population models of infection, but not for MDR/RR-TB treatment. Multiple cost-effectiveness models 
exist which include, but do not focus on, the health state of MDR/RR-TB active disease or the phases of 
MDR/RR-TB treatment. For example, cost-effectiveness models for new TB diagnostics include the possibility 
that undiagnosed and untreated TB could be drug-resistant TB and that this leads to higher treatment costs 
(e.g. see Menzies et al [93]). However, these models that included but were not developed for MDR/RR-TB 
led to simplifying assumptions on the MDR/RR-TB stages or states that precluded use of the models for un-
derstanding differences between MDR/RR-TB treatment regimens.   
One of the earliest cost-effectiveness analyses of MDR-TB treatment was from Peru, based on a pilot project 
from 1997 to 1999. The authors built an Excel model where the ingredients-based average costs were multi-
plied by the expected treatment outcomes of different strategies.[85] Results were presented as cost per 
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DALY averted (the equivalent of an ICER) for providing the second-line drugs. This type of Excel model where 
the average cost of treatment strategies was multiplied by the different patient outcomes was also used for 
an analysis in the Philippines.[86] A systematic review of the cost-effectiveness of MDR-TB treatment applied 
the same approach globally, adjusting the bottom-up cost components according to model of care (outpa-
tient or hospitalized) and WHO CHOICE inputs (e.g. cost per day in hospital), in order to provide a range of 
estimated costs for MDR-TB across different regions.[24] 
The Peru cohort was also the starting point for a dynamic state transition model (Figure 2.1). The state tran-
sition model started from a population who was susceptible to TB infection, followed them through latent TB 
infection, active TB and chronic TB or MDR-TB. MDR-TB costs and effectiveness were taken as average based 
on the same total costs and cohort outcomes as used in the Excel model (above). A similar approach of start-
ing with TB infection but not going into detail on MDR-TB treatment was used for modelling the roll-out of 
Xpert MTB/RIF (e.g. Menzies et al, [93]). The different health states included in the model reflect a different 
prioritization of the questions being asked. The Peru model is useful for understanding what would happen 
in absence of MDR/RR-TB treatment, showing on-going transmission to an uninfected population and also 
the lag in time (latent TB or latent MDR health states) between infection and active disease. However, treat-
ment for MDR/RR-TB is one health state for two populations (acquired MDR or primary MDR), a limitation 
when assessing differences in the effectiveness of MDR/RR-TB treatment.    
Figure 2-1 State transition model, Peru model [70] 
  
A more recently published cost-effectiveness model for MDR-TB used a decision-tree analysis to estimate 
the ICER of delamanid plus background regimen in Germany.[94] There were only five possible outcomes 
modelled: cure, treatment completed, failure, loss from treatment, or death. The time step was yearly and 
the time horizon 10 years. 
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Wolfson et al developed a cost-effectiveness model of MDR/RR-TB treatment for the UK (Figure 2-2), which 
was subsequently applied to Germany [54] as well as Estonia, Russia, South Africa, Peru, China, the Philip-
pines, and India [55]; it was also adapted to Korea [52] and Italy [56]. The model has six health states, where 
patients transition from having newly diagnosed MDR-TB, to sputum converted MDR-TB, to treatment com-
pletion and cure. Patients could also relapse, have surgery for MDR-TB, be lost from treatment or die.[53] 
Time to sputum conversion and rates of relapse are important drivers of cost in the model. The time step 
was monthly (28 days) and the time horizon 10 years. This model starts after diagnosis, at treatment initia-
tion, which is the same starting point for the patient level data within EDRweb. Risk of transmission or the 
impact of undiagnosed or untreated MDR/RR-TB therefore cannot be assessed using the UK model. For the 
South African context, the inclusion of surgery as health states (surgery, short term surgery outcomes, long 
term surgery outcomes) adds complexity for a very small proportion of patients. While surgery for chronic 
MDR/RR-TB, i.e. lobectomy, is expensive (estimated at $5,549 per event [25]), it is very rare in the SA NTP 
and is reserved for patients in whom individualized and extended chemotherapy has failed. Availability may 
be at certain treatment sites but is estimated at less than 5% of the XDR-TB cohort.[95] Conversely, the UK 
model does not include separate health states or transition probabilities for patients co-infected with HIV. 
While this simplification may be appropriate for low-prevalence settings such as the UK, it may not be appro-
priate for South Africa.  
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2.4 MDR/RR-TB  
As established in the introductory chapter (Introduction), MDR/RR-TB represents a significant public health 
problem for South Africa. According to the Global Tuberculosis Report 2016, only 6 countries accounted for 
60% of the new TB cases globally: India, Indonesia, China, Nigeria, Pakistan and South Africa. The report con-
cludes “Global progress depends on major advances in TB prevention and care in these countries.”[58] Im-
proved modelling of incidence in South Africa shows a declining trend in the incidence and prevalence rates 
over time [58] (Figure 2-3), likely a result in increased access to ART.[96]  
Figure 2-3 TB/HIV incidence in South Africa, per 100,000 population, 2000 to 2015 
 
Data source: WHO Global TB database http://www.who.int/tb/data/en/  
Figure 2-4 Number of MDR/RR-TB cases initiating and successfully treated, South Africa 2007 to 2013 
 
Data source: WHO Global TB database http://www.who.int/tb/data/en/  
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In 2015, there were 19,613 laboratory confirmed cases of MDR/RR-TB and 1,024 laboratory confirmed XDR-
TB. [58] More than 1/3 (36%) of diagnosed cases were not registered as having started on MDR/RR-TB treat-
ment (2015 cohort of 12,527 initiating).[58] Of the 10,614 patients who started treatment in 2013, only 48% 
were successfully treated (Figure 2-4).[58] According to Stats SA, there were 1,115 deaths due to MDR-TB 
and 162 deaths due to XDR-TB in 2015.[97] TB, including both drug resistant and drug sensitive forms, ac-
counted for 33,063 deaths in 2015. Although the number of deaths has been declining over time, TB has 
been the leading cause of death in South Africa for multiple years.[97]   
Standard of care treatment regimens and duration 
In line with WHO 2011 treatment guidelines [16], through mid-2016, the standard of care for newly diag-
nosed MDR/RR-TB treatment in South Africa was to use a standardized regimen, unless documented re-
sistance or intolerance to the drugs in the regimen requires an individualized regimen (Figure 2-5).[17,19] 
The initial diagnostic test for most TB patients is the Xpert MTB/RIF, which detects both TB and resistance to 
rifampicin. Patients can also be diagnosed on TB culture. Specimens that are culture positive are tested using 
line probe assay (LPA), which can detect both rifampicin and isoniazid resistance and therefore diagnose 
MDR-TB. All patients who are at least rifampicin resistant are initiated on MDR/RR-TB treatment regardless 
of whether a test for isoniazid resistance has been performed.  
Figure 2-5 Drug-resistant TB treatment guidelines, 2000 to 2016 in South Africa 
 
As of 2016, WHO-recommended standardized regimens for MDR/RR-TB are now categorized as either short-
course (9 to 12 months) or long-course (18 to 24 months).[14] Standard long-course MDR/RR-TB treatment 
is divided into two phases: 6 months (intensive phase) of 5 drugs (kanamycin, moxifloxacin, ethionamide, 
terizidone, and pyrazinamide) followed by 12 to 18 months (continuation phase) of 4 drugs (moxifloxacin, 
ethionamide, terizidone, and pyrazinamide). The intensive phase is set at 6 months in order that the average 
patient receives at least 4 months of treatment following culture conversion, where patients who were cul-
ture positive convert to a negative culture. The continuation phase similarly is based upon the length of the 
intensive phase, patients are expected to have at least 12 months of treatment with the continuation drugs 
while culture negative. Reversion of culture status (from negative back to positive) during treatment or inter-
ruptions in treatment may lead a clinician to extend the length of either the intensive or continuation 
phases.  
Patients with at least either preXDR- or XDR-TB are treated with individualized regimens which may include 
high-dose isoniazid, para-aminosalicylic acid (PAS), clofazimine, and/or capreomycin. Linezolid has been 
available but in a very limited way due to the cost prior to registration of a generic version and inclusion of 
linezolid in a public tender in 2016.[98] Although capreomycin is a cyclic peptide and therefore has a differ-
ent means of action against TB than the aminoglycides kanamycin and amikacin, it is not as commonly used 
as before [19] due to increasing evidence of cross resistance with the other second line injectables (SLD).  
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As indicated above, surgery for drug-resistant TB is very rare in South Africa and is reserved for patients in 
treatment has failed. It is estimated that less than 30 patients would have received surgery out of the more 
than 11,000 who initiated MDR/RR-TB treatment in 2014 in South Africa .[2,95]   
According to the WHO 2016 updated guidelines for the treatment of drug-resistant TB [14], core drugs were 
re-prioritized in terms of creating standard regimens (Table 2-4). In order to design an effective regimen, cli-
nicians are first asked to 1) choose 1 later-generation fluoroquinolone (group A); 2) add one second-line in-
jectable agent (group B); 3) add two or more from the other core second-line agents (group C); and 4) add 
pyrazinamide and any first line drug that may strengthen the regimen (group D1). Drugs from group D2 or 
D3 could be added if an otherwise effective regimen could not be composed.[20]   
Table 2-4 Standard regimens for long-course MDR/RR-TB treatment 
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New drugs Not included in 2011 classification, 
but with separate recommenda-
tions, e.g. Bedaquiline [31]; 
Delamanid [99] 
New drugs N/A in 2017 
 
Page | 27 
New drugs and drug regimens 
In January 2013, pre/XDR-TB patients were able to access bedaquiline under BCAP at five centralized 
M/XDR-TB hospitals in South Africa.[33,34] Following approval from the national regulatory authority at the 
end of 2014, in March 2015 bedaquiline was expanded to more sites nationally. Current indications for be-
daquiline [19] in South Africa include at least rifampicin-resistant patients with resistance to a fluoroquino-
lone or/and a second-line injectable drug (pre-XDR/XDR- TB), MDR/RR-TB with both inhA and katG muta-
tions, or toxicity to drug(s) in the standardized MDR/RR-TB regimen. As per labelling, bedaquiline treatment 
is for 24 weeks, during the intensive phase of second-line TB treatment. Patients with HIV infection are eligi-
ble for bedaquiline; appropriate ART regimen changes are made to either lopinavir/ritonavir or nevirapine as 
clinically indicated if the patient is on efavirenz.  
The WHO 2016 update to the treatment guidelines [14] preceded the meeting of the guidelines develop-
ment group and the issuance of updated recommendations for both bedaquiline [32] and delamanid [100]. 
As a result, some policy makers have recommended an updated classification to the 2016 WHO version, up-
grading the use of the new drugs (Table 2-5).[46,47] Importantly, under the new proposal, effective drug 
regimens could now be composed without second-line injectables. According to the authors of the proposal, 
“moreover having an oral Group B could mean that shortly it may be possible to have an injectable free-regi-
men to treat MDR-TB patients meaning potentially less toxicity, monitoring, and reduced hospital stay and 
visits, and possibly better adherence.”[46] A further call for use of an injection-free regimen was published in 
late 2017, which concluded that continued use of second-line injections without explaining the potential ef-
fects and offering alternatives would contravene ethical standards and human rights.[1] While not yet policy 
in South Africa, the SA NTP guidelines for bedaquiline allow for an injection-free regimen for patients that 




Page | 28 
Table 2-5 Proposed regimens for long-course MDR/RR-TB treatment 







































































HIV testing and treatment 
Access to HIV testing and treatment for MDR/RR-TB patients has improved rapidly in the last two decades in 
South Africa (Figure 2-6). In April 2010, the SA guidelines for antiretroviral therapy (ART) were updated to 
indicate that all M/XDR-TB patients, regardless of CD4 count were eligible for ART initiation.[101] In 2013, 
these guidelines were updated to include any TB, regardless of CD4 count. As of 2016, clinical providers initi-
ate (encourage) HIV testing to all clinic visitors, especially to all TB patients. ART is fast-tracked for patients 
who are ART-naïve when starting MDR/RR-TB treatment, regardless of CD4 count.     
Figure 2-6 ART eligibility guidelines for TB patients in South Africa, 2004 to 2016 
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Data collection 
The South African Electronic Drug Resistant Tuberculosis Register (EDRWeb) is a reporting database that col-
lects non-aggregated, patient-level data from drug-resistant TB treatment sites. Access to this central data-
base is granted to authorized users who can capture data for units dealing with RR-TB. This system is in-
tended to act as tool for providing quality data for program management, surveillance, monitoring and eval-
uation and supervision. It collects information on patient-level demographic data, case registration, Xpert 
MTB/RIF, line probe assay, sputum smear results, culture results, and drug sensitivity testing (DST), treat-
ment details, treatment outcome, adverse events and HIV information from facility TB registers. In South 
Africa this system has been implemented in all nine provinces and is being used in more than 50 units 
providing RR-TB treatment. It is the most complete dataset of RR-TB treatment (MDR/RR-TB, preXDR-TB, and 
XDR-TB) and outcomes in South Africa and is the cohort reported to the WHO.  
While EDRweb is the most complete dataset, there is evidence of substantial underreporting, particularly at 
the decentralized sites that began initiating MDR/RR-TB patients after 2012. A 2012 review of paediatric clin-
ical records in Cape Town, Western Cape found that 1/3 of patients were not recorded in EDRweb.[102] A 
national analysis for a sample of 2011 and 2013 adults initiating MDR/RR-TB treatment, only 62% and 53%, 
respectively, were reported in EDRweb.[103] The study had started by looking at diagnosis of MDR/RR-TB 
records from NHLS and then attempting to trace patients to treatment sites.  
The dataset also does not include all clinical factors of interest for RR-TB treatment. Aside from HIV status 
and sputum smear positivity, few other indicators of physical condition or mortality risk factors are included 
in EDRweb, such as hospitalization (for initiation or ADR), other comorbidities (such as diabetes), body mass 
index, serum albumin, haemoglobin, liver function or kidney function. For HIV-positive patients, the date of 
ART initiation and information on CD4 count at baseline or at any point during MDR/RR-TB treatment is not 
routinely captured. Out of the more than 90,000 records in EDRweb, there are fewer than 10,000 records 
with CD4 count or ART initiation date, despite more than 65% of the patients known to be infected with HIV. 
Other patient characteristics which are not reported but known to be clinically relevant are extent of dam-
age to the lungs, return to care after interruption, relapse, development of new resistance, HIV viral suppres-
sion, intolerance and toxicity to treatment regimens. Additionally, resource use is not captured and the 
EDRweb cannot be used to estimate the number of days hospitalized, visits to a clinic, or laboratory monitor-
ing tests done. 
In mid-2016, with support from Janssen Pharma, a new version of EDRweb was implemented with additional 
fields for data collection. Efforts began in 2017 to link EDRweb to the vital statistics register maintained by 
the Department of Home Affairs and to the laboratory information system of the NHLS. For bedaquiline pa-
tients in particular, EDRweb also serves as the monitoring system required for the regulatory review of be-
daquiline by the US FDA. However, the data used in this thesis was exported in May 2016 and represents the 
version of EDRweb which predated these amendments.   
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2.5 ESTIMATING THE EFFECTIVENESS OF MDR/RR-TB TREATMENT 
The most common outcome reported for RR-TB treatment is the end of treatment. This may be at 18-24 
months for the long-course regimen, or in some cases with extensive drug resistance, as long as 36 months. 
24-month outcomes sometimes include the category ‘still on treatment’ which is an indication that the re-
porting period (24-months) censored the end of treatment outcome. End of treatment outcomes that will be 
considered for this analysis, at the earliest reporting date, are indicated below (Table 2-6). Note that the 
terms reference the treatment course and not the patient, i.e. the treatment course failed to cure the 
MDR/RR-TB, not that the patient is failed or has failed.[104] For similar reasons, although the definitions of 
the ‘lost to follow-up’ or ‘lost from treatment’ or ‘lost from care’ are not different in content from previous 
definitions of ‘default’ or ‘defaulter’ the language defining the term has been revised.[104]  
Table 2-6 Table RR-TB patient outcomes 
OUTCOME DEFINITION OF CRITERIA 
Cured Treatment completed as recommended by the national policy without evi-
dence of failure AND three or more consecutive cultures taken at least 30 days 
apart are negative after the intensive phase, i.e. at least three consecutive cul-
tures after month 6. 
Completed Treatment completed as recommended by the national policy without evi-
dence of failure BUT no record that three or more consecutive cultures taken 
at least 30 days apart are negative after the intensive phase. 
Died A patient who dies for any reason during the course of treatment. 
Failed Treatment terminated or need for permanent regimen change of at least two 
anti-TB drugs because of: 
− lack of conversion by the end of the intensive phase, or 
 − bacteriological reversion in the continuation phase after conversion to neg-
ative, or 
 evidence of additional acquired resistance to fluoroquinolones or second-line 
injectable drugs, or 
− adverse drug reactions (ADRs). 
Lost to follow-up A patient whose treatment was interrupted for 2 consecutive months or more. 
Not evaluated A patient for whom no treatment outcome is assigned. (This includes cases 




The terms “conversion” and “reversion” of culture as used here are defined as 
follows: Conversion (to negative): culture is considered to have converted to 
negative when two consecutive cultures, taken at least 30 days apart, are 
found to be negative. In such a case, the specimen collection date of the first 
negative culture is used as the date of conversion. Reversion (to positive): cul-
ture is considered to have reverted to positive when, after an initial conver-
sion, two consecutive cultures, taken at least 30 days apart, are found to be 
positive. For the purpose of defining Treatment failed, reversion is considered 
only when it occurs in the continuation phase. 
Table reference: [18] 
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Culture conversion 
Short-term outcomes for RR-TB focus on 6 months, which is the time where most patients should be finish-
ing the intensive phase of treatment and starting the continuation phase. At 6 months, patients should still 
be in care, especially as the injectable drugs require daily visits to or by a healthcare worker. And, at 6 
months, patients should be culture negative. For those who were culture positive at the start of treatment, 
the indicator of proportion culture converted is tracked as well as the number of days from treatment initia-
tion to culture conversion. Culture conversion is defined as the first two consecutive negative cultures taken 
one month apart, when patient was initially sputum culture positive. The date of culture conversion is taken 
as the date of the sputum collection for the first negative culture. Therefore, culture conversion can only be 
measured retrospectively and also requires that the person remain in care for at least three culture sputa to 
be collected. Many of the cost-effectiveness models established for MDR/RR-TB are driven by the rates and 
time to culture conversion, as hospitalization is required in many contexts until culture negative.[53–55]  
Phase 2b randomized clinical trial evidence for the use of bedaquiline in addition to the standard treatment 
regimen for MDR-TB showed promising results in terms of efficacy with higher rates of culture conversion 
and cure compared to standard regimen plus placebo. An interim cohort analysis of the first 91 patients 
from the South African BCAP published in 2015 76% culture conversion among XDR-TB and preXDR-TB, how-
ever many patients had 6 months or less follow-up time.[34] Another interim cohort from a compassionate 
access program in France (2015) reported that at 6 months, 97% (28 of 29) of culture positive patients had 
culture converted.[105] 
Mortality 
The Phase 2b trial of bedaquiline reported a statistically significant imbalance in mortality 10/79 deaths oc-
curring patients exposed to bedaquiline (12.7%) and 2 deaths (2/81, 2.5%) in the placebo arm.[30] As a re-
sult, interim WHO guidelines recommend limited use of bedaquiline only in RR-TB when there is resistance 
to fluoroquinolones and when there are no other treatment options.[31] An interim cohort analysis of the 
first 91 patients from the South African BCAP published in 2015 reported 3 (3.3%) deaths among XDR-TB and 
preXDR-TB, however many patients had 6 months or less follow-up time.[34] At 120 weeks, the open-label 
trial TMC207-C209 reported 16 deaths out of 233 enrolled patients (6.9%), all of which were considered not 
related to bedaquiline.[106] Another interim cohort from a compassionate access program in France (2015) 
reported that at 6 months, 1/35 patients had died (3%) and 97% (28 of 29) of culture positive patients had 
culture converted.[105] Each were single arm, non-randomized studies, however, and without a control 
group the signal of excess mortality from the Phase 2b bedaquiline trial could not be confirmed or refuted.  
In March 2017 [32], the WHO updated its 2013 conditional recommendations [31] for the use of bedaquiline 
for the treatment of MDR/RR-TB. Encouraging results from the compassionate use program [34] and the 
public sector roll-out of bedaquiline in South Africa was among the evidence considered by the guidelines 
development group in revising the recommendations.[32] These results included a rate of deaths for pa-
tients on bedaquiline of 7.9%, similar to previous reports. In comparison, the Phase 2b TMC207-C208 trial 
where the placebo arm reported 2.5% mortality had restricted enrolment of those with second-line re-
sistance or use of ARVs; only 19 of the 132 patients in the study were HIV-infected (14·4%).[30] The 19.8% 
mortality for patients with second-line resistance receiving bedaquiline through compassionate use access 
[34] reported in the revised WHO recommendations for bedaquiline is therefore encouraging.[32] Addition-
ally, the revised recommendations included observational reporting from the EDRweb where the mortality 
rates on bedaquiline were lower than for the patients not on bedaquiline.[32]  
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Disability from TB 
The disability of having active TB disease (and being in hospital or in regular care) as well co-infection with 
HIV and TB, was a specific ranking of health states for persons to consider in the GBD 2010 study (Table 2-
7).[74] The disability may persist for years after cure, especially if extensive damage to the lung prior to cure, 
e.g. bronchiectasis or if an adverse drug reaction caused permanent disability, e.g. profound hearing loss. 
One study of the lung impairment following drug-sensitive TB cure calculated that most of the disutility of 
having active TB is not the acute, symptomatic period, but rather the life-long chronic lung impairment after 
cure.[69] The analysis drew on studies of lung function of TB cases and controls, which showed that approxi-
mately 10% of TB cases had severe lung function impairment after cure.[69]  Disability from MDR/RR-TB may 
have also started prior to diagnosis and initiation of MDR/RR-TB, e.g. if the patient was already in very poor 
health at the time of diagnosis.  
The disability weight of MDR/RR-TB was not specified in the 2010 GBD reference or the 2013 update.[74,75] 
It may be that the burden of having TB is an appropriate applicable weight. In the 2016 GBD study, disability 
weights for TB with HIV/AIDS were estimated for drug-susceptible, MDR/RR, and XDR-TB without anaemia 
and with mild, moderate or severe anaemia. Weights and confidence intervals differed by the status of anae-
mia, but not whether the TB was drug-susceptible, resistant or extensively resistant.[107] However, 
MDR/RR-TB is usually more disabling than TB – patients are often hospitalized, there is greater stigma at-
tached because of greater fear, the treatment duration is longer, and the mortality is higher. DALYs were in-
tended to be neutral of duration, so that the duration of disability could be adjusted according to the specific 
conditions being compared.[73] This assumption was investigated in the 2013 revision of disability weight-
ings and it was noted that for HIV, the fact that it was a chronic disease with no cure lead to it having a 
higher disability weighting than the regression co-efficient to adjust for the temporary symptoms.[75] A simi-
lar difference may occur with MDR/RR-TB or XDR-TB given the poor prognosis compared to drug-sensitive 
TB. Further, it is unclear from the weighting whether the active TB infection period should be applied 
throughout treatment (the full 18 to 24 months) or only during the sputum culture positive intensive phase. 
The health states described are based on symptoms, which are alleviated before the course of anti-TB antibi-
otics are completed.   
For the 2010 GBD assessment, TB without HIV was described as “has a persistent cough and fever, is short of 
breath, feels weak, and has lost a lot of weight” and TB with HIV was described as “has a persistent cough 
and fever, shortness of breath, night sweats, weakness and fatigue and severe weight loss.”[74] Thus, the 
difference between having TB or TB with HIV/AIDS was in effect described as having night sweats and ‘se-
vere weight loss’ rather than a ‘lot of’ weight loss. The 2016 GBD study indicated a definition of “has a persis-
tent cough and fever, shortness of breath, night sweats, weakness and fatigue and severe weight loss” for 
patients with TB and HIV co-infection; no difference in the description was made for drug-resistant TB. 
[107]A South African household survey using the GBD 2010 methodology concludes there was a ‘moderate 
correlation’ between the local study and the 2010 GBD study, and reports a Pearson’s correlation coefficient 
of 0.44 (p=0.0015).[79] The authors also concluded that the South African population from Cape Town 
seemed to value physical mobility over cognitive functioning.[79] The conclusion from the 2010 GBD study 
that the disability weights from different contexts are similar therefore was in question based upon this local 
study. The main reason for using disability weights from a different context is non-availability; therefore, 
where weights are available for South Africa, these should parameterize a cost-effectiveness model for 
South Africa. For TB and HIV (Table 2-7), the South African weights were the highest (greatest disability) 
among reviewed disability studies for TB without HIV infection (0.368) and symptomatic, pre-AIDS HIV 
(0.417).[79] GBD 2013 had the 2nd highest weights for TB without HIV and symptomatic HIV and the highest 
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weights for TB with HIV and HIV not on ART and therefore the GBD 2013 values are the closest to the local 
ranking.   
Table 2-7 HIV/TB disability weights from using the Global Burden of Disease methodology 
Description^ Value (95% CI) Source 
TB without HIV infection: has a persistent cough and 
fever, is short of breath, feels weak, and has lost a 
lot of weight” 
0.333 (0.224-0.454) GBD 2013, [75]  
TB without HIV infection 0.331 (0.222-0.450) GBD 2010, [74] 
TB without HIV infection 0.308 (0.264-0.353) Europe, [77] 
TB cases 0.271 GBD 2004, as cited in [75]  
TB without HIV infection 0.368 (0.260-0.430) South Africa, [79] 
TB with HIV infection: has a persistent cough and fe-
ver, shortness of breath, night sweats, weakness and 
fatigue and severe weight loss. 
0.408 (0.274-0.549) GBD 2013, [75] 
TB with HIV infection 0.399 (0.267-0.547) GBD 2010, [74] 
TB with HIV infection 0.383 (0.345-0.435) Europe, [77]  
TB with HIV infection (mapped to AIDS, not on ARVs) 0.505 GBD 2004, as cited in [75]  
HIV infection, on ART: has occasional fevers and in-
fections. The person takes daily medication that 
sometimes causes diarrhea 
0.078 (0.052-0.111) GBD 2013, [75] 
HIV infection, on ART 0.053 (0.034-0.079) GBD 2010, [74] 
HIV/AIDS cases, receiving ART 0.108 (0.089-0.132) Europe, [77] 
HIV/AIDS – AIDS cases on ART 0.167 GBD 2004, as cited in [75]  
HIV infection, AIDS, not on ART: has severe weight 
loss, weakness, fatigue, cough and fever, and fre-
quent infections, skin rashes and diarrhoea 
0.582 (0.406-0.743) GBD 2013, [75] 
HIV infection, AIDS, not on ART 0.547 (0.382-0.715) GBD 2010, [74] 
AIDS cases, not receiving ART 0.574 (0.518-0.635) Europe, [77] 
AIDS cases: not on ARV 0.505 GBD 2004, as cited in [75]  
HIV infection, symptomatic, pre-AIDS: has weight 
loss, fatigue, and frequent infections 
0.274 (0.184-0.377) GBD 2013, [75] 
HIV infection, symptomatic, pre-AIDS 0.221 (0.146-0.310) GBD 2010, [74] 
HIV/AIDS - HIV cases  0·135 GBD 2004, as cited in [75]  
HIV infection, symptomatic, pre-AIDS 0.417 (0.285-0.502) South Africa, [79] 
^ Bolding indicates value selected to be used in analysis.  
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2.6 ADVERSE DRUG REACTIONS DURING MDR/RR-TB 
In the Phase IIb randomized control trial for bedaquiline where bedaquiline or placebo was added to a stand-
ard background regimen, 99% of participants in the treatment arm and 98% of the participants in the pla-
cebo arm experienced one or more adverse events. Most of these events were categorized as being related 
to the treatment, 70% (bedaquiline) and 69% (placebo) for the two arms, respectively.[30] The duration of 
drug-resistant TB treatment is longer (usually 9-24 months) than for drug-sensitive TB (usually 6-9 months) .  
The standard  treatment regimens for MDR/RR-TB  are complicated and include 4 to 7 drugs with differ-
ent[16] mechanisms of action, including oral bacteriostatic drugs such as cycloserine, terizidone, ethiona-
mide; aminoglycoside and cyclic peptide injectables; fluoroquinolones (e.g. moxifloxacin, ofloxacin, gatifloxa-
cin, and levofloxacin); and newer agents such as bedaquiline (a diarylquinoline) and delamanid (a nitroimid-
azole). See Table 2-10. Many of the drugs have known toxicities, especially at the doses and durations re-
quired to treat resistant strains of TB. There is limited clinical trial data on dosage and related side effects, 
particularly among drugs which have been repurposed for MDR/RR-TB and therefore were approved without 
specific clinical trials for their use in MDR/RR-TB, e.g. clofazimine and linezolid. As a result, ADR are very 
common during drug-resistant TB treatment. A systematic review and meta-analysis of published literature 
through October 2012 found that 57.3% of included patients had experienced at least one type of AE, includ-
ing mild to severe events.[3] For example, in the South African study indicated above with 99% incidence of 
AE, injection site pain was the second most commonly reported clinical AE. Injection site pain was only re-
ported in this cohort in patients refusing to continue with the injections for reason of pain.  
The most common ADR during MDR/RR-TB treatment in the SA NTP are indicated in the treatment guide-
lines from 2013 [17] and 2015 [19], along with suspected drugs and guidelines on prophylaxis (if available), 
screening or laboratory monitoring, and management. The list (see Table 2-8), while helpful to keep track of 
all the different possibilities, does not indicate the varying severity or duration that the ADR impact on the 
patient’s health state and ability to function. Psychosis and severe depression, associated with the use of ter-
izidone or the related drug cycloserine, could lead to violence against others or the patient, including sui-
cide.[34,108–110] The temporary, drug-induced thyroid dysfunction often needs to be treated – more pills 
to take – and the effects persist for the duration of the ethionamide, typically 18-24 months.[111–114] Hear-
ing loss from the aminoglycoside IAs is permanent and disabling.[1,115,116]  
 “I thought I was going to die because of the medicines…it was that bad.” – 40-year-old male patient 
in India.[48]  
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Table 2-8 Literature on ADR associated with MDR/RR-TB treatment (based upon [17,19]) 
Adverse reaction Associated TB drugs 
Arthralgia/arthritis Pyrazinamide, Fluoroquinolones 
Bone marrow toxicity Linezolid 
 
Electrolyte disturbances (hypokalaemia, hypo-
magnesemia) 
Second-line injectables 
Gastro-intestinal intolerance, including gastritis, 
nausea, and vomiting 
Ethionamide, Para-aminosalicylic acid, Pyra-
zinamide, Ethambutol, Clofazimine 
Hepatitis and hepatoxicity Pyrazinamide, Para-aminosalicylic acid, Ethiona-
mide, Fluoroquinolones 
Hypothyroidism Ethionamide, Para-aminosalicylic acid 
Optic neuritis Ethambutol, Linezolid 
Ototoxicity, including hearing loss and tinnitus Second-line injectables 
Peripheral neuropathy Cycloserine/Terizidone, Ethambutol, Fluoroquin-
olones, Second-line injectables, Ethionamide, 
Linezolid 




Renal failure and nephrotoxicity Second-line injectables 
 
Seizures Cycloserine/Terizidone, Fluoroquinolones 
 
ADR can lead to the clinician or patient interrupting, stopping, or reducing the dosage of treatment before 
completion, and therefore may increase the risk of mortality, resistance, or treatment failure.[117] In quali-
tative studies, patients cite side effects as a major reason for why they stopped treatment.[118,119]  
“I took fewer drugs, but the effect was terrible. Better I die than going again through all this. . . . I felt 
I was dying because of prothionamide . . . because of cycloserine, I was having hallucinations . . . I 
had ulcer due to PAS . . . I didn’t want to continue.” - MDR/RR-TB patient who was lost from care 
[118] 
Either sequelae from the ADR or the untreated TB disease may lead to reduced quality of life.[120] However, 
the high mortality, risk of transmission, and limited alternatives mean that clinicians and patients with drug-
resistant TB are left with little choice. On average, each patient experiences 3 to 8 ADR during the course of 
MDR/RR-TB treatment.[108,121,122] ADR are most frequent during the first 6 months of treatment 
[108,122], which also coincides with the intensive phase using injectables. 
ADR experienced during RR-TB treatment may be underreported if relying on routine reporting; only serious 
adverse events are required to be reported to the MCC.  The National Pharmacovigilance Centre in South 
Africa recommends use of its new forms for ADR experienced during RR-TB treatment and encourages re-
porting of all ADR, however, these forms are not well known or used at RR-TB treatment centres. ADR which 
led to a treatment change or a serious outcome (e.g. hospitalization or death) are therefore documented 
more commonly than those that the patient complains of but did not affect treatment outcome (e.g. head-
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aches, gastro-intestinal complaints). Reports of ADRs therefore are usually from clinical trials of new and re-
purposed drugs or file reviews rather than routine reporting. Even among peer-reviewed published observa-
tional cohorts, reporting of ADR is inconsistent. Of 74 studies included in a recent systematic review of 
MDR/RR-TB treatment, only 44 reported on adverse events, and only 26 of these indicated a drug related to 
the ADR.[5] During the monthly visits to the outpatient clinics for MDR/RR-TB treatment, treatment guide-
lines do not require that patients be prompted to self-report AE. In some cases, patients may have discussed 
AE with the counsellor, nurse, or clinician but if the healthcare worker did not note the discussion in the 
medical file. This may result in an under-reporting of AEs, particularly those are mild to moderate (grade 1-
2). A South African study where patients were prompted in their local language and with visual aids to iden-
tify AEs found that, on average the clinicians had noted 1.4 AE per patient while patients reported 8.6 AE 
each.[123] Also, while guidelines indicate monitoring for certain AEs, implementation may differ from in-
tended practice. Facilities may not have the staff, equipment, or budget required for the recommended 
monitoring schedule.[116] This is especially true for audiology (e.g. a study reporting ADR from Ethiopia 
[124]), which, until recently, required a special sound proof room for testing. A qualitative study published in 
2009 found that while 63% of the MDR/RR-TB patients interviewed reported having symptoms of ototoxicity 
– either tinnitus or hearing loss – none (0%) had been referred to a specialist for care.[125] 
Clinicians cannot actively screen for symptoms or document patient complaints when the patient is not in 
care. Loss to follow-up is also high during MDR/RR-TB treatment. A global meta-analysis reported 23% as lost 
from treatment or with unknown outcomes.[8]  And, it is high in the SA NTP, with rates in excess of 
25%.[13,126,127] A study of a cohort in Johannesburg reported 13.5% loss to follow-up within the first 6 
months of treatment.[128] From the same clinic, 53.5% of MDR/RR-TB patients missed at least one appoint-
ment.[129] A counselling toolkit for decentralized treatment programmes provides guidance to patients on 
dealing with the side-effects of treatment in order to improve adherence and completion of the course.[127]  
Further, ADR can occur even after treatment has been stopped or completed. For hearing loss, the aminogly-
cosides persist in the ear for long after treatment has been completed or discontinued [130]; ototoxicity is 
known to occur even after treatment discontinuation.[125,131]  
ADR grading 
For record keeping, clinical trials and pharmacovigilance, it is important to have some understanding of the 
severity of the ADR experienced by the patient. While mild nausea may not require medical intervention, 
does not persist, and does not interfere with a patient’s daily activities, severe nausea may require hospitali-
zation. Thus, naming of the ADR is not sufficient to determine its (potential) impact on patient well-being 
and costs of treatment. Unfortunately, grading of ADR is subjective according to patient report and clinician 
experience for many ADR. For laboratory abnormalities, there are now extensive tables, often specific to the 
patient population and/or indicated disease which help to assign a grading to the ADR.[132–135] For exam-
ple, anaemia is considered mild (grade 1) when 9.5 gm/ dL < Hb < 10.5 gm/dL and life threatening (grade 4) 
when Hb < 6.5 gm/dL.[132] For ADR that are not as quantifiably measured as laboratory tests or which are 
not included in the tables being referenced, a more general grading based upon impairment of patient func-
tionality and activities is assessed by the clinician (Table 2-9). Clinicians may monitor mild reactions and con-
tinue TB treatment, but at grade 4 hospitalization, medical interventions, and interruption of TB therapy and 
other actions are immediately taken.  
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Table 2-9 ADR severity grading, based upon DAIDS toxicity table[133] 
Severity Grading Explanation 
Mild (1) Awareness of the symptoms, but does not interfere with daily activities, 
limited duration, no medical intervention indicated. 
Moderate (2) Interferes with some daily activities. Minimal medical intervention indi-
cated 
Severe (3) Prevents normal functioning; significant impairment of functioning. Re-
quires medical intervention, including possible hospitalization. 
Life threatening (4) Immediate significant medical intervention or therapy, including probable 
hospitalization, is required to prevent death or disability. 
Death (5) Death  
ADR and HIV 
In some settings, particularly sub-Saharan Africa, TB and HIV are inextricably linked. Treatment of HIV and TB 
co-infection results in high pill burden and potentially increased toxicity. Effective ART regimens include 
three drugs, usually two nucleoside reverse transcriptase inhibitors (NRTIs) with either a non-nucleoside re-
verse transcriptase inhibitor or protease inhibitor (PI) in resource-limited countries. Toxicities can be over-
lapping, such as potential renal impairment from antiretrovirals including tenofovir and anti-TB medications 
kanamycin/amikacin; peripheral neuropathy from stavudine and zidovudine, ethionamide and linezolid; 
bone marrow suppression from zidovudine and linezolid; nausea and vomiting potentially from zidovudine 
and ethionamide and para-aminosalicylic acid; or psychiatric symptoms associated with efavirenz and cyclo-
serine and terizidone.[16,136] HIV infection, even for the ART naïve, and particularly for those who have ad-
vance HIV disease or immunosuppression may also pose its own risk for ADR. For example, thioacetazone 
was removed from TB treatment recommendations early in the HIV epidemic because of an increased risk of 
Stevens-Johnson syndrome in HIV-infected patients.[137]  Table 2-10 below highlights the overlapping toxici-
ties of ART and second-line TB treatment regimens. 
Table 2-10 ADR associated TB and HIV drugs (based upon [17,136]) 




Bone marrow toxicity Linezolid 
Rifampicin 
Zidovudine 
Electrolyte disturbances (hypokalaemia, 
hypomagnesemia) 
Second-line injectables  



























Lactic acidosis Linezolid Stavudine 
Didanosine 
Optic neuritis Ethambutol 
Linezolid 
 
Ototoxicity (hearing loss and tinnitus) Second-line injectables  









Pyschiatric symptoms, including psycho-




















Bedaquiline-associated ADR   
The Phase 2b clinical trial of bedaquiline noted no statistically significant difference in the frequency or se-
verity of ADR in the bedaquiline arm or placebo arm.[30] Among the 79 treated with bedaquiline, 5% (n=4) 
experienced an event leading to treatment discontinuation; 43% (n=34) experienced a grade 3 or 4 event; 
70% (n=55) experienced an event related to treatment (ADR); and 99% (n=78) experienced any adverse 
event. Among the 81 treated with placebo plus background regimen, 6% (n=5) experienced an event leading 
to treatment discontinuation; 36% (n=29) experienced a grade 3 or 4 event; 69% (n=56) experienced an 
event related to treatment (ADR); and 98% (n=79) experienced any adverse event.[30] In a large, multi-cen-
tre observational study, bedaquiline was interrupted for 11.9% (n=51/428), but only 5.8% (n=5.8%) experi-
enced an interruption due to adverse events.[138] An interim cohort analysis of the first 91 patients from 
the South African BCAP published in 2015 reported few severe adverse events among XDR-TB and preXDR-
TB, however only severe or serious events were reported.[34]  
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As per the full prescribing information for Sirturo, bedaquiline is associated with QT prolongation, especially 
when used with other drugs that prolong the QT interval.[139] As a result, both initial ECG screening and 
monthly monitoring are recommended while on bedaquiline treatment. Bedaquiline is contraindicated in 
patients with a QTcF (QT interval corrected using Fridericia’s formula) over 500ms at baseline or who have a 
history of QT prolongation (e.g. congenital QT prolongation).[19,31,139] Bedaquiline may be interrupted if 
QTcF increases by more than 50ms from baseline or if it exceeds 500ms during treatment [19,31,139]; ECGs 
should be repeated prior to interrupting treatment as readings may vary with each measurement.[139] QT 
prolongation is monitored as it is associated with Torsade de Pointes (TdP), a type of ventricular tachycardia 
which could lead to sudden cardiac death. In the multi-centre study referenced above, of the 33 deaths 
(33/428), only one had ECG abnormalities, the patient also had severe hypokalaemia and this was found to 
be the cause of the cardiac arrest.[138]  
Bedaquiline is one of many drugs that is associated with QT interval prolongation. Other classes of drugs 
which are known to prolong the QT interval include fluoroquinolones[140–143]an which core drugs for the 
treatment of MDR/RR-TB and XDR-TB. Protease inhibitors, used in second-line ART, can also lead to drug-
induced QT prolongation.[142] Not all patients who experience drug-induced QT prolongation develop TdP, 
although the risk exponentially increases with each increase of 10ms for patients with QTcF intervals >500ms 
or who have an increase in more than 60ms from baseline.[140,143] In one review article, it was noted that 
the incidence of TdP with moxifloxacin use was between 1:100,000 to 1:1,000,000 exposures.[140] Addition-
ally, not all episodes of TdP are fatal, it may self-resolve and the symptoms of dizziness and tachycardia also 
resolve.[140] Management of drug-induced QT prolongation is thus focused on prevention of QT prolonga-
tion and TdP, early detection, and stopping of the suspected drug.[140–142] Prevention and monitoring are 
built into the treatment guidelines for the use of bedaquiline, such as excluding patients who have a history 
of congenital QT prolongation syndrome or baseline QTcF exceeding 450ms.[19,31,139] The costs of manag-
ing QT prolongation once experienced are therefore limited (stop bedaquiline).[19,31,139]  
Bedaquiline also has drug-drug interactions that need to be considered, especially for patients who are on 
ART. Co-administration of bedaquiline and efavirenz is contraindicated in the South African treatment guide-
lines.[19] In South Africa at the time of this study (2016), the recommended first line ART regimen in the 
public sector was a fixed dose combination of tenofovir, efavirenz, and lamivudine. Thus, the standard first-
line ART regimen is contra-indicated during bedaquiline treatment. HIV-positive patients in South Africa The 
need to modify the ART regimen during bedaquiline treatment could potentially add to the costs of the 
treatment regimen.  
Because of how bedaquiline is metabolized, the protease inhibitor lopinavir/ritonavir significantly increases 
the exposure to bedaquiline.[144,145] Potentially, the increased exposure could increase the risk of QT pro-
longation or other safety concerns. Thus, the researchers recommended a reduced dosing regimen for be-
daquiline when used with lopinavir/ritonavir.[145] However, at the time of this study (2016), the bedaquiline 
dosing was common across ART and non-ART patients, regardless of the ART regimens. Additionally, with the 
roll-out of dolutegravir in South Africa as the preferred ART regimen[146], the continued role for lopinavir/ri-
tonavir during bedaquiline treatment is unknown. 
Disability from ADR 
ADR, whether permanent or temporary, can also lead to disability. Weights of relevance to common ADR 
during MDR/RR-TB are presented below (Table 2-11, Table 2-12). The commonality of the value or prefer-
ence for different health states across contexts (e.g. Peru compared to the USA) [74] continues to be ques-
tioned, particularly for contexts where coping mechanisms may be less available.[75–78] It is important to 
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recognize that differences across contexts or cultures or even test-retest within the same participants may 
be different for different disabilities.[71] Mahapatra, Salomon and Nanda (2000) describe this as whether 
the community being sampled has ‘crystallized’ it’s values or preferences for a particular health state.[71] 
They note that some health states are considered ‘universally’ bad and there is a high degree of consistency, 
while others change with the valuation method, the description of the condition, or even from test to retest 
checks for consistency.[71] For example, use of a wheel chair in a context where well-designed wheel-chairs 
are affordable and where public transport, schools, shops, housing and other buildings are accessible to per-
sons in wheel chairs may result in less limitation of functioning than in a context where none of these condi-
tions apply.  
As can be seen in the table below (Table 2-11), the disability weights for hearing loss are inconsistent across 
studies. Profound hearing loss in the GBD 2010 was valued at 0.031 and then in the GBD 2013 at 0.204, 
nearly a 7-fold increase. Complete hearing loss in the GBD 2013 was weighted as 0.215, but in a South Afri-
can study it was weighted as 0.405, nearly a 2-fold difference. The difference in disability weighting within 
the GBD 2013 for profound hearing loss (always has great difficulty hearing in any situation and is not able to 
use a phone) compared to complete hearing loss (cannot hear at all) was only a difference of 0.011, or 5%. 
The disability weight assigned to moderate hearing loss in the South African study was 10-times the weight 
assigned to complete hearing loss in the GBD 2010.   
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Table 2-11 Disability weights for hearing loss using the Global Burden of Disease methodology 
Description Value (95% CI) Source 
Hearing loss, moderate: has difficulty hearing a normal 
voice and great difficulty following a conversation in a 
noisy environment 
0.023 (0.013-0.038) GBD 2010, [74] 
Hearing loss, moderate: is unable to hear and under-
stand another person talking in a noisy place (for ex-
ample, on an urban street), and has difficulty hearing 
another person talking even in a quiet place or on the 
phone 
.037 (0.028-0.045) Europe, [77] 
Hearing loss, moderate 0.357 (0.240-0.437) South Africa, [79] 
   
Hearing loss: severe has great difficulty hearing in any 
situation or in using a phone. 
0.032 (0.018 – 0.051) GBD 2010, [74] 
Hearing loss, severe 0.158 (0.105-0.227) GBD 2013, [75] 
Hearing loss, untreated 0.213-0.233 GBD 1996, as cited in [76] 
Hearing loss, severe 0.152 (0.125-0.187) Europe, [77] 
   
Hearing loss: profound always has great difficulty hear-
ing in any situation and is not able to use a phone. 
 GBD 2010, [74] 
Hearing loss, profound 0.031 (0.018 – 0.49) GBD 2010, [74] 
Hearing loss, profound 0.204 (0.134-0.288) GBD 2013, [75] 
Hearing loss, profound: is unable to hear and under-
stand another person talking, even in a quiet place, is 
unable to take part in a phone conversation, and has 
great difficulty hearing anything in any other situation. 
Difficulties with communicating and relating to others 
often cause worry, depression or loneliness. 
0.235 (0.197-0.274) Europe, [77] 
   
Hearing loss: complete cannot hear at all, even loud 
sounds. 
0.033 (0.020-0.052) GBD 2010 [74] 
Hearing loss, complete 0.215 (0.144-0.307) GBD 2013, [75] 
Hearing loss, complete 0.405 (0.282-0.479) South Africa, [79] 
^ Bolding indicates value selected to be used in analysis.  
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Disability weights for other ADR that are frequent during MDR/RR-TB were also reviewed. Few weights were 
available from the South African study, but again the differences between the SA study and the global and 
European contexts were marked. For major depressive disorder Table 2-12, which may occur during 
MDR/RR-TB treatment, either because of the disease and its poor outcomes or as an adverse drug reaction 
to the terizidone, the SA disability weightings were the lowest among reviewed weights (0.344 for severe 
episode).[79] A meta-analysis of the safety of cycloserine and terizidone included reports of 450 patients 
treated with terizidone across 10 studies, 72% of the patients were from South Africa.[147] Three-quarters 
of the reports of ADR were psychiatric, including psychoses (14%), depression (7%), suicidal ideation (2%), 
and suicide (1%).[147]   
Table 2-12 Disability weights for major depressive disorder using the Global Burden of Disease methodology  
Description Value (95% CI) Source 
Major depressive disorder: mild episode has con-
stant sadness and has lost interest in usual activities. 
The person can still function in daily life with extra 
effort, but sleeps badly, feels tired, and has trouble 
concentrating. 
0.159 (0.107 – 0.223) GBD 2010, [74] 
Major depressive disorder: moderate episode has 
constant sadness and has lost interest in usual activi-
ties. The person has some difficulty in daily life, 
sleeps badly, has trouble concentrating, and some-
times thinks about harming himself (or herself). 
0.406 (0.276-0.551) GBD 2010, [74] 
Major depressive disorder: moderate episode 0.294 (0.248 – 0.341) Europe [77] 
Major depressive disorder: moderate episode 0.270 (0.192 – 0.317) South Africa [79] 
Major depressive disorder: severe episode has over-
whelming, constant sadness and cannot function in 
daily life. The person sometimes loses touch with re-
ality and wants to harm or kill himself (or herself). 
0.655 (0.469 – 0.816) GBD 2010, [74] 
Major depressive disorder: severe episode 0.571 (0.509 – 0.635) Europe [77] 
Major depressive disorder: severe episode 0.344 (0.224 – 0.436) South Africa [79] 
^ Bolding indicates value selected to be used in analysis.  
In contrast, the SA disability weights for moderate anaemia (0.298, [79]) were nearly 2-times greater than 
the 0.149 value of the GBD 2013.[75] Linezolid is associated with anaemia (low red blood cell count) during 
MDR/RR-TB treatment, as well as leukopenia (low white blood cell count) and thrombocytopenia (low plate-
let count).[148]  In a systematic review of linezolid for the treatment of MDR/RR-TB, 58.9% of the 107 pa-
tient reports reviewed experienced ADR associated with linezolid use, of which 68.4% had major ADR, de-
fined as requiring interruption or cessation of linezolid. Most common were anaemia (38.1%) and peripheral 
neuropathy (47.1%), but also thrombocytopenia (11.8%).[148] In South Africa, now that linezolid is available 
on public tender, it is commonly prescribed alongside bedaquiline for pre/XDR-TB.[19] in the most recent 
GBD study (2016) disability weights for TB with HIV/AIDS were estimated for drug-susceptible, MDR/RR, and 
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XDR-TB according to the occurrence and severity of anaemia.[107] The combined disability weights used for 
HIV/TB co-infection in the 2016 GBD ranged from 0.408 (95% CI: 0.274–0.549) for disease without anaemia 
to 0.495 (95%CI 0.353–0.64) for HIV/TB disease with severe anaemia, a difference in weight of 0.087.[107] 
Thus, the combined disability weights of the 2016 GBD are equivalent to the 2013 GBD disability weights 
combined for the co-morbidity using a the multiplicative method described previously [80,83]. For example, 
person who has TB with HIV infection (2013 dw = 0.408, converted score = .592) who has severe anaemia 
(2013 dw=0.149, converted score=0.851) would have a combined score of 0.504 or disability weight of 
0.496.[75]  
Table 2-13 Disability weights for anaemia disorder using the Global Burden of Disease methodology 
Description Value (95% CI) Source 
Anaemia, moderate feels moderate fatigue, weak-
ness, and shortness of breath after exercise, making 
daily activities more difficult. 
0.058 (0.038-0.086) GBD 2010, [74] 
Anaemia, moderate 0.052 (0.034-0.076) GBD 2013, [75] 
Anaemia, moderate 0.045 (0.035-0.054) Europe [77] 
Anaemia, moderate 0.298 (0.189-0.388) South Africa [79] 
Anaemia, severe feels very weak, tired and short of 
breath, and has problems with activities that require 
physical effort or deep concentration. 
0.164 (0.112-0.228) GBD 2010, [74] 
Anaemia, severe 0.149 (0.101-0.209) GBD 2013, [75] 
Anaemia, severe 0.118 (0.098-0.145) Europe [77] 
Note: in the analysis presented in Chapter 8, disability weights from anaemia and other ADR experienced 
during MDR/RR-TB treatment were not added to the model 
Other conditions that are associated with ADR during MDR/RR-TB treatment are listed below (Table 2-14). 
Ethionamide, one of the core drugs for MDR/RR-TB treatment standard of care in South Africa and para-ami-
nosalicylic acid, used in individualized XDR-TB regimens [17,19], are both associated with hypothyroidism.  
The 2010 GBD did not include the condition; in the European disability weight study and the 2013 GBD, it 
was described as has a person who has ‘low energy and feels cold’.[75,77] Other symptoms are dry skin, con-
stipation, hair loss, and slow heart rate although the diagnosis in South Africa is usually made through rou-
tine testing of the thyroid stimulating hormone (TSH).during MDR/RR-TB treatment.  Half of a cohort of pa-
tients from Lesotho experienced elevated TSH levels [111], for example, and other studies in Southern Africa 
show similar high rates.[108,112,149] Moderate to severe hypothyroidism requires treatment with levothy-
roxine (assuming that the ethionamide cannot be interrupted).[17]   
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Table 2-14 Disability weights other ADR associated with MDR/RR-TB treatment using the Global Burden of 
Disease methodology 
Description Value (95% CI) Source 
Chronic kidney disease (stage IV) tires easily, 
has nausea, reduced appetite and difficulty 
sleeping 
0.105 (0.069-0.154) GBD 2010, [74] 
Chronic kidney disease (stage IV) 0.108 (0.09-0.132) Europe [77] 
End-stage renal disease: on dialysis sometimes 
feels tired and down, and has some difficulty 
with daily activities. 
0.573 (0.397 – 0.749) GBD 2010, [74] 
   
Diarrhoea: severe has diarrhoea three or more 
times a day with severe belly cramps. The per-
son is very thirsty and feels nauseous and 
tired.   
0.281 (0.184-0.399) GBD 2010, [74] 
Diarrhoea: severe 0.247 (0.164–0.348) GBD 2013, [75] 
Diarrhoea: severe 0.239 (0.202–0.285) Europe [77] 
   
Hypothyroidism 0.019 (0.010-0.032) 
 
GBD 2013, [75] 
Hypothyroidism has low energy and feels cold. 0.022 (0.017-0.028) Europe [77] 
Note: in the analysis presented in Chapter 8, disability weights from anaemia and other ADR experienced 
during MDR/RR-TB treatment were not added to the model 
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2.7 CONCLUSION AND UNANSWERED QUESTIONS 
This chapter reviewed existing literature with regards to the proposed CEA of the use of bedaquiline for 
MDR/RR-TB treatment. There are both conclusions that can be made from this review that will inform the 
methods and input parameters for the CEA and a set of unanswered questions that will be further investi-
gated through the remainder of the thesis.  
First, this chapter began by reviewing previously published CEA on MDR/RR-TB treatment and bedaquiline 
for MDR/RR-TB treatment. While these studies provided important insights, parameters, assumptions and 
model structures did not fit well with the current context and intervention mix and therefore it was not clear 
that it would be appropriate to use the results of the previously published literature. Thus, having reviewed 
the existing literature, the overall question of the thesis remains unanswered. 
• What is the incremental cost-effectiveness of a MDR/RR-TB treatment regimen inclusive of bedaqui-
line compared to an injection-based regimen in the South African context?  
It is noted here and will be discussed again in the limitations to the study (Chapter 9) that there is an unan-
swered question and continued uncertainty regarding the imbalance in mortality observed in the Phase 2b 
randomized clinical trial of bedaquiline.[30] This question cannot be completely resolved  using observa-
tional data such as what is presented here from the SA NTP roll-out of bedaquiline and will require reporting 
from the Phase 3 trial (underway) as well as active pharmacovigilance. Within the Phase 2b study, the pla-
cebo arm experienced mortality of 2.5% compared to bedaquiline at 12.7%.[30] Both arms of the study had 
mortality rates that were substantially lower than the approximately 20% mortality within the SA NTP 
MDR/RR-TB cohort, as is routinely reported to the WHO [2] and described in Chapter 3. If the relative risk 
from the Phase 2b study was applied to the SA mortality from the IA-based regimens (approximately 5 x 
higher for bedaquiline), the expected mortality from bedaquiline would be 100% mortality. This has not 
aligned to the experience with the roll-out in South Africa and thus was not used. Observational data from 
South Africa (2014 to 2016) was submitted to the WHO for its revision of the recommendations for bedaqui-
line.[32] Additionally, the guidelines development group assessed multiple studies that were similarly obser-
vational, mostly compassionate use access programmes such as the BCAP implemented in South Africa.[32–
34] While the consistency of the reported results from the observational studies was encouraging, “the 
panel emphasized that due to limitations in the design of these observational studies, potential serious bi-
ases could have been introduced, especially for outcome assessment.”[32] 
Secondly, the chapter reviewed the underlying assumption of the analysis; that CEA of the two interventions 
should be used to inform health policy. Thus, the second part of the chapter presented a review of the use of 
cost-effectiveness analysis for decision making with regards to health interventions. It is appropriate to con-
clude that CEAs are useful and important, although not sufficient, for policy making. For the context of South 
Africa and the interventions being compared, an ICER approach from a provider (the government of South 
Africa through the public health facilities) perspective which uses DALYs as the effectiveness will provide 
meaningful information for decision makers. With this conclusion, existing cost-effectiveness models and 
structures were reviewed to determine if appropriate for use in the South African context. It was found that 
while the health state models generally offered a useful framework for comparing MDR/RR-TB policies, that 
previously published model structures did not include health states for ambulatory (out-patient) MDR/RR-TB 
treatment or HIV/TB co-infection.  
• What is the impact of including HIV specific health states and costs in the cost effectiveness model 
for MDR/RR-TB in the context of a high burden of HIV/TB co-infection? 
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This chapter also reviewed the state of MDR/RR-TB in SA and the issues around HIV co-infection. It is clear 
that MDR/RR-TB is significant public health problem that consumes a high level of resources and represents 
a disease burden for the population. With the chapter, the context for the current standard of care and the 
proposed new intervention, a bedaquiline-based regimen, was also reviewed. The evidence that bedaquiline 
is an effective treatment for MDR/RR-TB has been reconfirmed by a WHO systematic review.[32] Remaining 
questions to be answered: 
• What is the timing of outcomes that occur before 18-24 months? 
• Do transition probabilities differ by HIV and ART status? 
• How does the interim effectiveness of bedaquiline for improved culture conversion translate into 
final MDR/RR-TB treatment outcomes?  
There is also strong evidence that ADR are common during MDR/RR-TB treatment. Although there is much 
evidence that ADR are frequent during MDR/RR-TB treatment, specification of the costs of ADR prevention, 
monitoring, and management during MDR/RR-TB treatment has not been the focus of the MDR/RR-TB cost 
analyses. This is in part due to the limited information about the costs of ADR management in particular; 
monitoring is often done according to guidelines and is included in many costs. Additionally, even where 
there is information about the costs of ADR management, it is difficult to apply across settings as manage-
ment depends on availability of services which may be quite specialized and expensive during treatment of 
MDR/RR-TB (e.g. dialysis and cochlear implants). Disability weights were also reviewed, and a local study was 
identified measuring the valuation of a South African community for different health states. The disability 
weights from the SA study [79] were found to be much different than those from the global [74,75] and Eu-
ropean contexts.[77] The following unanswered questions would need to be resolved for the inclusion of 
ADR impact within a cost-effectiveness model: 
• What is the frequency of specific ADR at specific severity during MDR/RR-TB treatment? 
• Do ADR occur at similar frequency, duration, and severity when HIV-infected or when on HIV treat-
ment? 
• What is the cost of ADR management, as a function of the expected costs and the expected frequen-
cies of ADR during MDR/RR-TB treatment? 
Finally, the literature review concludes that the overall question of the thesis is still unanswered.  
• Does the inclusion of the cost and burden of ADR associated with MDR/RR-TB treatment affect the 
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3 RESULTS: TIMING OF MORTALITY DURING MDR/RR-TB TREATMENT 
3.1 SYNOPSIS 
Formal citation: Schnippel K, Firnhaber C, Ndjeka N, Conradie F, Page-Shipp L, Berhanu R, Sinanovic E. Persis-
tently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. The 
International Journal of Tuberculosis and Lung Disease. 2017 Oct 1;21(10):1106-11.  
A 2015 meta-analysis which reported adult mortality in TB/HIV MDR/RR-TB patients of 1.8 to 87.8% (pooled 
proportion of 38%; 95%CI: 28 to 48.1%) indicated that the cohorts with the lower rates of mortality were  
likely to be more recent [12]. Older cohorts, with no or limited access to ART, had higher rates of mortality 
[12]. As ART eligibility criteria have expanded over time in South Africa, moving from a low CD4 (< 200 cells/ 
mm3) threshold in 2010 to ART for all HIV-positive regardless of CD4 by the end of 2016, this would be ex-
pected to improve survival of MDR/RR-TB patients co-infected with HIV. Other guidelines changes have also 
been implemented since 2011 in an effort to improve MDR/RR-TB treatment outcomes, including rapid mo-
lecular diagnostics and decentralized, deinstitutionalized treatment for MDR/RR-TB. This chapter consists of 
a manuscript which describes mortality in the national, public-sector 2012 to 2014 cohort (covering patients 
on treatment from 2012 to 2016).  
The study is limited by its use of the national, routinely captured treatment database, the EDRweb. Im-
portantly, EDRweb begins at the point of MDR/RR-TB treatment initiation rather than diagnosis. Patients 
who died or never initiated after diagnosis are likely different from those that did initiate treatment. The 
more limited cohort of survivors of the period from diagnosis to treatment initiation were not at risk of 
death, by the definition of the cohort (sometimes described as an ‘immortal bias’). The discussion and con-
clusions of this chapter address other limitations of the routinely captured data. 
Contribution to the thesis and novelty 
The TB and HIV epidemics in South Africa are both rapidly changing and diverse across the provinces. By ana-
lysing and presenting the most recent complete national cohorts for MDR/RR-TB, the results of this chapter 
improve the fit of the cost-effectiveness model and the generalizability of the results to the SA NTP. This pa-
per was the first to match the EDRweb dataset to the vital statistics register to validate the vital status of pa-
tients and to more precisely measure the timing of mortality. The finding that the mortality rates differ so 
substantially over the period of treatment has implications for cost-effectiveness and budgeting for the pro-
gram. For example, if mortality is within the first weeks, the expected cost saving from adoption of short-
course treatment may not be realized if it was assumed that most MDR/RR-TB patients incurred the full 
costs of long-course treatment.     
Role of the candidate 
Based upon the background and literature review, the candidate identified that it was necessary to extract 
transition probabilities for the MDR/RR-TB health state model from a dataset rather than from published 
literature. She received the national case register from the NDOH, merged the data with the vital statistics 
from the Department of Home Affairs, and created an analytic dataset. The candidate also designed and im-
plemented the statistical analysis, using tests of the Cox proportional hazards model to diagnose the change 
in hazards of mortality over time. She wrote the first draft of the manuscript and revised based on com-
ments from co-authors and from reviewers. The co-authors approved the final version.  
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Abstract 
Objective 
To describe timing and predictors of mortality of multi-drug and rifampicin-resistant tuberculosis (MDR/RR-
TB) patients reported from the South African electronic drug-resistant TB register 2012 - 2014. 
Design 
We present time to event survival analysis and Cox proportional hazards regression. Identity numbers were 
matched to the national vital statistics register. 
Results 
A total of 20,653 patients were included in the analysis, with a median age of 35 (IQR: 28, 43). Over half 
were male (53.0%, n=10,944). Most were HIV-positive (68.9%, n=14,174), most of whom were on antiretro-
viral therapy (ART, 88.0%, n=12,471).  
At 24 months, 4,689 patients had died (22.9%); 2,072 deaths (42.6%) were reported within 12 weeks of 
MDR/RR-TB treatment initiation. From week 12-24, there were 717 deaths/18,048 persons; 59.5% of the 
mortality occurred within the first 24 weeks.  
During the first 12 weeks, adjusted hazard of mortality was highest for patients missing a baseline culture 
result (aHR: 3.78, 95%CI: 2.94, 4.86) and HIV-positive, ART naïve (aHR: 3.40, 95%CI: 2.90, 3.99). Patients initi-
ating MDR/RR-TB treatment within 4 weeks of diagnosis had higher mortality compared to those with de-
layed initiation (aHR: 1.57, 95%CI: 1.41, 1.75).  
Conclusion 
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Background 
Rifampicin-resistant (RR) tuberculosis (TB), and multi-drug resistant (MDR-TB) that is resistant to both rifam-
picin and isoniazid is a growing public health concern. In 2015, there were 580,000 cases of MDR/RR-TB 
across the world and an estimated 190,000 persons with MDR/RR-TB died.[58] Globally, only 52% of 
MDR/RR-TB patients (2013 cohort) successfully completed treatment or were cured.[58] 
According to the WHO, South Africa has among the world’s highest burdens of MDR/RR-TB as well as drug-
sensitive TB and TB/HIV co-infection.[58] In 2015, there were 19,613 laboratory confirmed MDR/RR-TB cases 
diagnosed in South Africa.[58] UNAIDS estimates that 7.0 million South Africans are infected with HIV;[150] 
57% of the 294,603 reported TB cases in South Africa in 2015 were are HIV positive.[58] 
Prior to 2011, drug-resistance testing in South Africa was primarily phenotypic and targeted towards patients 
who were known contacts of MDR/RR-TB, had a prior history of TB treatment (any outcome), or who were 
failing first-line treatment (persistent smear positive). Genotypic testing for rifampicin and isoniazid re-
sistance using the Genotype MTBDRplus line probe assay (LPA, Hain Lifescience, Germany) became available 
from the National Health Laboratory Services (NHLS) in 2010. In 2011, NHLS implemented Xpert MTB/RIF 
(GeneXpert, Cepheid, USA) as the first-line test for TB in South Africa, replacing smear microscopy. In 2011, 
the South African National TB Programme (NTP) updated its treatment guidelines in alignment with the 2011 
WHO recommendations[16] and adopted a policy framework for decentralized, out-patient treatment initia-
tion for smear-negative MDR/RR-TB patients without additional drug resistance.[151] However, the routine 
recording and reporting mechanism, EDRweb, remained unchanged. 
Despite these policy changes, there were only modest gains in treatment success as reported in the EDRweb 
and deaths remained high. In the 2013 MDR/RR-TB cohort in South Africa (n=10,614), 48% were successfully 
treated and 22% died; compared to 45% success and 18% mortality for the 2011 MDR/RR-TB cohort 
(n=6,523).[58] The persistently high mortality is described by presenting survival analyses of routinely re-
ported data from the SA NTP for patients initiating MDR/RR-TB treatment from 2012 to 2014. 
 
Methods 
Standard of care 
Through 2016, the standard of care for MDR and RR-TB patients in South Africa was a standardized regimen: 
6 months of 5 drugs (kanamycin, moxifloxacin, ethionamide, terizidone, and pyrazinamide) followed by 12 to 
18 months of 4 drugs (moxifloxacin, ethionamide, terizidone, and pyrazinamide).[17,19] Since 2011, pro-
vider-initiated HIV counselling and testing for all MDR/RR-TB patients is standard of care in South Africa. As 
per guidelines, antiretroviral therapy (ART) should be fast tracked in ART-naïve HIV-positive MDR/RR-TB pa-
tients regardless of CD4 count.  
Inclusion and exclusion 
All drug-resistant TB cases registered within the South African electronic drug-resistant TB register (EDRweb) 
was exported on 5 May 2016. Cases initiating treatment before 1 January 2012 or after 30 April 2014 were 
excluded. Each patient contributed at least 24 months of follow-up time prior censoring at 30 April 2016. 
Patients reported as transferred in or out; with missing or invalid treatment initiation dates; without docu-
mented rifampicin resistance; with XDR-TB or had documented resistance to fluoroquinolones (e.g. ofloxacin 
or moxifloxacin) or second-line injectable drugs (e.g. amikacin, kanamycin, or capreomycin); or who died on 
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or before day of treatment initiation were excluded from the analysis (Figure 3-1). Starting from 6 months 
prior to the analysis period (i.e. from 1 July 2011), where two or more cases had identical SA identity (ID) 
numbers and/or combination of surname, date of birth, and sex, the initial case record was maintained and 
subsequent case records excluded.  
Time to event 
The primary outcome for analysis was all-cause mortality. Final treatment outcomes (cure, treatment com-
pletion, treatment failure, and loss from treatment) including death from any cause are reported in EDRweb 
as per WHO definitions.[18] Valid patient SA ID numbers from EDRweb were matched to the national vital 
statistics register (through April 2016) to ascertain any additional report of deaths during the 24 months of 
follow-up. Deaths from either the EDRweb or the vital statistics register were combined. 
Time to event analysis started from the date of MDR/RR-TB treatment initiation.  The date of death was ob-
tained from the vital statistics register, otherwise the EDRweb date of final treatment outcome was used. 
Deaths from the vital statistics register were censored at 24 months, according to cohort reporting stand-
ards. For patients missing an outcome, data was censored at 24 months and patient assumed to be alive. 
Definitions and statistical analysis 
HIV status was categorized as HIV negative, HIV-positive on ART, HIV-positive and no ART reported (ART na-
ïve), or HIV status unknown. Characteristics of the TB disease included method of diagnosis (phenotypic, 
LPA, Xpert MTB/RIF, or could not be determined), extrapulmonary or pulmonary TB, history of previous TB 
treatment or no TB history reported, initial sputum smear microscopy results (negative, positive, or not re-
ported), and initial sputum culture results (negative, positive, or contaminated or not reported).  
All analyses were done in Stata v14 (College Station, TX). Cox proportional hazards were estimated, adjusted 
by co-variates, and results presented with 95% confidence intervals (CI). Proportional hazards assumption 
was tested using scaled Schoenfeld residuals. Based on the non-proportionality of the entire 24 months, 
analysis was split into 0 to 12 weeks, 12 to 24 weeks, and 24 to 104 weeks.   
 
Ethics 
The study protocol was approved by the Human Research Ethics Committees of the University of Witwaters-
rand (#M150340, March 2015) and the University of Cape Town (490/2015, July 2015). The requirement to 
obtain informed patient consent for individual patients was waived for this retrospective analysis of rou-
tinely reported data.  
 
Results 
Baseline characteristics of the 20,653 patients contributing follow-up time are presented in Table 3-1. The 
median age at initiation was 35 (IQR: 28, 43) and 53.0% were male (n=10,944). Most were HIV-positive 
(68.9%, n=14,174), most of whom were on ART (88.0%, n=12,471/14,174). Nearly half (45.2%, n=9,481) did 
not have history of prior TB treatment documented in the register.  
Vital status was ascertained for 46.0% (n=9,503) of the cohort. HIV-positive patients on ART (48.9%, 
n=6,100/12,471) and HIV-positive, ART naïve patients (48.7%, n=829/1,703) were more likely to have been 
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matched to the vital statistics register compared to HIV-negative (40.0%, n=2,236/5,596) and HIV status un-
known (38.3%, n=338/883); Pearson chi-squared test p-value<0.000. There were 4,980 deaths from any 
source (Table 3-2). These included 4,199 deaths reported in EDRweb, 490 deaths ascertained from the vital 
statistics register and included in the analysis, and 291 deaths reported only in the vital statistics register 
which were censored at 24 months and patients analysed as alive. Nearly all (89.6%, n=4,199) of the 4,689 
deaths (22.7% of the cohort) were reported in EDRweb. The majority (57.1%, n=280/490) of newly ascer-
tained deaths were among EDRweb patients reported as lost from treatment; this represented 6.3% of the 
total loss from treatment (n=280/4,478). Patients missing an EDRweb treatment outcome accounted for 
19.4% (n=95/490) of the newly ascertained deaths.   
There were 2,072 deaths reported within 12 weeks (44.2% of 4,689), an incidence rate of 8.99 deaths per 
1,000 person-weeks. From week 12 to 24, 18,048 persons remained and experienced 717 deaths; the inci-
dence rate was 3.46 deaths per 1,000 person-weeks. From week 24 to 104, the 16,615 persons remaining 
experienced 1,790 deaths, an incidence rate of 1.78 per 1,000 person-weeks. 
Figure 3-2 and Figure 3-3display the Kaplan-Meier survival curves for all MDR/RR-TB patients and for pa-
tients disaggregated according to their HIV status. HIV-positive ART naïve and HIV-unknown patients experi-
enced the worst survival rates (p<0.000, log-rank test). Cox proportional hazards analysis results are pre-
sented in Table 3-3 separately for the initial 12 weeks, week 12 to 24, and week 24 to 104. During the first 12 
weeks, patients with a missing or contaminated baseline culture result (aHR: 3.78, 95%CI: 2.94, 4.86) and 
ART naïve HIV-positive (aHR: 3.40, 95%CI: 2.90, 3.99) had the highest reported adjusted hazard of mortality. 
During this period, patients initiating MDR/RR-TB treatment within 4 weeks of diagnosis had a higher ad-
justed hazard of mortality compared to those with delayed initiation (aHR: 1.57, 95%CI: 1.41, 1.75).  
Baseline characteristics less strongly predicted mortality or survival after the initial 24 weeks. While the pa-
tients who were ART naïve HIV-positive at baseline were still at the highest risk of mortality during the pe-
riod 24 to 104 weeks (aHR: 1.56, 95%CI: 1.28, 1.89), this risk was similar to patients on ART (aHR: 1.51, 
95%CI: 1.34, 1.69). Adjusted hazards of mortality increased for males, for patients with a history of prior TB 
treatment, for patients initiating in 2013, and for patients missing a diagnosis date after the initial 24 weeks 
but were lower for other baseline characteristics tested. 
 
Discussion 
In 2011, South Africa updated its standardized treatment regimen for MDR/RR-TB, adopted rapid genotypic 
testing for TB and rifampicin resistance, and increased access to MDR/RR-TB treatment with the decentrali-
zation of care and introduction of outpatient initiation of second-line treatment.[152] Yet, mortality during 
MDR/RR-TB treatment has remained persistently high, at 18% in the 2011 cohort and 22% in the 2013 co-
hort.[58] We analysed cases reported in EDRweb from 2012 to 2014 and found 44.2% of the deaths occurred 
within the first 3 months of the 24 months of MDR/RR-TB treatment. The estimated incidence rate was 8.99 
deaths/1,000 person-weeks before week 12 compared to 1.78/1,000 person-weeks after week 24. 
The persistent high mortality in the SA NTP treatment cohort may reflect improved linkage to care (reduc-
tion in initial loss to follow up) - as fewer are dying prior to treatment initiation (e.g. at home or in commu-
nity) but are instead dying while on treatment and, thus, now recorded. One study from South Africa 
demonstrated that mortality immediately following sputum collection for the diagnosis of MDR-TB was 
high[153], but the time period from sputum collection until treatment initiation is not captured within 
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EDRweb’s treatment cohort. Another study on the linkage to treatment after diagnosis showed that 17.5% of 
a South African cohort died before initiation in the period 2011-2012 when the median days to initiation was 
33; in 2013-2014, 5.8% died before initiation with median of 14 days to initiation.[154] Multiple studies in 
South Africa have confirmed that the introduction of decentralized, outpatient care[155] and rapid molecu-
lar diagnosis reduced the time to treatment initiation from months to days.[103,156,157] The cohort ana-
lysed here does show approximately ½ of the patients initiated MDR/RR-TB treatment within 4 weeks of di-
agnostic sputum collection. However, the earlier initiation was associated with a higher mortality hazard, 
suggesting that the more ill patients with a higher risk of death are now able to start on treatment prior to 
death, but are still at high risk of death.    
While there was significant non-reporting of the SA identity number (53.6%) required for ascertaining vital 
status, nearly all of the deaths identified in the vital statistics register were also reported within EDRweb 
(89.6%). HIV-positive patients were more likely to have had an SA ID recorded and therefore an opportunity 
to ascertain the additional mortality from the vital statistics register. The number of patients lost to follow-
up as per EDRweb now found to have died was low--6.3% of all patients (n=280/4,478), or 16.1% of patients 
with valid ID (n=280/1,744). These findings were different compared to the over 30% mortality among HIV-
positive patients lost to follow-up from an ART clinic in Johannesburg, South Africa.[158] Further research is 
needed to understand whether these surviving patients are truly no longer in treatment and doing well or if 
the case register was not able to identify that patients have returned to treatment, changed treatment sites 
within South Africa, or emigrated from South Africa.   
Limitations 
The large cohort size and real-world experience captured in EDRweb are strengths of this analysis, however, 
routinely collected data also has limitations in its completeness. A 2012 review of paediatric clinical records 
in one province found that 1/3 of patients were not recorded in EDRweb.[102] A national analysis for a sam-
ple of 2011 and 2013 adults initiating MDR/RR-TB treatment, only 62% and 53%, respectively, were reported 
in EDRweb.[103] Reasons why patients were included or not included in EDRweb was not explored In this 
analysis. If SA NTP MDR/RR-TB patients not reported in EDRweb differ in terms of baseline characteristics or 
treatment outcomes from those in the EDRweb, the analysis presented here would provide more under-
standing of the treatment cohorts reported to the WHO, but may not reflect the SA NTP as a whole.    
Another limitation of this study is that aside from HIV status and sputum smear positivity, few other indica-
tors of physical condition or mortality risk factors are included in EDRweb, such as hospitalization, other 
comorbidities, body mass index, serum albumin, or haemoglobin. For HIV-positive patients, the date of ART 
initiation and information on CD4 count at baseline or at any point during MDR/RR-TB treatment is not rou-
tinely captured, so the mortality observed here could not be analysed by CD4 strata. Given the high mortal-
ity for ART naïve, HIV/TB co-infected patients[159] and guidelines for immediate ART initiation[17], it is pos-
sible that the HIV-positive not on ART who survived the full 104 weeks were initiated on ART but EDRweb 
was not updated. Inclusion of persons on ART in the category would underestimate the risk of mortality for 
these patients. Similarly, mortality for HIV-positive patients newly initiating ART (<6 months) is higher than 
for patients who are stable on ART treatment[159], but without start date or ART duration this could not be 
differentiated in the current analysis. Published cohorts from South Africa indicate approximately 40% of pa-
tients ‘on ART’ during MDR/RR-TB treatment initiated ART after initiating MDR/RR-TB.[127,128] In light of 
the very high and rapid mortality reported here, additional monitoring, more frequent visits, or access to in-
patient or step-down care until stabilized on MDR/RR-TB treatment, including patients who are HIV-positive 
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and not virally suppressed, may be required for some patients. It is important to note that the association of 
HIV with early mortality shown here cannot indicate direction or causality. ART naïve, HIV-positive patients 
shown to have higher mortality are unlikely to have been in care for their HIV prior to the MDR/RR-TB diag-
nosis and therefore more likely to have been in poorer health. Similarly, the high adjusted hazard of mortal-
ity for patients missing their baseline sputum culture result may have been because patients died prior to 
providing sputum for testing. 
While 59% deaths occurred within the first 24 weeks from initiation of MDR/RR-TB treatment, mortality con-
tinues throughout the 24 months of follow-up and following treatment completion (as evidenced by censor-
ing of deaths identified through the vital statistics register). Baseline characteristics analysed here did not 
help in identifying who was at highest risk for this later mortality. Extent of damage to the lungs, relapse, de-
velopment of new resistance, poor adherence to second-line TB treatment, poor adherence or inadequate 
viral suppression on ART for HIV-positive patients, intolerance and toxicity to treatment regimens, and other 
medical or social predictors of this late mortality need to be further explored to improve survival.   
 
Conclusions 
Processes and data collection tools to link diagnosed TB patients with TB treatment initiation have important 
limitations which need to be addressed to optimally inform policy recommendations. Persistently high mor-
tality during MDR/RR-TB treatment in South Africa was highest in the first 12 weeks following treatment ini-
tiation.   
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Figures 
Figure 3-1 Cohort inclusion 
 
Duplicate case record: Same date of treatment initiation, treatment site and either SA ID number or combi-
nation of surname, date of birth, and sex 
Prior case record: Same SA ID number or combination of surname, date of birth, and sex as a case record 
with different treatment initiation date during the period 1 July 2011 to 30 April 2014. Initial case record in 
period was maintained and subsequent record(s) excluded.   
All records 1 January 
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Tables 
Table 3-1 MDR/RR- TB case outcomes, change in outcomes once matched to vital status registry (n=20,653) 
  All MDR/RR-TB 
  n=20,653 
Sex Male 10,944 (53.0%) 
 Female 9,709 (47.0%) 
Age Median (IQR) 35 (IQR: 28, 43) 
HIV status HIV-negative 5,596 (27.1%) 
 HIV+, on ART 12,741 (60.4%) 
 HIV+, not on ART 1,703 (8.2%) 
 HIV unknown 883 (4.3%) 
History of TB treatment No history or missing 9,329 (45.2%) 
 Prior TB 11,324 (54.8%) 
ID number Vital status ascertained 9,503 (46.0%) 
 South African ID missing or invalid 11,150 (54.0%) 
Site of TB Pulmonary 17,169 (83.1%) 
 Extrapulmonary 281 (1.4%) 
 Missing 3,203 (15.5%) 
Diagnostic method^ Phenotypic 1,418 (6.9%) 
 Line probe assay 10,521 (50.9%) 
 Xpert MTB/RIF 7,391 (35.8%) 
 Could not be determined 1,323 (6.4%) 
Base or initial smear Negative 6,250 (30.3%) 
 Positive 9,937 (48.1%) 
 Missing 4,466 (21.6%) 
Base or initial culture Negative 2,202 (10.7%) 
 Positive 13,361 (64.7%) 
 Contaminated or missing 5,090 (24.6%) 
Year treatment start 2012 7,308 (35.4%) 
 2013 9,710 (47.0%) 
 2014 (January – April) 3,635 (17.6%) 
Time to initiation < 4 weeks from diagnosis sputum date 9,907 (48.0%) 
 After 4 weeks 7,250 (35.1%) 
 Could not be determined 3,496 (16.9%) 
ART: Anti-retroviral therapy; ID: identity number; IQR: inter-quartile range; Xpert MTB/RIF: GeneXpert for 
mycobacterial tuberculosis and rifampicin resistance 
^ Calculated using earliest sputum date for a rifampicin resistant result. Could not be determined includes patients who 
were categorized as “Laboratory confirmed MDR-TB” but without a reported rifampicin resistant laboratory test date.  
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Table 3-2 MDR/RR-TB case outcomes, updated vital status (n=20,653) 
 EDRweb Change (% difference 
from EDRweb) 
Vital status updated 
All patients (n=20,653)    
Died 4,199 (20.3%) +490 (11.7%)  4,689 (22.7%) 
Lost from treatment 4,478 (21.7%) -280 (6.3%) 4,198 (20.3%) 
Missing results 1,550 (7.5%) -95 (6.1%) 1,455 (7.0%) 
Failed treatment 559 (2.7%) -50 (8.9%)  509 (2.5%) 
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Table 3-3 Cox proportional hazards with 95% confidence (CI) intervals for mortality during MDR/RR-TB, ad-
justed by baseline patient characteristics 
  aHR (95%CI) aHR (95%CI) aHR (95%CI) 
All patients  0 to 12 weeks  
N=20,653 
12 to 24 weeks 
N=18,048 
24 to 104 weeks 
N=16,615 
 Deaths 2,072 717 1,790 
Sex Female Referent Referent Referent 
 Male 0.89 (0.81, 0.97) 0.98 (0.85, 1.14) 1.15 (1.04, 1.26) 
Age Years 1.03 (1.03, 1.03) 1.02 (1.02, 1.03) 1.02 (1.01, 1.02) 
History No history reported Referent Referent Referent 
 Prior TB treatment 0.90 (0.81, 0.97) 1.01 (0.86, 1.17) 1.32 (1.20, 1.46) 
HIV status HIV negative Referent Referent Referent 
 HIV+, on ART 1.95 (1.73, 2.21) 1.76 (1.44, 2.14) 1.51 (1.34, 1.69) 
 HIV+, not on ART 3.40 (2.90, 3.99) 2.50 (1.88, 3.32) 1.56 (1.28, 1.89) 
 HIV unknown 2.08 (1.69, 2.57) 2.08 (1.45, 2.98) 1.49 (1.16, 1.92) 
Site of TB Pulmonary TB* Referent Referent Referent 
 Extrapulmonary TB 1.08 (1.04, 1.12) 1.09 (1.02, 1.16) 1.01 (0.96, 1.05) 
Diagnostic method Phenotypic Referent Referent Referent 
 Line probe assay 1.15 (0.95, 1.39) 1.25 (0.89, 1.77) 0.90 (0.75, 1.08) 
 Xpert MTB/RIF 0.97 (0.80, 1.19) 1.14 (0.80, 1.63) 0.89 (0.73, 1.08) 
 Not reported 1.11 (0.87, 1.41) 1.52 (0.99, 2.34) 0.91 (0.72, 1.18) 
Base or initial smear Negative Referent Referent Referent 
 Positive 1.18 (1.05, 1.33) 1.21 (1.00, 1.46) 1.12 (1.00, 1.26) 
 Missing or unknown 1.56 (1.35, 1.79) 1.37 (1.07, 1.76) 1.02 (0.87, 1.20) 
Base or initial culture Negative Referent Referent Referent 
 Positive 2.34 (1.85, 2.97) 1.32 (0.99, 1.77) 1.31 (1.10, 1.56) 
 Contaminated or unknown 3.78 (2.94, 4.86) 1.59 (1.14, 2.22) 1.52 (1.24, 1.86) 
Vital status No valid South African ID Referent Referent Referent 
 Confirmed in register 0.71 (0.65, 0.77) 1.00 (0.86, 1.16) 1.06 (0.96, 1.16) 
Year initiate 2012 Referent Referent Referent 
 2013 0.98 (0.88, 1.09) 0.93 (0.78, 1.11) 1.15 (1.03, 1.29) 
 2014 0.87 (0.76, 1.00) 0.83 (0.66, 1.05) 0.87 (0.75, 1.01) 
Time to initiation after 4 weeks Referent Referent Referent 
 within 4 weeks of diagnosis 1.57 (1.41, 1.75) 1.52 (1.27, 1.81) 1.29 (1.16, 1.44) 
 Could not be determined 1.02 (0.88, 1.20) 0.96 (0.73, 1.25) 1.28 (1.10, 1.50) 
 
Bolded text indicates statistical significance at p<0.05  
aHR: adjusted proportional hazard ratio; ART: Anti-retroviral therapy; ID: identity number; Xpert MTB/RIF: 
GeneXpert for mycobacterial tuberculosis and rifampicin resistance 
* Pulmonary TB includes cases with both extrapulmonary sites and pulmonary TB and those cases with no 
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4 RESULTS: TYPES AND SEVERITY OF ADR DURING MDR/RR-TB TREATMENT 
4.1 SYNOPSIS  
Formal citation: Schnippel K, Berhanu RH, Black A, Firnhaber C, Maitisa N, Evans D, Sinanovic E. Severe ad-
verse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Af-
rica: a retrospective cohort study. BMC Infectious Diseases. 2016 Oct 21;16(1):593.  
This chapter presents data collected through a retrospective, patient-level medical file review at two Johan-
nesburg MDR/RR-TB clinics. The frequency, types, severity and outcomes of adverse events documented in 
the files are described. The published manuscript also reports on patient characteristics and treatment char-
acteristics associated with the most frequent and most severe events with the intent that if adverse events 
can be predicted they can be prevented or mitigated. The retrospective clinical file review was designed to 
address the first objective of the overall thesis, to describe the overall frequency, type, and severity of ADR 
experienced during MDR/RR-TB treatment. The cohort consists of a census of all eligible patients who initi-
ated treatment at one of two large, public-sector MDR/RR-TB outpatient clinics located within the Helen Jo-
seph and Charlotte Maxeke Academic Hospitals, respectively, in Johannesburg, South Africa. 
Contribution to the thesis and novelty 
Previous observational studies and meta-analysis of ART during MDR/RR-TB treatment had not been satisfy-
ing in establishing whether initiation of treatment for both HIV and MDR/RR-TB within weeks of each other 
was the safest course of action. This chapter presents a novel analysis which could help to explain why even 
the direction of the evidence as to the impact of ART initiation on ADR during MDR/RR-TB treatment was 
uncertain: competing risks. The methodology for competing risks analysis is now common to studies on can-
cer recurrence; it is now standard practice to adjust the risk of cancer recurrence having accounted for the 
possibility that the cancer did not recur because the patient died. This manuscript was the first publication to 
use the methodology to adjust the incidence of ADR: patients with the highest risk of mortality (those who 
are HIV-positive and not stable on ART prior to MDR/RR-TB treatment initiation) also have the highest risk of 
ADR.      
Role of the candidate 
The candidate worked with the clinicians to design a case record form and database to extract relevant fields 
from the medical records and reviewed and queried data captured. She designed and implemented the sta-
tistical analysis, and explained the importance of its use both to the co-authors and through the methods 
section for reviewers and readers. The candidate wrote the first draft of the manuscript and revised based 
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Abstract 
Background:  
According to the World Health Organization, South Africa ranks as one of the highest burden of TB, TB/HIV 
co-infection, and drug-resistant TB (DR-TB) countries. DR-TB treatment is complicated to administer and re-
lies on the use of multiple toxic drugs, with potential for severe adverse drug reactions. We report the occur-
rence of adverse events (AEs) during a standardised DR-TB treatment regimen at two outpatient, decentral-
ized, public-sector sites in Johannesburg, South Africa. 
Methods: 
We reviewed medical records of the six-month intensive treatment phase for rifampicin-resistant (RR) TB 
patients registered May 2012 - December 2014. Patients contributed follow-up time until death, loss from 
treatment, censoring (6 months) or data extraction. A standardized regimen of kanamycin, moxifloxacin, 
ethionamide, terizidone, and pyrazinamide was used according to national guidelines. AEs were graded using 
the AIDS Clinical Trial Group scale. We present subhazard ratios from competing risk analysis for time to se-
vere AE, accounting for mortality and loss from treatment.  
Results: 
Across the two sites, 578 eligible patient files were reviewed. 36.7% were categorized as low weight (<50 kg) 
at DR-TB initiation. 76.0% had no history of TB treatment prior to the current episode of RR-TB. 26.8% were 
diagnosed with RR-TB while hospitalized, indicating poor clinical condition. 82.5% of patients were also HIV 
positive, of whom 43.8% were on ART prior to RR-TB treatment and 32.1% initiated ART with or after RR-TB 
treatment. Median CD4 count was 114.5 (IQR: 45-246.5). Overall, 578 reports of AEs were captured for 204 
patients (35.3%) and 110 patients (19.0%) had at least one severe AE reported. Patients with at least one AE 
experienced a median of 3 (IQR: 2-4) AEs per patient. HIV-positive patients with CD4 counts <100 cells/mm3 
and those newly initiating ART were more likely to experience a severe AE (sHR: 2.76, 95% CI:  1.30 – 5.84 
and sHR: 3.07, 95% CI:  1.46 – 6.46, respectively).  
Conclusion:  
Severe AE are common during the first 6 months of RR-TB treatment and HIV-positive patients newly initiat-
ing ART have the highest subdistribution hazard ratio for severe AE, accounting for the competing risks of 
death and loss from treatment.  
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Introduction 
South Africa has  made progress in controlling the TB epidemic; the 2015 Global Tuberculosis Report high-
lights a declining incidence and prevalence of TB for South Africa [160].  Despite the progress seen tubercu-
losis has been the most common cause of death in South Africa from 2005-2014 [161] and the, number of 
persons diagnosed with drug-resistant (DR-TB) TB has increased significantly over the last decade from 2,000 
patients in 2005 to 18,734 in 2014 [160].  
In 2011, South Africa adopted a policy of universal rifampicin (RIF) resistance testing using Xpert MTB/RIF 
(Cepheid, USA) as the first-line TB diagnostic in the country. Reporting of DR-TB now focuses on RIF resistant 
TB (RR-TB), which includes RIF resistance with unknown or pending sensitivities to other drugs, mono-RIF 
resistant TB, multi-drug resistant (MDR) TB that is resistant to both RIF and isoniazid (INH),  extensively drug 
resistant (XDR) TB which is MDR TB plus resistance to second-line drugs from the fluoroquinolone and inject-
able aminoglycoside or cyclic peptide classes, or preXDR TB which is MDR TB plus resistance to either a fluo-
roquinolone or a second-line injectable drug [18]. The South African National TB Programme (NTP) treat-
ment guidelines for RR-TB indicate 18-24 months of treatment [17]. All RR-TB patients are  started on the 
standardized second-line MDR TB regimen until further resistance is either confirmed or ruled-out at which 
point the patient may be switched to an individualized second-line TB regimen (if preXDR or XDR TB) or INH 
may be added to the regimen (if mono-RIF resistant) [17].  
Second-line TB treatment is complicated to administer, with frequent and potentially severe adverse drug 
reactions (ADR) [3,117]. Adding to the complexity of treatment, an estimated 60% of all TB patients [160] 
and up to 80% of RR-TB patients in South Africa [13] are also HIV-infected and therefore eligible for an-
tiretroviral therapy (ART). RR-TB treatment and ART present overlapping toxicities which may be worsened 
by concomitant use, for example both kanamycin and tenofovir may cause renal dysfunction [136].  
ADR can negatively impact the effectiveness of RR-TB treatment in many ways. Patients or clinicians may in-
terrupt, reduce dosage, or stop treatment in an attempt to alleviate side effects. This results in an increased 
risk of acquiring additional drug resistance, failing treatment, or dying from TB. ADR themselves may also 
result in hospitalization, permanent disability, or death. Only 49% of the 2012 cohort of MDR TB patients in 
South Africa were cured or successfully completed treatment, below both the global average (50%) and tar-
gets (75%) [160]. Thus, evidence of the burden and risks of ADR during RR-TB treatment is important for 
both patients and clinicians to manage this complexity. In order to quantify the burden of ADR during outpa-
tient RR-TB treatment in the context of high co-infection with HIV, we present the results of a medical file 
review of routinely reported adverse events (AE) from two decentralised public-sector sites within South Af-
rica.   
 
Methods 
The study was conducted at the TB Focal Point clinics at Helen Joseph and Charlotte Maxeke Academic Hos-
pitals in Johannesburg, South Africa. Patients with laboratory diagnosis of pulmonary or extrapulmonary RR-
TB are referred to these NGO-supported, outpatient, public-sector facilities for initiation of second-line TB 
treatment and further drug resistance testing. Patients are referred from surrounding primary health care 
centres, private facilities, Helen Joseph and Charlotte Maxeke inpatient wards, and surrounding hospitals. A 
census of medical files for patients who enrolled for second-line TB treatment at Helen Joseph (May 2012 to 
June 2014) or Charlotte Maxeke (May 2012 to December 2014) were reviewed retrospectively in September 
2014 and April 2015, respectively. Only patients with documentation of at least rifampicin resistance, i.e. RIF 
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resistance detected by Xpert, RIF mono-resistance or MDR-TB diagnosed by LPA, poly resistance, or XDR TB 
were included in the study.   
Standard of care treatment 
Upon referral the patient undergoes HIV counselling and testing, patients are educated about the length and 
toxicities of RR-TB treatment, and given resources for screening of exposed family members. Patients are 
then examined and evaluated by a medical officer. All RIF resistance diagnosed by Xpert is treated presump-
tively as MDR-TB as per the South African National TB Programme (NTP) guidelines [17]. The intensive phase 
of treatment (approximately 6 months) consists of a five-drug regimen including the second-line injectable 
kanamycin, moxifloxacin, ethionamide, terizidone, and pyrazinamide [16,17]. The continuation phase of 
treatment (18 to 24 months) includes moxifloxacin, ethionamide, terizidone, and pyrazinamide. Treatment 
dose is adjusted for patient weight, with patients 33 to 50 kg receiving smaller doses of kanamycin (500 - 750 
mg vs. 1000 mg), ethionamide (500 mg vs. 750 mg), and pyrazinamide (1000 – 1750 mg vs. 2000 – 2500 mg) 
than patients weighing 51 to 70 kg [17]. Linezolid and bedaquiline were not available at the study sites dur-
ing the study period [19]. 
Since 2010, all HIV-positive patients with RR-TB in South Africa are eligible for antiretroviral therapy (ART) 
initiation regardless of CD4 count [101] within two weeks of RR-TB treatment initiation. The 2010 South Afri-
can ART guidelines also indicated eligibility for HIV-infected patients with TB co-infection at CD4 <350 cells 
mm3 and for any patient with CD4 <200 cells mm3 [101]. Eligibility was expanded in 2013 to include all pa-
tients with any TB to include all patients with CD4 count <350 cells mm3 [162]. Patients not currently on ART 
are initiated at the RR-TB site and patients currently on ART can receive ART from the RR-TB site for the du-
ration of second-line TB treatment. From 2010, most South African ART patients in the public sector are initi-
ated on a standard, first-line three-drug regimen of tenofovir, efavirenz or nevirapine, and lamivudine or 
emtricitabine. From 2013, a fixed-dose combination of tenofovir, efavirenz, and emtricitabine has been the 
preferred first-line ART regimen [162].  
Patients are asked to return at two weeks and subsequently reviewed monthly by a TB nurse or medical of-
ficer for adherence to therapy, evaluation of side effects and treatment response. Sputum samples for smear 
microscopy and TB culture are collected monthly in pulmonary TB patients to assess for sputum smear and 
culture conversion. As per NTP treatment guidelines, baseline laboratory tests are conducted prior to treat-
ment initiation to assess for anaemia and renal, thyroid and liver function. If HIV co-infected, laboratory tests 
to monitor HIV treatment (CD4 count and HIV viral load) or ART toxicities are integrated. Every two months 
during the six-month intensive phase of treatment blood work is repeated. Additional or more frequent la-
boratory testing may be ordered if clinically indicated. Audiology testing for hearing loss is conducted 
monthly during the six month intensive phase due to the high rates of aminoglycoside induced hearing dys-
function [116]. Electrocardiograms for monitoring were not included in the guidelines for the standard RR-TB 
regimen at the time of the study.  
Adverse events and drug reactions 
For most of the period under review, pharmacovigilance requirements were for targeted spontaneous re-
porting to the national regulatory agency, the Medicines Control Council. Programmatic pharmacovigilance 
for HIV and TB, including RR-TB was in the process of being rolled out by the National Pharmacovigilance 
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Centre [163]. According to the regulatory form which is separate from the medical file, ‘advice about volun-
tary reporting’ requests clinicians to please report all ‘serious reactions and interactions with all products’ to 
the Medicines Control Council.   
Most of the AEs identified in this file review were found in the clinical progress notes section of the medical 
files. Causality was not routinely documented. AEs such as weight loss could be related to adverse drug reac-
tions from second-line TB treatment or ART, or HIV or TB morbidity. Pre-existing conditions at the time of 
RR-TB treatment initiation were noted under patient medical history and co-morbidities and therefore not 
included in the adverse events. However, if pre-existing conditions worsened during treatment it would be 
reported.    
AEs of interest were those most likely to be adverse drug reactions and defined prior to the review as includ-
ing renal dysfunction, hypokalaemia, ototoxicity, vestibular dysfunction, severe anaemia, psychosis and de-
pression, peripheral neuropathy, seizures, hypothyroidism, nausea and/or vomiting, and joint pain. Other 
AEs identified during the review were recorded and categorized during data analysis. Standard of care does 
not include routine screening for gastro-intestinal disorders such as nausea or vomiting or mental health 
such as depression, insomnia, or insomnia; AEs captured were as reported by patients with during routine 
visits.  
AEs were graded either at the time of the event (in the clinical notes) or during the file review by the treating 
clinician as mild (grade 1), moderate (grade 2), severe (grade 3), potentially life-threatening (grade 4), or fa-
tal (grade 5) according to the AIDS Clinical Trials Group grading system [164]. AEs included those detected 
clinically and through laboratory testing. Where outcome of the AE (e.g. death, hospitalization, permanent 
disability, drug discontinuation, and/or drug dose reduction) was available in the file it was also captured. 
Deaths that were not reported as an outcome of an AE, i.e. those thought to be from TB, were not re-catego-
rised as an AE.  
Statistical analysis  
We present descriptive analysis of the number of AEs by patient, types of AE reported, and severity of AEs 
identified from the medical record review, including frequencies and proportions.  
We used time to event analysis to present the mean time from second-line TB treatment initiation to (first) 
severe adverse event (grade 3 or higher). Follow-up is censored at 6 months after second-line TB treatment 
initiation, final outcome (i.e. death or loss from treatment for at least 2 months), transfer to another site, or 
data extraction (September 2014 for Helen Joseph and April 2015 for Charlotte Maxeke). We used compet-
ing risk regression method from Fine and Gray [165] to determine if occurrence of a severe AE was associ-
ated with a priori identified patient demographic and clinical characteristics. Because loss from treatment 
may represent unreported mortality, both death and loss from treatment were considered to be the risks 
competing with report of a severe AE. Univariate (crude) subdistribution hazard ratios (sHR) with 95% confi-
dence intervals (CI) are presented. All analysis was completed in Stata v14 (College Station, TX).   
Characteristics considered included: HIV status (HIV negative, HIV-positive on ART prior to RR-TB diagnosis 
and initiation defined as at least 30 days prior to RR-TB treatment start, HIV-positive initiated on ART at or 
after RR-TB initiation, or HIV positive not on ART or ART unknown); age category (10-24, 25-39, 40-54, 55 
years or older), and sex. We also examined markers of severity of illness: report of cough, fever, weight loss, 
or night sweats, low weight at treatment initiation (<50 kg), diagnosed with RR-TB during hospitalization for 
any cause, and CD4 count at RR-TB treatment initiation as documented in the patient file (HIV negative, HIV-
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positive with CD4 >100 cells/ mm3, or HIV-positive with CD4 <100 cells/mm3). Information on pre-existing 
conditions or self-reports of prior TB treatment (none, first-line regimen, or regimen that included strepto-
mycin) were also considered. All patients were on standardized treatment regimens for RR-TB; patients diag-
nosed with XDR TB were transferred out to initiate individualized treatment at another site and therefore 
exposure was censored.  
Ethics, consent and permissions 
Ethical approval without patient informed consent for this de-identified medical record review was obtained 
from the Human Research Ethics Committees of the University of the Witwatersrand and the University of 
Cape Town.   
 
Results 
Across the two sites, 578 files were available for review and patients eligible for the study, patient character-
istics are reported in Table 4-1. Patients presented with RR-TB at a median age of 35 (IQR: 29-42 years) and 
49.0% were male. One-third of the patients (36.7%) were categorized as low weight (<50 kg) at initiation of 
second-line TB treatment, the median weight at initiation was 54 kg (IQR: 47.9-61.5). Only 1.2% reported a 
history of TB treatment with an injectable drug (streptomycin) and the majority (76.0%) had no history of 
any TB treatment prior to the current episode of RR-TB. Approximately one-quarter (26.8%) of the patients 
were diagnosed with RR-TB while hospitalized, indicating poor clinical condition.     
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Table 4-1  Characteristics of patients at initiation of second-line TB treatment (n=578) 
Characteristic Description Count Proportion  
Sex Male 283 49.0% 
 Female 295 51.0% 
Age 10-24 years 56 9.7% 
 25-39 years 338 58.5% 
 40-54 years 163 28.2% 
 55+ years 21 3.6% 
Weight (kg) Low weight (<50 kg) 195 36.7% 
  >51 kg 337 63.3% 
 Missing 46 8.0% 
TB foci  Pulmonary 541 93.6% 
 Extrapulmonary only 37 6.4% 
Prior TB No history of TB treatment 439 76.0% 
 Prior first-line TB treatment 119 20.6% 
 Prior TB treatment with streptomycin 7 1.2% 
 Unknown 13 2.2% 
Current TB diagnosis MDR-TB (INH and RIF resistance) 182 31.5% 
 RIF mono-resistant TB 198 34.3% 
 RIF resistant, sensitivities unknown 191 33.0% 
 XDR TB (second-line resistance) 7 1.2% 
Presenting symptoms Cough 281 65.9% 
 Any of cough, weight loss, fever, night sweats 453 78.4% 
Sputum smear microscopy Positive (scanty or higher) 284 49.1% 
 Negative or unknown 294 50.9% 
Level of care at TB diagnosis Outpatient, ambulatory 406 70.2% 
 Inpatient, hospitalized 155 26.8% 
 Missing 17 2.9% 
MDR-TB: Multi-drug resistant tuberculosis; RIF: rifampicin; INH: isoniazid; XDR TB: extensively drug-resistant 
tuberculosis 
HIV infection was the most common co-morbidity reported as 82.5% (n= 477/578) were HIV positive (Table 
4-2). Of those who were HIV positive, 43.8% were on ART at least 30 days prior to RR-TB treatment initiation 
with a median 332 days on ART (IQR: 160, 991) and 31.9% initiated ART with or after RR-TB treatment with a 
median time to ART initiation of 26 days after RR-TB treatment (IQR: 14, 42). Of the 77.8% of HIV-positive 
patients with CD4 counts reported at RR-TB treatment initiation, the median CD4 was 114.5 (IQR: 45-246.5). 
Half (50.2%) were on the standard first-line regimen for the public sector ART program (tenofovir, efavirenz, 
and lamivudine or emtricitabine). Few other co-morbidities were reported, with no one co-morbidity affect-
ing 10 or more patients. Diabetes mellitus (1.9%), renal insufficiency (1.4%), and hepatitis or liver dysfunc-
tion (1.2%) were the three most common co-morbidities other than HIV. Seven women (2.4% of women) 
were pregnant during RR-TB treatment.    
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Table 4-2 Co-morbidities, clinical conditions and chronic medications (n=578) 
Characteristic Description Count Proportion  
HIV status Negative 95 16.4% 
 Positive 477 82.5% 
 Unknown 6 1.0% 
CD4 count^ (n=477) Low (<100 cells/mm3) 173 36.3% 
 >100 cells/mm3 198 41.5% 
 Missing 106 22.2% 
ART status (n=477) Not on ART 116 24.3% 
    Median CD4 count 156.5 IQR: 65, 255 
 Initiated ART with or after RR-TB 153 32.1% 
    Median CD4 count 100.5 IQR: 42.5, 221.5 
    Median days RR-TB at ART initiation 26 IQR: 14, 42 
 On ART prior to RR-TB initiation 209 43.8% 
    Median CD4 count 101 IQR: 41, 253 
    Median days on ART at RR-TB initiation 332 IQR: 160, 991 
ART regimen (n=362) TDF + 3TC or ETC + EFV  182 50.23% 
 D4T or AZT + 3TC + EFV 34 9.4% 
 TDF + 3TC + LPV/r 3 0.8% 
 D4T or AZT + 3TC + LPV/r 46 12.7% 
 Other regimen 53 14.6% 
 Missing 44 12.2% 
Reported co-morbidities Hepatitis or liver disorder 7 1.2% 
 Epilepsy 6 1.0% 
 Psychiatric disorder 5 0.9% 
 Diabetes mellitus 9 1.6% 
 Renal dysfunction 8 1.4% 
Pregnancy (n=295) Pregnant  7 2.4% 
Contraception (n=295) Using hormonal contraceptive 16 5.4% 
ART: antiretroviral therapy; TDF: tenofovir; 3TC: lamivudine; EFV: efavirenz; LPV/r: lopinavir/ritonavir  
^ CD4 count at RR-TB treatment initiation 
Adverse events 
Overall, 578 reports of AEs were captured for 204 patients (35.3%) and 110 patients (19.0%) had at least one 
severe AE (grade 3+). Patients with at least one reported AE experienced a median of 3 AEs (IQR: 2-4) per 
patient.  
Gastro-intestinal AEs were the most common, with 138 reports of vomiting, nausea, abdominal pain, epi-
gastric discomfort, diarrhoea, constipation, loss of appetite, or weight loss. Although most nausea and vom-
iting reported (67.1% of 70 reports) was mild to moderate (Figure 4-1), it was the second most commonly 
reported severe AEs (11.8% of all the severe AEs). The most common severe AE reported was hearing loss or 
ototoxicity (Figure 4-2). In total, 114 reports of hearing loss were noted affecting 17.3% of patients 
(n=100/578). Of the hearing loss AEs reported, 61 (53.5%) were categorised as grade 3+. Renal dysfunction 
or failure accounted for 10.3% of all severe AEs, with 20 episodes reported. Psychosis (6.7%), neuropathy 
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(6.1%) and hepatitis or liver dysfunction (5.6%) were also among the most frequent severe AEs reported. 
Rare severe AE reports included deep vein thrombosis (n=2), sepsis (n=1), miscarriage (n=1), suicidal 
thoughts (n=1), and neuroleptic malignant syndrome (n=1).   
 




Page | 71 
Figure 4-2 Counts of most frequent severe adverse events by HIV and ART status (n=110) 
 
Kanamycin was listed as the suspected drug causing AE or severe AE for 54.4% (111/204) of patients experi-
encing an AE.  Among the 309 AEs with at least one suspected drug listed, kanamycin was listed 175 times 
(56.6%). Of the severe AEs with at least one suspected drug listed, terizidone was listed 32/126 times 
(25.4%). Less than 5% (n=26) of the AEs had hospitalization documented as an outcome of the AE. Nearly 
20% (n=109) of identified AEs resulted in the suspected drug being discontinued and an additional 10% 
(n=57) resulted in the dose of the suspected drug being reduced.   
Subdistribution hazard ratios of severe AE 
Of the 578 patient files reviewed, 18 did not contribute to the time-to-event analysis as patient either died 
or were transferred out prior to returning to the clinic after RR-TB treatment initiation. The 560 that were 
included contributed 52,684 person-days of follow-up with a median exposure of 70 days. There were 107 
severe AEs analysed, giving an incidence rate for severe AE of 0.74 per person year.  
HIV-positive patients with low CD4 counts (<100 cells/mm3) and those who initiated ART with RR-TB treat-
ment both were approximately 3 times more likely to experience a severe AE  with crude sHR: 2.76 (95% CI:  
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1.30 – 5.84) and sHR: 3.07 (95% CI:  1.46 – 6.46), respectively (Table 4-3). Patients previously treated for TB 
with a regimen including streptomycin were also more likely to experience a severe AE, sHR: 3.49 (95% CI:  
1.52 – 8.02), all were ototoxicity. Subdistribution hazard ratios for categorized age, low weight at treatment 
initiation, smear microscopy positive, recent hospitalization, sex, cough at initiation, or pre-existing renal, 
liver, or psychiatric conditions were not statistically different.   
Table 4-3 Risks of severe (grade 3+) adverse events during first 6 months of RR-TB treatment 
Characteristic Description sHR^ 95% CI 
Age category 10–24 years 0.70 0.31 – 1.58 
 25–39 years Referent  
 40–54 years 0.92 0.61 – 1.39 
 55 years + 1.93 0.85 – 4.37 
HIV and CD4 status HIV negative Referent  
 HIV+, CD4>100 cells/mm3 1.81 0.84 – 3.89 
 HIV+, CD4<100 cells/mm3 2.76 1.30 – 5.84 
HIV and ART status HIV negative Referent  
 HIV+, initiated ART prior to RR-TB 1.77 0.83 – 3.77 
 HIV+, initiated ART with or after RR-TB 3.07 1.46 – 6.46 
 HIV+, not on ART  1.15 0.43 – 3.10 
Weight (kg) Weight >51 kg Referent  
 Low weight (<50 kg) 1.43 0.97 – 2.10 
Prior TB treatment No TB history reported Referent  
 History of first-line TB treatment 1.33 0.85 – 2.07 
 History of streptomycin for TB treatment 3.49 1.52 – 8.02 
Referring site Outpatient facility Referent  
 Inpatient facility 1.11 0.74 – 1.70 
Sex Female Referent  
 Male 0.83 0.57 – 1.22 
Smear microscopy Sputum smear negative or not reported Referent  
 Sputum smear positive (scanty or higher) 1.00 0.69 – 1.47 
Presenting symptom No cough Referent  
 Any cough 1.37 0.90 – 2.08 
Co-morbidities No reported pre-existing renal insufficiency, 
liver or psychiatric disorder 
Referent  
 Pre-existing renal, liver, or psychiatric condi-
tion 
0.47 0.11 – 1.93 
ART: antiretroviral therapy; RR-TB: Rifampicin resistant tuberculosis; sHR: subdistribution hazard ratio;  
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Competing risk regression sHR can be displayed as a graph of the cumulative incidence (of the risk analysed) 
function over the time at risk. Figure 4-3shows patients initiating ART with or after RR-TB treatment had the 
highest sHR of experiencing a severe AE versus HIV-negative patients, HIV-positive patients who had been on 
ART prior to RR-TB diagnosis, and HIV-positive patients never on ART. As a comparison, the cumulative inci-
dence function of death during RR-TB treatment, accounting for the competing risk of loss from treatment, is 
shown for the same HIV and ART categories (Figure 4). HIV-positive patients who did not initiate ART either 
before or at RR-TB initiation were more than 3 times more likely to die during RR-TB treatment than HIV-
negative patients (sHR: 3.25, 95% CI: 1.17 – 9.02). Figure 4-4shows the cumulative incidence function for 
mortality during second-line TB treatment was highest for HIV-positive patients never on ART versus HIV-
negative, HIV-positive patients who had been on ART prior to RR-TB diagnosis, and HIV-positive patients ini-
tiating ART along with or after RR-TB treatment.  
 
 
Figure 4-3 Cumulative incidence function after competing risk regression of any severe adverse event 
 
Figure 3 Legend: Competing risk accounting for loss from treatment and death during treatment, by HIV and 
ART status 
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Figure 4-4 Cumulative incidence function after competing risk regression of death during RR-TB treatment 
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Discussion 
During the first six months of RR-TB treatment in a context where 82.5% of patients were also infected with 
HIV, 35.3% of patients experienced at least 1 AE. This incidence was less than reported in a meta-analysis of 
adverse drug events during the 18 to 24 months of treatment of MDR-TB, which found 57.3% of patients 
(260/534) experienced at least one AE [3]. One of the included studies, from a similar context in South Af-
rica, reported that 99% of the 71 patients in that cohort experienced at least one AE [108]. The meta-analysis 
did not report whether the AEs were mild, moderate, severe, life threatening, or fatal [3]. In our cohort, the 
incidence of severe AEs during the first 6 months of treatment was 19.0%, far higher than the 6.9% reported 
in a large cohort of HIV positive, ART naïve MDR TB patients also from South Africa [109].  
Kanamycin was listed as the suspected drug causing AE or severe AE for 54.4% of cohort patients experienc-
ing an AE. Kanamycin, along with other aminoglycosides, is associated with ototoxicity (hearing loss and ves-
tibular dysfunction) and renal dysfunction [17,109,116,166]. While an effective agent against drug-resistant 
TB [16], multiple trials are underway to develop an injection-free regimen for treating RR-TB in an attempt to 
reduce the overall burden of ADR and improve adherence to long-term therapy [167].  
Our finding that patients recently initiating both ART and RR-TB treatment have an increased sHR for severe 
AE during the first 6 months (sHR: 3.07) has not been previously reported. The WHO recommendation to im-
mediately initiate ART was based upon lower risk of death but found that there was ‘very low quality of evi-
dence’ as to whether concomitant use of ART and RR-TB treatment led to more severe AE or drug interac-
tions [16]. A previous systematic review of the use of ART during second-line TB treatment concluded there 
was insufficient data as to whether concomitant use of ART and RR-TB treatment increased the risk of ADR 
[136]. A study of XDR TB patients in South Africa found that there was no difference in the proportion of pa-
tients (using chi-squared test) with a severe AE reported for HIV-positive patients on ART compared to HIV-
negative patients [168].  Our finding of the higher sHR for severe AE may be because other studies did not 
differentiate the grade of AE, had insufficient numbers of patients on ART, or did not differentiate the time 
on ART. Additionally, using the competing risk methodology to calculate sHR accounting for the competing 
risk of death and loss from treatment was useful in the context of very high early mortality for patients not 
on ART. The increased sHR point to a need for additional or more frequent monitoring for AE for patients 
initiating both ART and RR-TB treatment at the same time. These patients may also benefit from inpatient 
treatment initiation where they can be more closely monitored and managed.   
The cumulative incidence function for mortality accounting for the competing risk of loss to treatment indi-
cated that patients not on ART are most at risk of death and therefore our results are consistent with studies 
and guidelines that indicate early initiation of ART for patients with TB [169–171] and drug-resistant TB 
[16,136]. This reversal of risk (patients with highest relative sHR of mortality have the lowest relative sHR of 
severe AE) also highlights the need for greater access to ART and initiation at higher CD4 counts. In our 
study, there was a high proportion of patients with very low CD4 counts not on ART despite increasing ac-
cess to ARVs in South Africa; patients with CD4<100 cells/mm3 also had a higher sHR of severe AE (sHR: 
2.76). Further, a quarter of the patient files reviewed in this study were diagnosed with RR-TB while hospital-
ized although testing for RIF resistance is available at the lowest levels of the public health system in South 
Africa. Again, this represents delays in diagnosis and case finding at the primary health care level leading to 
hospitalization and late diagnoses.   
While most nausea and vomiting were reported as mild to moderate (67.1% of 70 reports) this AE can im-
pact on both adherence and effectiveness of treatment. Because of AEs, the treating clinicians discontinued 
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or reduced the dosage of the suspected drug for 17.3% of patients (100/578), a similar proportion to the 
21% calculated from a patient-level meta-analysis of MDR-TB studies [8].  Because of overlapping toxicities, a 
patient who experienced an AE during RR-TB treatment may no longer be eligible for standard ART or sec-
ond-line TB treatment regimens, for example because of drug-induced liver or kidney injuries. Fewer effec-
tive drugs in the second-line TB regimen is associated with lower probability of treatment success [8] and 
consequently higher risk of acquired additional resistance.    
Prior exposure to streptomycin may be a risk factor for ototoxicity during RR-TB treatment with increased 
aminoglycoside cumulative dose [116]. In our cohort, although the numbers of patients with prior exposure 
were small (1.2%), this was the strongest predictor of a severe AE (sHR: 3.30), with all severe AEs related to 
ototoxicity. With the introduction of Xpert MTB/RIF diagnosis, the ‘retreatment’ regimen containing strepto-
mycin was phased out and as of end 2013 is no longer in use in the South African NTP [172]. While the lack 
of history of prior TB treatment may reduce the risk of some types of ADR, from a public health perspective 
the 76.0% of patients in this cohort without any prior TB history is concerning as it indicates primary trans-
mission of RR-TB.    
Limitations 
The lower rates of ADR in this cohort may be a result of both the lack of routine reporting and retrospective 
study design. During the monthly visits to the outpatient clinic, patients are not prompted to self-report AE. 
In some cases, patients may have discussed AE with the counsellor, nurse, or clinician but if the healthcare 
worker did not note the discussion in the medical file it would not have been counted in this review. This 
may have resulted in an under-reporting of AEs, particularly those that were mild to moderate (grade 1-2). 
Also, while guidelines indicate monitoring for certain AEs, implementation may differ from intended prac-
tice. One challenge that both sites noted during the study was that it was difficult to access audiology 
screening for patients due to concerns about infection control as audiology services were not co-located 
within the TB clinic. Additionally, this study focused on the first 6 months of treatment, the intensive phase, 
which includes kanamycin. It is possible that some patients who did not experience an ADR during the first 6 
months would be affected in subsequent months or that an ADR would be detected in subsequent months, 
specifically aminoglycoside ototoxicity is known to occur even after treatment discontinuation [131]. 
Another limitation of this study which is the inability to distinguish between the AE and ADR. For this reason, 
events described in this analysis were described as AE rather than the more specific term ADR. This limita-
tion is common to studies describing ADR and AE and must be taken into consideration when trying to draw 
conclusions across studies. For example, in the South African study indicated above with 99% incidence of 
AE, injection site pain was the second most commonly reported clinical AE. Injection site pain was only re-
ported in this cohort for patients refusing to continue with the injections for reason of pain. This study also 
did not try to distinguish whether the AE was related to the ART or second-line TB treatment.  
Finally, the study period preceded the roll-out of bedaquiline and linezolid in the South African NTP. These 
two drugs are now available for patients who experience toxicity to one of the drugs of the standard regi-
men [19] and use of the new and re-purposed drugs may affect the profile of ADR experienced by patients 
with drug-resistant TB in South Africa.  
Conclusions 
Severe adverse events are common during the first 6 months of second-line treatment and HIV-positive pa-
tients on ART have the highest relative subdistribution hazard ratio of experiencing a severe AE, accounting 
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for the competing risk of death and loss from treatment. Patients whose clinical condition requires immedi-
ate initiation of ART and RR-TB treatment may benefit from intensive monitoring  or even  inpatient treat-
ment initially  to watch  for severe AEs.  
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5 RESULTS: META-ANALYSIS OF ADR DURING MDR/RR-TB TREATMENT 
5.1 SYNOPSIS  
Formal citation: Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Adverse drug reactions dur-
ing drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. Jour-
nal of Antimicrobial Chemotherapy. 2017 Apr 16. doi: 10.1093/jac/dkx107.  
Supplemental materials appended (Annex – Supplemental materials for meta-analysis of ADR in HIV settings) 
 
This chapter presents a systematic review and meta-analysis of studies reporting on adverse drug reactions 
or adverse events during treatment for MDR/RR-TB. Articles could be from any period, but the treatment 
regimens needed to be aligned to the WHO recommended standard long-course regimens 2011 to 2016; 
therefore, most articles were during this period. In order to be included, articles had to report on the HIV 
status of included patients. Only those cohorts where at least 20% of the patients were known to be HIV-
infected were included. The intent was to capture the frequency, types, severity and outcomes of adverse 
events documented. However, because of inconsistencies in reporting and descriptions of the reported ADR, 
the meta-analysis was limited to the prevalence of the ADR, disaggregated by whether severe to serious or 
mild to moderate. The published manuscript also reports on a systematic review of comparisons presented 
between HIV-infected and HIV-negative patients with regards to frequency, types, or outcomes of ADR re-
ported.  
Contribution to the thesis and novelty 
Based on both the clinical file review (Manuscript 2) and Literature Review, the question of whether HIV-in-
fected patients experience the same rates of ADR during MDR/RR-TB treatment had not been answered. 
Most MDR/RR-TB studies are observational and relatively small, which led to uncertainty and imprecision in 
the estimates of ADR prevalence. In order to include a burden of ADR in the cost-effectiveness model, it was 
important to first understand whether estimates for HIV-negative populations could be applied in a high HIV 
prevalence setting such as South Africa. This analysis was novel in limiting the focus to settings with a high 
proportion of HIV-infected patients rather than grouping all settings together. Because all studies found 
were observational and the question was prevalence (frequency of) ADR rather than treatment effect or rel-
ative risk, the metaprop command in Stata was used. Metaprop manages the variance of a meta-analysis, 
but relies on a binomial distribution appropriate for binary questions such as whether a patient experienced 
an ADR or not.   
Role of the candidate 
The candidate wrote the protocol for the systematic review and revised based on review of results from ini-
tial searches. The candidate screened all titles and abstracts if needed for duplicates and inclusion criteria 
(700+), retrieved and screened articles that could not be excluded based on abstract review. She also re-
trieved and hand searched the reference lists for articles identified as reviews. The candidate extracted rele-
vant fields from the articles, designed and performed the statistical analysis on captured fields. The candi-
date wrote the first draft of the manuscript and revised based on comments from co-authors and from re-
viewers. The co-authors approved the final version. 
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Abstract 
Objective 
To estimate the prevalence of adverse drug reactions or events (ADR) during drug-resistant tuberculosis (DR-
TB) treatment in the context of settings with high HIV prevalence (at least 20% of patients) by conducting a 
systematic review and meta-analysis of articles in PubMed and Scopus. Pooled proportions of patients expe-
riencing adverse events and relative risk with 95% confidence intervals (CI) were calculated. 
Results 
The search yielded 24 studies, all observational cohorts. Ten reported on number of patients experiencing 
ADR and were included in the meta-analysis representing 2,776 study participants of which 1,981 were 
known to be HIV-infected (71.4%). An average of 83% (95%CI: 82%, 84%) of patients experienced one or 
more ADR. Among the 7 articles (n=664 study participants) with information on occurrence of severe ADR, 
24% (95%CI: 21%, 27%) patients experienced at least 1 severe ADR during DR-TB treatment. Sixteen of the 
24 studies analysed the relative risk of ADR by HIV infection, nine of which found no statistically significant 
association between HIV-infection and occurrence of drug-related ADR. There was insufficient information 
to disaggregate risk by concomitant treatment with HIV antiretrovirals or by immunosuppression (CD4 
count). 
Conclusions 
No randomized clinical trials were found for WHO-recommended treatment of DR-TB treatment where at 
least 20% of the cohort was co-infected with HIV. Nearly all patients (83%) experience ADR during DR-TB 
treatment. While no significant association between ADR and HIV co-infection was found, further research is 
needed to determine whether concomitant antiretrovirals or immunosuppression increases the risks for HIV-
infected patients.  
  
 
Page | 81 
Introduction 
The World Health Organization (WHO) estimates that in 2015, 580,000 of the 6.1 million persons who were 
notified as tuberculosis (TB) cases had a drug-resistant strain of the disease. Only 20% were diagnosed and 
initiated on treatment of which 52% had successful outcomes.[58] Access to drug-resistant TB treatment is 
limited by timely diagnosis of resistance, availability of treatment, staff capacity, high early mortality, and 
cost.  
Patients resistant to rifampicin alone or in combination with any other first-line or second-line drugs require 
second-line treatment. Rifampicin resistant (RR-) TB includes multi-drug resistant (MDR-) TB, resistant to 
both isoniazid and rifampicin, and extensively drug resistant (XDR-) TB, MDR-TB that is also resistant to both 
a fluoroquinolone and a second-line injectable drug. The duration of drug-resistant TB treatment is longer 
than for drug-sensitive TB (typically 9-24 months) and standard regimens for MDR/RR-TB include 4 to 7 
drugs with different[16] mechanisms of action, including oral bacteriostatic drugs; aminoglycoside and cyclic 
peptide injectables; fluoroquinolones; and newer agents such as bedaquiline and delamanid.    
 Many of the drugs have known toxicities, especially at the doses and durations required to treat resistant 
strains of TB and there is limited clinical trial data on dosage and related side effects. As a result, adverse 
drug reactions (ADR) are very common during drug-resistant TB treatment. A systematic review and meta-
analysis of published literature through October 2012 found that 57.3% of included patients had experi-
enced at least one type of ADR, including mild to severe events.[3]  ADR can lead to the clinician or patient 
interrupting, stopping, or reducing the dosage of treatment before completion, and therefore may increase 
the risk of mortality, treatment failure, or death.[117] Either sequelae from the ADR or the untreated TB dis-
ease may lead to reduced quality of life.[120] However, the high mortality, risk of transmission, and limited 
alternatives mean that clinicians and patients with drug-resistant TB are left with little choice.   
Within the last decade, there has been escalated progress for drug-resistant TB drug development; new 
treatments are being developed and multiple drugs are entering or in clinical trials.[167,173] Knowing 
whether the rates of ADR experienced in clinical trials for new drugs are of concern requires a better under-
standing of the base case scenario. Additionally, in efforts to improve treatment outcomes existing drugs 
such as linezolid (an oxazolidinone) and clofazimine are being re-purposed for drug-resistant TB treatment. 
Because the drugs have existing regulatory approval for other indications, randomized controlled trials are 
not required in many settings and available understanding of the potential side effects and optimal doses for 
the regimens are limited to observational cohorts.[98,174] Additionally, the sickest patients or those with 
HIV, advanced HIV, or other comorbid conditions are often excluded from clinical trials. For high prevalence 
HIV-settings, this can limit applicability of clinical trial data to patients co-infected with HIV and other comor-
bid conditions.  Yet, in some settings, particularly sub-Saharan Africa, TB and HIV are inextricably linked. 
Treatment of HIV and TB co-infection results in high pill burden and potentially increased toxicity. Effective 
ART regimens include three drugs, and toxicities can be overlapping.[16,136] HIV infection, even for the ART 
naïve, and particularly for those who have advance HIV disease or immunosuppression may also pose its 
own risk for ADR.  
To understand the association between HIV infection and treatment and the prevalence of ADR during drug-
resistant TB treatment, we systematically reviewed and conducted a meta-analysis of peer-reviewed pub-
lished literature to identify the types, frequencies, severity and seriousness of ADRs associated with the pre-
2016 WHO-recommended regimens for drug-resistant TB in settings with HIV co-infection of at least 20%.  
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Methods 
Literature search was done in PubMed (inclusive of MEDLINE) and Scopus. The title, abstract, and full text 
were searched for adverse or toxicity or side effects or safety or tolerability AND drug-resistant or multi-drug 
resistant or second-line treatment or rifampicin-resistant AND tuberculosis or TB AND human immunodefi-
ciency virus or HIV or acquired immune deficiency syndrome or AIDS. No date ranges were set; the search 
was initially done on 11 February 2016 and then updated on 4 August 2016. Retrieved results were de-dupli-
cated. Conference proceedings and conference abstracts were not included in the search because of limited 
presentation of results in abstract format. Manuscripts in languages other than English were excluded.  
Titles and abstracts were screened and the following excluded from the articles to be retrieved: opinion 
pieces, editorials; guidelines; case reports; and studies with no reports of drug-resistant TB treatment, e.g. 
drug-sensitive TB treatment, laboratory testing, bench research, pharmacokinetic studies, and diagnostic 
tools, methods, or algorithm. Systematic reviews and meta-analyses identified during the screening were not 
included in this systematic review, but were retrieved and a manual search done of the references. 
If from the title or abstract it was clear that the article did not meet inclusion criteria or if an exclusion crite-
ria was present, the article was excluded from further review. For any abstracts which met inclusion criteria 
or for which the abstract was not sufficiently detailed to determine eligibility, the full text was retrieved and 
reviewed. Retrieved full texts were reviewed for inclusion and exclusion criteria (Table 11-1). Based on the 
articles retrieved, the included articles were further classified according to whether they reported on only 
severe (i.e. events that were severe in intensity[133]) or serious ADR (i.e. death or a life-threatening experi-
ence; hospitalization or prolongation of hospitalization; persistent significant disability; or congenital anom-
aly[117]), only on one ADR (e.g. hearing loss), or only on the ADR probably related to one drug (e.g. clo-
fazimine). These more limited sub-analyses were analysed separately from studies reporting on multiple 
drugs, events, and of different severity gradings. 
If the same cohort was reported in multiple eligible manuscripts, the article with the most information on 
ADR (if treatment outcome and ADR described separately) or the most complete follow-up (if interim results 
and final results) was included. In one case, each article separately reported on one specific ADR and both 
papers were included in the analyses for those two individual ADRs.  
Analysis 
Available data was extracted related to the number of severe ADR or AE during treatment, disaggregated by 
type of ADR, suspected drug, grading of ADR severity, HIV and ART status of the patient, and whether the 
ADR led to the drug being stopped, hospitalization, or death. Severity was extracted as per categorization 
within the articles as severe or worse (severe, life threatening or fatal or grades of 3 to 5) or non-severe 
(mild or moderate or grades of 1 to 2). Extracted ADRs included categories for ADRs that have known associ-
ations to the anti-TB drugs in the WHO pre-2016 regimens,[16,117] including: gastrointestinal symptoms, 
ototoxicity, psychiatric disorder, electrolyte imbalance, anaemia, thyroid dysfunction, liver dysfunction, kid-
ney dysfunction, dermatologic problems, peripheral neuropathy, arthralgia, cardiac (e.g. QT prolongation), 
systemic symptoms (e.g. fatigue, general malaise), and seizures. Other reactions were captured and de-
scribed as reported. Bias was not explicitly assessed as intention was to include observational studies. 
Extracted data was captured in MS Access 2013 and then imported to Stata v14 (College Station, TX) for 
analysis. The Stata function metaprop[175] was used to create forest plots and analysis of the point and con-
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fidence interval estimates for the prevalence of ADR out of all patients, as well as disaggregates when possi-
ble (sub-analyses). Metaprop was used as it is based on binomial distribution appropriate for analysing pro-
portions and is less likely to produce unallowable intervals even when the proportions are close to 0 or 
1.[176] The Stata function metan was used for sub-analyses to estimate the relative risk of HIV infection for 
experiencing an ADR.[177]   
Results 
Across PubMed, Scopus, and reference searches, 727 citations were identified (Figure 5-1), of which 137 
were found to be duplicates. Titles and abstracts of the remaining 590 citations were screened for inclusion 
and exclusion criteria. Fifty-four articles were retrieved for full-text review, at which point 30 more were ex-
cluded.  
Data was extracted from the remaining 24 articles (Table 11-2 Included articles, reporting on multiple ADR 
and suspected drugsTable 11-2 and Table 11-3), all of which were not randomized and only 7 of which were 
prospective. Analysis was limited by the reported data which was not consistent across all studies; the stud-
ies were further classified as having a diverse scope of ADR included in the reporting (12 studies, n=2,941 
patients[108,114,123,124,168,178–184]). Within the articles that had a diverse coverage, eight reported on 
both the numbers of patients experiencing ADR and the total number of ADR experienced and two provided 
only a count of patients who had experienced an ADR; these ten[108,114,123,124,168,178–181,184] were 
included in the meta-analysis of the proportion of patients experiencing an ADR. Two other diverse coverage 
studies reported on the count of ADR but not the count of patients and were included in sub-analyses. A fur-
ther 12 studies included only in sub-analyses were those that described only severe (4 studies, n=421 pa-
tients[34,185–187]) or serious ADR (1 studies, n=1,390 patients[109]); only the ADR related to a drug of in-
terest (1 studies, n=85 patients[188]); or only a particular type of ADR of interest—hypothyroidism (3 stud-
ies, n=468 patients[111–113]), hearing loss (2 studies, n=588 patients[115,189]), and peripheral neuropathy 
(1 study, n=246 patients[190]).  
Cohorts from eight countries were included (five African countries: Botswana, Ethiopia, Lesotho, Namibia, 
and South Africa; Haiti; India; and the United States). Sixty percent (15/25) were from South Africa. The me-
dian proportion of HIV-infected patients within the studies was (unweighted) 63.4% (IQR: 39.1%, 74.4%) of 
the 4,682 participants. Of the 22 studies reporting patients on HIV treatment, the ART coverage of HIV-in-
fected patients was high (median 90.2%, IQR: 70.8% to 100%). ART was usually reported as binary (on ART or 
not on ART). Six studies further classified ART as having been initiated prior to or during MDR/RR-TB treat-
ment, including two that estimated the number of months prior to MDR/RR-TB treatment. Eighteen studies 
indicated a median CD4 count; the median CD4 count reported was 202 (IQR: 90 to 329).  
Of the total 6,139 drug-resistant TB patients, 10.1% (n=622) had second-line drug resistance in addition to 
rifampicin resistance, including XDR-TB. All 10 studies that were not limited to a specific drug or ADR de-
scribed a drug regimen which included cycloserine or terizidone. The most commonly reported other drugs 
were pyrazinamide (8/10 studies), amikacin or kanamycin (8/10 studies), ethionamide (8/10), para-ami-
nosalicylic acid (6/10), moxifloxacin (5/10), levofloxacin (3/10) and ofloxacin (2/10).  
Patients experiencing ADR 
For the 10 studies (n=2,776 patients) included in the main meta-analysis (of which 1,943 were HIV-infected), 
1,725 experienced at least one ADR, with a pooled proportion of 83% (95%CI: 82% to 84%) out of all patients 
(Figure 5-2). Seven studies (n=664) reported on the number of patients who experienced at least 1 severe (or 
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worse) ADR during treatment (Figure 5-3).[34,114,168,180,183,185,186] The proportion of patients experi-
encing at least 1 severe or worse ADR ranged from 13% to 43%, with an overall estimate of 24% (95%CI: 21% 
to 27%).  
Reported ADRs by type 
As shown in Figure 5-4, gastrointestinal related ADR, including vomiting, nausea, and diarrhoea, were the 
most commonly reported ADR overall 837/4,498 (18.6%) events disaggregated by ADR type. Of the severe 
events, gastrointestinal-related ADR (151/743 severe events, 20.3%) were also the most commonly re-
ported. Ototoxicity, including hearing loss and tinnitus, was the second most common for all ADR (n=746, 
16.6%) and severe ADR (n=139, 18.7%) as well. Psychiatric events including depression, suicidal ideation and 
suicide accounted for 13.7% of all ADR reported. For severe ADR, hypothyroidism (n=118, 15.9%), peripheral 
neuropathy (n=69, 9.3%), psychiatric disorders (n=61, 8.2%), arthralgia (n=57, 7.7%), and dermatologic symp-
toms (n=56, 7.5%) were the next most commonly reported events.  
Ten studies[108,115,123,168,178,179,181,182,189,191] reported on hearing loss believed to be a result of 
treatment with aminoglycosides amikacin and kanamycin; an additional study indicated that hearing was not 
routinely tested and was therefore excluded from this sub-analysis[124] (Figure S1).  The estimated propor-
tion of all patients experiencing any hearing loss across these studies was 36% (95%CI: 34% to 38%).   
Reported ADR by suspected drug 
None of the included studies systematically reported on drug(s) suspected to cause the ADR described with 
the exception of studies addressing a single ADR of interest, e.g. the papers describing hypothyroidism as-
cribed whether its occurrence was related to the use of para-aminosalicylic acid and/or ethionamide. While 
there was one paper focused on clofazimine, the described ADR were not attributed to clofazimine. Across 
the 628 ADR from 12 papers covering 3,326 patients which had counts of any, severe or serious ADR associ-
ated with (a) specific drug(s), the second-line injectables combined (kanamycin, amikacin, and capreomycin) 
had 273 reports. Para-aminosalicylic acid and/or ethionamide (the studies indicated that it was unknown 
which of the two was more likely) were implicated in 235 events, and cycloserine/terizidone were men-
tioned 92 times.    
Relative risk of ADR by HIV infection and HIV treatment 
Sixteen[109,111,112,123,124,178,180,181,185,186,189] of the reviewed studies included information about 
the relative risk of ADR by HIV infection, most used the Pearson chi-squared test for difference of propor-
tions (Table 1). Nine studies found no statistically significant association between the proportion of patients 
experiencing any ADR by HIV status.[109,111,112,123,124,178,180,185,189] One study found that HIV-in-
fected patients were at a 4-fold higher cumulative hazard of moderate-to-severe ADR (95%CI: 1.5 to 10.5) 
compared to HIV-negative patients.[181] A single study reported that HIV-negative patients experienced 
more severe ADR.[186] Disaggregation of counts of patients experiencing any ADR by HIV status was limited 
to 2 studies, and therefore was not tested through the meta-analysis. 
There were more differences by HIV status found in individually reported ADR. Two studies found that HIV 
was associated with an increased odds of experiencing hearing loss[179,192] for patients on amikacin or 
kanamycin; two others found an association with peripheral neuropathy and either HIV or HIV treatment 
(e.g. stavudine).[124,179] An association with HIV was also noted for psychosis and hypothyroidism (sus-
pected drugs not indicated).[179] In contrast, no association was found with 17/18 reported ADR statistically 
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tested and 21/21 ADR statistically tested in two studies.[108,193] In one study that focused on peripheral 
neuropathy, risk was differentiated by incident or prevalent ADR at the start of drug-resistant TB treatment. 
There was no association with HIV for incident peripheral neuropathy, but prevalent peripheral neuropathy 
was much more likely for patients who were HIV-infected and the risk was increased for those with pro-
longed prior exposure to stavudine.[190] Disaggregation of ototoxicity by HIV status was available for 4 stud-
ies,[108,181,189,192] the pooled relative risk by HIV infection across these studies was not statistically sig-
nificant (RR: 1.17, 95%CI: 0.93 to 1.47).  
Discussion  
Many of the drugs currently used for drug-resistant TB treatment have not undergone robust clinical trials 
and optimal dosage and side effects are poorly described. This is exacerbated for HIV-Infected patients 
where HIV and ART interactions have not been thoroughly investigated and resulting in inadequate evidence 
as to the impact of these treatments in the context of high prevalence of HIV co-infection. To understand the 
prevalence of adverse drug reactions associated with drug-resistant TB treatment, we searched for studies 
reporting on ADR during drug-resistant TB treatment where at least 20% of the patients were known to be 
infected with HIV. Data was extracted from 24 studies for the systematic review, but quantitative meta-anal-
ysis was limited by inconsistent definitions and reporting categories. No randomized control trials with at 
least 20% of the patient population HIV-infected were identified; this clearly creates a gap in knowledge. Of 
the 24 studies, 10 counted the patients who experienced at least 1 ADR and could be included in the main 
meta-analysis (n=2,776 of which there were n=1,943 HIV-infected); for these studies the pooled proportion 
of patients experiencing an ADR was 83% (95%CI: 82% to 84%).   
The 83% experiencing at least one ADR is significantly higher than a previous systematic review and meta-
analysis that did not focus on high-burden HIV settings, where 57% of included patients experienced at least 
one type of ADR, including mild to severe events.[3] HIV could increase the number of ADR due to overlap-
ping toxicities from treatment, but also because of poor clinical condition and advanced disease at presenta-
tion, including low CD4 count and low body mass index. Although the observational studies reviewed here 
presented a larger cohort of HIV-infected patients on drug-resistant TB treatment, there was limited analysis 
of why or how HIV co-infected drug-resistant TB patients may have had a higher number of reported ADR. 
There was insufficient disaggregation of the data presented in the included studies to estimate a pooled rela-
tive risk by HIV-status so as to know whether the difference in pooled proportions (83% vs 57%) was due to 
chance or statistically significant. Of the studies that tried to look at ADR by HIV status, more than half found 
that there was no association or increased risk, but the statistical methods used were not adjusted for po-
tential confounders. One study remarked that while HIV-infected patients experienced fewer ADR, they ex-
perienced more death;[168] this may be an indication that the competing risk of death for patients not on 
ART is the reason that they do not (live long enough to) experience ADR. A study published after the search 
and systematic review found that HIV-infected patients newly on ART are at increased risk of ADR, if the 
competing risk of early mortality from not being on ART is accounted for in the analysis.[194]    
Fewer than 10 of the studies disaggregated reported ADR by severity, among them, the pooled proportion of 
patients experiencing at least one severe or worse ADR was 24% (95%CI: 21% to 27%). While additional re-
ports would have improved the analysis, severity of the ADR does not always correlate with impact on qual-
ity of life and adherence: i.e. pain from injections and nausea from ethionamide although both considered to 
be ‘mild’ in severity are likely to have outsize impact on adherence and loss from care due to the significant 
impact on patient’s quality of life.  
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Meta-analysis was limited by non-standard definitions of ADRs, severity of ADRs, and outcomes of the ADR. 
For example, sometimes the number of patients was reported and in other cases the number of events. Pro-
spective studies sometimes indicated a standard definition of ADR that was defined in advance, such as 
those required for clinical trials.[132,133] However, in addition to the potential biases of observational co-
horts, few of the studies were prospectively or explicitly designed to report on ADR. Thus, within patient rec-
ords, ADR that were more severe or more frequent or more surprising may have been more likely to be rec-
orded by the clinician. Within observational reporting, again, those ADR that seemed more interesting may 
have been more likely to have been included in the write up of the cohort. As noted in many of the studies, 
ADR which led to a treatment change or a serious outcome (e.g. hospitalization or death) are documented 
more commonly than those that the patient complains of but did not affect treatment outcome (e.g. head-
aches, gastrointestinal complaints). And finally, in choosing whether to publish, again there might have been 
bias. The retrieval and review of studies that summarized only ADR from one particular drug (e.g. clo-
fazimine) or only a specific type of ADR (e.g. hypothyroidism, ototoxicity, and peripheral neuropathy) or only 
those that were serious or severe are examples of how the publication bias potentially affected the availabil-
ity of evidence related to the prevalence of ADR during DR-TB treatment. In 2016, the WHO recommended a 
shorter 9-to 12-month regimen for patients who are unlikely to have second-line drug resistance, despite 
indicating “very low certainty in the evidence”, anticipating that reduced exposure time would reduce the 
burden of ADR.[14] Studies of the shorter regimen were excluded from the meta-analysis and the compara-
ble burden of ADR for the short-course treatment was not evaluated.    
Given the high toxicity associated with drug-resistant TB new drugs will be needed to replace the currently 
recommended regimens. New drug classes like bedaquiline and delamanid, the first new anti-TB drugs ap-
proved in 40 years, offer promise for a well-tolerated, injection free, effective drug-resistant TB regimen. Be-
daquiline and delamanid use is recommended where there is either resistance or toxicity to older treat-
ment.[14] Current research priorities include trials of new regimens (rather than adding new drugs to old 
regimens) where the intention is to both shorten exposure time and to replace the injectables (e.g. kanamy-
cin, amikacin, and capreomycin) and all its associated higher risks of ADR.[173]  However, it is crucial that 
these trials include those who are infected with HIV. There is a clear imperative for programmes and coun-
tries to develop and implement robust pharmacovigilance systems with standardized reporting at minimum 
of the number of patients affected, the number of events experienced, the severity of events, and the sus-
pected causative agent to allow for meta-analysis and review; particularly as new drugs are rapidly intro-
duced into patient care. 
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Figure 5-2 Forest plot of estimate of overall proportion of patients experiencing one or more adverse drug 




Page | 89 
Figure 5-3 Forest plot of estimate of proportion of patients experiencing one or more severe, life threatening, 
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Figure 5-4 Frequency of all adverse drug reactions and severe adverse drug reactions reported by type. 
All ADR: 4,498 events across 4,274 patients from 18 studies with counts of ADR by type  
At least severe ADR: 743 events across 3,284 patients from 11 studies with counts of severe ADR by type 
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Table 5-1 Relative risk of ADR by HIV status 
First author Year % HIV Relative risk of ADR by HIV status 
Brust[108] 2013 81.3% Difference in proportions ADR experienced not statistically significant for 21 individual ADR tested. 
Charles[178] 2014 24.5% Difference in proportions ADR experienced not statistically significant, p=0.185. 
Jacobs[179] 2012 72.6% HIV-infected patients more likely to have had peripheral neuropathy (p<0.001); psychosis and confusion (p=0.04); hearing 
loss (p=0.047); thyroid dysfunction (p<0.001). 
Difference in proportions ADR experienced by HIV-infected on ART or not on ART not statistically significant, p=0.432. 
Kelly[123] 2016 74.4% Difference in number of ADR experienced not statistically significant as recorded in interviews (p=0.277) and medical rec-
ords (p=0.098). 




2013 71.9% Difference in proportions ADR experienced not statistically significant. Difference in proportions severe ADR experienced 
not statistically significant. Difference in proportions ADR experienced by HIV-infected on ART or not on ART not statisti-
cally significant. Difference in proportions severe ADR experienced by HIV-infected on ART or not on ART not statistically 
significant. 
Sagwa[181] 2014 52.5% Cumulative hazard of moderate-to-severe ADR, HIV-infected HR: 4.0, 95%CI: 1.5 to 10.5. Additional analysis reported in 
2013 [193] no statistically significant difference of proportions for 17 ADR tested, only abdominal pain associated with HIV 
p=0.02. Effect modification from HIV in adjusted relative risk analysis for nausea and joint pain. 
Shean[168] 2013 41.7% Difference in proportions ADR experienced not statistically significant, p=0.26. Difference in number of ADR experienced 
not statistically significant, p=0.15. Difference in number of severe ADR experienced not statistically significant, 0.01. 
Patients who died were more likely to be HIV-infected (p=0.01) 
Burgos[185] 2005 22.9% Difference in proportions severe ADR experienced not statistically significant, p=0.520 
Kvas-
novsky[186] 
2011 52.4% HIV negative experienced more severe ADR than HIV-infected, difference in proportions p<0.01. Difference in proportions 
ADR experienced not statistically significant for HIV-infected on ART or not on ART, p=0.33 
Van der 
Walt[109] 
2013 39.1% Difference in proportions of serious ADR experienced by ART naïve HIV-infected not statistically significant, p=0.083. 
Conradie[190] 2014 80.9% Incident peripheral neuropathy not associated with HIV, HR: 1.00 (95%CI: 0.35 to 2.91). Prevalent peripheral neuropathy 
associated with HIV, HR: 3.21 (95%CI: 1.25 to 8.22), risk was also associated with duration of exposure to stavudine. 
Harris[192] 2012 57.0% HIV-infected patients were more likely to experience hearing loss, OR 3.25 (95% CI: 1.65 to 6.37). 
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Mo-
dongo[112] 
2012 63.4% Difference in proportions experiencing hypothyroidism not statistically significant. 
Mo-
dongo[189] 
2014 65.9% Difference in proportions experiencing hearing loss not statistically significant. 
Satti[111] 2012 67.6% Difference in proportions experiencing hypothyroidism not statistically significant, p=0.172 
^ Excluded as all patients were HIV-infected: Issakidis 2012[114], Umanah 2015[184], Andries 2013[113] 
# Did not disaggregate ADR by HIV status: Ndjeka 2015[34], Seung 2009[187], Thee 2014[183], Padayatchi 2014[188], Seddon 2013[182] 
 
ADR: Adverse drug reaction; ART: Antiretroviral therapy; CI: Confidence interval; HR: Hazard ratio; OR: Odds ratio
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6 RESULTS: CEA BEDAQUILINE 
6.1 SYNOPSIS 
Formal citation: Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E. Incremental Cost Effectiveness 
of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analy-
sis. Applied Health Economics and Health Policy. 2017 Oct 4:1-2. 
In order to assess the cost-effectiveness of a bedaquiline-based regimen for MDR/RR-TB treatment in a 
high-HIV prevalence setting from the perspective of the South African public health sector, we established a 
Markov model for ambulatory treatment of MDR/RR-TB parameterized using clinical outcomes from the 
South African National TB Programme (SA NTP) before (2012 - 2014) and after (2015 – 2016) bedaquiline 
roll-out. The results indicate that providing bedaquiline for all MDR/RR-TB patients costs less than the cost 
of procurement for the drug because of savings from an injection-free treatment regimen. The ICER of 
US$1,242 per additional DALY averted is below the 2015 per capita GDP for South Africa of US$5,718, 
which is considered very cost effective.[42,91] Further, providing bedaquiline for all MDR/RR-TB patients 
could increase the treatment success rate in South Africa from 56.3% on a non-bedaquiline regimen to 
60.6% and is affordable in the South African context (cost USD 2.6 million over a 10-year horizon). 
Contribution to the thesis and novelty 
As of August 2017, the five studies identified that analysed the cost-effectiveness of bedaquiline [52–56], in 
addition to the original analysis included in the WHO recommendations [31] considered bedaquiline added 
on to the standard regimen rather than replacing the injection. This analysis was the first to use evidence 
from programmatic roll out to show what may happen using a new regimen. Additionally, Although South 
Africa has one of the highest burdens of MDR/RR-TB in terms of total incident cases, most cost-effective-
ness models for MDR-TB have been built for Europe and other settings with low HIV prevalence and hospi-
tal-based treatment.  
Role of the candidate 
The candidate designed the Markov health state model and built the decision tree within TreeAge. She ran 
different versions to balance the availability of data, the complexity of the model, and the reasonableness 
of the outputs for the base case outputs. The candidate also collected ingredients costs from public sector 
price lists and calculated transition probabilities from the EDRweb cohort. The candidate wrote the first 
draft of the manuscript and revised in response to inputs from co-authors. She revised the article based 
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6.2 TREE STRUCTURE CEA BEDAQUILINE 
For this analysis, a Markov model with monthly steps was built in TreeAge Pro 2015 (TreeAge Software, 
Williamstown, MA) The model was structurally the same for all treatment Markov nodes (i.e. SOC for all 
MDR/RR-TB, SOC for MDR/RR-TB and bedaquiline for patients who failed MDR/RR-TB treatment, and be-
daquiline for all MDR/RR-TB patients), but transition probabilities and costs were different for each of the 
modelled regimens. Markov health states were constructed to represent initiation MDR/RR-TB treatment 
(with the possibility of hospitalization), intensive phase, and culture negative continuation phase of treat-
ment. Tunnel states for treatment were created to ensure that patients receive at least 6 months of inten-
sive phase regimen and at least 12 months in the continuation phase of treatment for MDR/RR-TB patients 
and 18 months in the continuation phase of treatment for XDR-TB, as per current SA NTP treatment guide-
lines.[17] If the patient fails to sputum culture convert after 6 months of treatment, the patient would tran-
sition in the model to XDR-TB treatment. Failure during XDR-TB treatment transitions to palliative care.  
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Model overview 
The Markov model was parameterized using South African data where available. The costs are presented 
from the perspective of the South African public health sector, which includes both costs that are part of 
the South African National TB Programme as well as the costs of hospitalization or utilization of primary 
health care clinics. Monthly costs for drugs, laboratory tests, procedures and investigations, clinic visits and 
hospital inpatient days, were extracted from public sector databases. 
 Transition probabilities for the South African context standard of care were calculated using Stata v14.1 
based on the dataset described in Chapter 3which excluded patients on bedaquiline. Separate transition 
probabilities were estimated for patients known to be HIV-negative, HIV-positive on ART, and HIV-positive 
not on ART. Differences in effectiveness of culture conversion for bedaquiline were extracted from pub-
lished literature. The model and probabilities can also be represented as a tree.  
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Sensitivity of the results to the model inputs was tested using one-way sensitivity analysis.  
Although not described in the manuscript, the assumption regarding the assumed discount rate of 3% was 
also tested as per recommended methods for cost-effectiveness analysis.[40,195] Results are presented in 
the table below. 
Table 6-1 Incremental cost-effectiveness ratios compared standard of care for MDR/RR TB regimens, differ-
ing discount rate assumptions 
  0% discount rate 3% discount rate 
(base case) 
6% discount rate 
SOC (injection-based)    
 Cost $4,641 $4,439 $4,267 
 Effect 5.91 5.12 4.48 
Bedaquiline for XDR-TB    
 Cost $4,556 $4,356 4187 
 Effect 5.94 5.14 4.50 
 ICER More effective, cost 
saving 
More effective, cost 
saving 
More effective, cost 
saving 
Bedaquiline for all MDR/RR TB    
 Cost $4,867 $4,648 $4,489 
 Effect 6.11 5.29 4.63 
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HIV-negative treatment states 
For HIV-negative populations, treatment states included initiation (Tx0), intensive phase (Tx_inten), contin-
uation phase (Tx_cont), cure (Cure MDR), death (Death – Soc), lost from MDR/RR-TB treatment (Lost MDR), 
failed and intensive phase for XDR-TB treatment (XDR_Tx_cult+), continuation phase XDR TB treatment 
(XDR_Tx_cont), failed XDR-TB treatment, or lost from XDR-TB treatment.  
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HIV-positive treatment states 
For HIV-positive populations, treatment states included initiation (Tx0) as either HIV on ART (Tx0 HIV) or 
ART naïve (Tx0 HIV no ART), intensive phase (Tx_cult+ HIV), continuation phase (Tx_cont HIV), cure (Cure 
MDR HIV), death (Death – Soc), lost from MDR/RR-TB and HIV treatment (Lost MDR HIV), failed and inten-
sive phase for XDR-TB treatment (XDR_Tx_cult+ HIV), continuation phase XDR TB treatment (XDR_Tx_cont 
HIV), failed XDR-TB treatment, or lost from XDR-TB and HIV treatment treatment (Lost XDR HIV).  
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XDR-TB treatment states 
Because all patients with XDR-TB at initiation were excluded from the analysis, the XDR-TB treatment states 
start with the intensive phase (XDR_Tx_cult+ HIV or XDR_Tx_cult+). Similarly, because of the model struc-
ture that to complete the intensive phase of MDR/RR-TB treatment – either transitioning to MDR/RR-TB 
continuation phase or as treatment failure to XDR-TB intensive phase – an HIV-patient must be initiated on 
ART, all HIV-positive patients who have survived and transitioned to the XDR-TB health states are assumed 
to be on ART. In the model, patients can transition to the continuation phase XDR-TB treatment 
(XDR_Tx_cont HIV or XDR_Tx_cont), failed XDR-TB treatment (Fail XDR), or lost from XDR-TB (Lost XDR) and 
lost from XDR-TB and HIV treatment (Lost XDR HIV).   
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No treatment comparison arm 
For the no treatment arm, initial distribution was to either HIV-positive on ART or HIV-positive ART naïve, or 
HIV-negative. Patients could continue in that initial distribution until death. 
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Abstract 
Background 
Nearly 20,000 people were diagnosed with multi-drug and rifampicin-resistant (MDR/RR-TB) in South Africa 
in 2015; yet, only ½ of the patients who start treatment are expected to have a successful outcome. There 
is increasing evidence of the effectiveness and safety of new drug regimens containing bedaquiline for 
MDR/RR-TB; however, it is uncertain whether they are affordable for high burden, limited-resource set-
tings. 
Methods 
We established a Markov model for ambulatory treatment of MDR/RR-TB in a high-HIV prevalence setting, 
parameterized using clinical outcomes from the South African National TB Programme (SA NTP) before 
(2012 - 2014) and after (2015 – 2016) bedaquiline roll-out.  The effectiveness of treatment was evaluated in 
disability adjusted life years (DALYs). Ingredient costs from the provider perspective were collected in 2016 
South African Rand and converted to US$, including bedaquiline at US$675.23 per 6-month treatment 
course. Culture conversion rates were derived from the Phase 2b trial of bedaquiline and disability adjust-
ments were adapted from published literature. Costs and effectiveness were discounted at 3%. 
Results 
For non-bedaquiline regimens, the total expected cost over the 10-year time horizon for a MDR/RR-TB pa-
tient was US$4,439 and disability-adjusted survival of 5.1 years. Replacing capreomycin with bedaquiline 
for patients who failed MDR/RR-TB treatment and required XDR-TB treatment resulted in cost savings 
($4,356, 1.8% less) and similar effectiveness (0.02 DALYs averted). As a result, the standard regimen (no be-
daquiline) was dominated. Replacing kanamycin with bedaquiline so that all MDR/RR-TB patients access 
bedaquiline cost US$4,647 (4.3% more) and averted 0.17 DALYs compared to the no bedaquiline regimen. 
The incremental cost effectiveness ratio was US$1,242 / DALY averted.  
Conclusion 
Markov modelling indicates providing bedaquiline for all MDR/RR-TB patients could increase the 24-month 
treatment success rate in South Africa from 56.3% using the current regimen to 60.6%, at an incremental 
cost of $2.6 million over a 10-year horizon, less than 1% of the estimated US$425 million SA NTP annual 
budget.  
Key points for decision makers 
Providing bedaquiline for all MDR/RR-TB patients costs less than the cost of procurement for the drug be-
cause of savings from an injection-free treatment regimen.  
Providing bedaquiline for all MDR/RR-TB patients could increase the treatment success rate in South Africa 
from 56.3% on a non-bedaquiline regimen to 60.6%, at an incremental cost of US$2.6 million over a 10-year 
horizon.  
 
Page | 103 
Introduction 
According to the World Health Organization (WHO), globally in 2015, there were 580,000 incident cases of 
rifampicin-resistant (RR) TB. In the same year, an estimated 190,000 persons died from RR-TB and multi-
drug resistant (MDR) TB, RR-TB that is also resistant to isoniazid. Across all countries reporting to the WHO, 
among patients initiating treatment, only 52% of MDR/RR-TB patients (2013 cohort) were successfully 
treated [58].  
Results from the Phase 2b clinical trials of bedaquiline, a novel agent for the treatment of RR TB, demon-
strated significant benefits in terms of both the proportion of patients who sputum culture converted and 
the time to culture conversion [30]. In March 2017, the WHO updated its 2013 conditional recommenda-
tions for the use of bedaquiline [32] based upon a growing body of evidence including observational results 
from public-sector use of bedaquiline in South Africa. While further evidence is still needed to resolve un-
certainty around the safety of bedaquiline use [32]; results such as those from a 15-country multi-centre 
study [138] are encouraging enough that policy makers [46,47] and clinical researchers [196] are consider-
ing whether bedaquiline could replace second-line injectables as a core MDR/RR-TB drug.   
South Africa is categorized by the WHO as being a high TB, high HIV/TB, and high MDR/RR-TB burden coun-
try [58]. Approximately 295,000 TB cases initiated treatment in South Africa in 2015, of which 57% were 
known HIV-positive and 19,613 were diagnosed as MDR/RR-TB [58]. In October 2014, the South African 
Medicines Control Council regulatory authority approved the use of bedaquiline for treatment of MDR/RR-
TB. Starting in March 2015, the SA NTP began the process of rolling out bedaquiline as an additional drug to 
strengthen the existing regimens for MDR/RR-TB, particularly where there was either resistance to or intol-
erance of fluoroquinolones and/or second-line injectable drugs. 
Despite the revised WHO recommendations, encouraging treatment outcomes and concessional pricing for 
high-burden countries, further roll-out of bedaquiline in South Africa and other resource-limited settings is 
uncertain where the drug is priced at ZAR 9,950 (US$675.23) per 6-month treatment course. An exploratory 
cost-effectiveness analysis of bedaquiline was used for the 2013 WHO recommendations, but with uncer-
tainty around whether bedaquiline would increase cure by reducing loss to treatment follow-up, death or 
failure [197]. Cost-effectiveness studies published since then have been largely for cohorts where, unlike in 
South Africa, MDR/RR-TB patients are hospitalized until culture conversion. In these settings, the high cul-
ture conversion rates of bedaquiline and therefore shorter duration of hospitalization lead it to be cost-ef-
fective [52,54] or even cost saving compared to the standard regimen [53]. A Markov model established for 
the United Kingdom [53] was applied to seven countries with a high burden of MDR/RR-TB, including South 
Africa [55]. For South Africa, the analysis indicated that bedaquiline could be cost saving relative to the 
standard regimen because of a large reduction in the number of persons requiring extensively drug-re-
sistant (XDR)-TB treatment (having failed MDR/RR-TB treatment). However, the model assumed a very low 
rate of treatment success on the standard regimen (23.6%) compared to the routinely reported success 
rate for MDR/RR-TB treatment in South Africa (49% [58]) and did not have separate costs or transition 
probabilities for HIV infection.  
In order to estimate the incremental cost-effectiveness of a bedaquiline-based regimen for the treatment 
of MDR/RR-TB, we established a novel Markov model for ambulatory treatment of MDR/RR-TB in a high-
HIV prevalence setting, parameterized using evidence from the SA NTP.  
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Methods 
2.1 Setting and standard of care 
Since 2011, patients without extensive drug resistance (XDR-TB) in South Africa are eligible for ambulatory 
treatment [17]. If hospitalized for treatment initiation, treatment guidelines indicate that patients can be 
discharged once sputum smear microscopy negative if MDR/RR-TB (e.g. within two weeks) and once spu-
tum culture negative if XDR-TB. From 2011 through 2016, the standard of care for both MDR- and RR-TB 
patients in South Africa was a standardized regimen: 6 months (intensive phase) of 5 drugs including both a 
second-line injectable and a fluoroquinolone followed by 12 to 18 months (continuation phase) without the 
injectable drug [17,19]. Patients with resistance to or intolerance of fluoroquinolones and/or second-line 
injectable drugs are treated with individualized regimens. Roll-out of bedaquiline and linezolid started in 
March 2015, other drugs for individualized regimens include the injectable capreomycin, para-aminosacylic 
acid (PAS), and/or clofazimine [19]. The individualized regimens follow the principles of ensuring at least 
two core effective second-line drugs; thus, where patients do not have second-line drug resistance, bedaq-
uiline can be added in single-drug substitution. Evidence from the SA NTP’s large-scale use of bedaquiline, 
including in an individualized, all-oral long-course regimen for MDR/RR-TB patients (i.e. if the patient had 
experienced toxicity or resistance to kanamycin) was used to parameterize a cost-effectiveness model.  
In South Africa, since 2011, HIV testing is offered to all MDR/RR-TB patients and antiretroviral therapy (ART) 
is initiated once a patient has stabilized on TB treatment (typically after 2-8 weeks) in ART-naïve HIV-posi-
tive patients, regardless of CD4 count [17]. The standard first-line ART regimen for adults and adolescents 
in South Africa is a fixed dose combination of tenofovir, lamivudine or emtricitabine, and efavirenz. Eligibil-
ity for ART has been increasing over time in South Africa, first for those with very low CD4, then for preg-
nant women and TB patients, and as of 2016 all patients are eligible to initiate ART regardless of CD4 count. 
As a result, a significant proportion of HIV-positive patients starting MDR/RR-TB treatment are already on 
ART [128,198]. 
2.2 Health states for MDR/RR-TB treatment 
A Markov model with monthly steps was built in TreeAge Pro 2015 (TreeAge Software, Williamstown, MA) 
to analyse the incremental cost-effectiveness of two different strategies for the inclusion of bedaquiline 
within the long-course MDR/RR-TB treatment regimens for South Africa: 1) XDR only: standard of care for 
MDR/RR-TB and bedaquiline containing regimen for patients who fail treatment and require XDR-TB treat-
ment or 2) All MDR/RR-TB:  bedaquiline containing regimen for both MDR/RR-TB and XDR-TB. The bedaqui-
line strategies were compared with: 3) MDR/RR-TB treatment without bedaquiline and 4) No MDR/RR-TB 
treatment.  
Markov health states were constructed to represent initiation of MDR/RR-TB treatment (with the possibility 
of hospitalization), intensive phase, and culture negative continuation phase of treatment (Figure 6-7). Tun-
nel states for treatment were created to ensure that patients receive at least 6 months of intensive phase 
regimen and at least 12 months in the continuation phase of treatment for MDR/RR-TB patients and 18 
months in the continuation phase of treatment for XDR-TB, as per current SA NTP treatment guidelines 
[17]. If the patient fails to sputum culture convert after 6 months of treatment, the patient would transition 
in the model to XDR-TB treatment. In this analysis, patients initiating as XDR-TB (i.e. already have extensive 
resistance at diagnosis) were excluded. Failure during XDR-TB treatment transitions to palliative care. Sur-
gery for RR-TB is very rare in the SA NTP and therefore was not included as a Markov health state in the 
model. From any treatment state, patients could be lost from treatment or die. Patients lost from treat-
ment could return to treatment with either MDR/RR-TB or XDR-TB within the first 12 months or remain lost 
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from care until death, but incur no further costs. After successful treatment completion, simulated patients 
experience background mortality and die from other causes.  
2.3 HIV and ART status 
Initially, patients are distributed in the model to the initiation of MDR/RR-TB treatment according to 
whether HIV-negative or HIV-positive. If HIV-positive, the model further differentiates as to whether the 
patient is on ART or not. Based on previous South African studies indicating more than 50% of patients on 
ART at initiation [128,198], 60% of the HIV-positive cohort was assumed to be on ART and 40% not on ART 
at MDR/RR-TB treatment initiation. In South Africa, HIV-positive patients, including those on ART, are also 
eligible for bedaquiline but the efavirenz is replaced by either lopinavir/ritonavir or nevirapine during be-
daquiline treatment. After successful MDR/RR-TB treatment completion, patients continue to incur costs 
for ART. 
2.4 Transition probabilities and effectiveness of bedaquiline 
Monthly transition probabilities during treatment (Table 6-2) were derived from the observational cohort 
of public sector SA NTP patients as reported in the national electronic drug-resistant TB case register 
(EDRweb), as exported on 5 May 2016. MDR/RR-TB treatment is a notifiable disease in South Africa and 
public sector hospitals and clinics managing MDR/RR-TB treatment have used EDRweb since 2009 
[13,103,199]. For the non-bedaquiline regimens, transition probabilities are based on the cohort starting 
treatment between 1 January 2012 and 30 April 2014, in order that each patient could contribute at least 
24 months of follow-up time prior to the censor date of 30 April 2016. Valid patient South African identity 
(ID) numbers, if available within the dataset, were matched to the national vital statistics register. Any addi-
tional report of deaths during the 24 months MDR/RR-TB treatment were combined with the deaths in 
EDRweb; thus, the mortality rate in this cohort are higher than EDRweb reporting alone. Patient and treat-
ment characteristics of the cohort, as well as survival analysis and proportional hazards ratios have been 
separately reported[199]. Rates of loss from treatment and death were derived using the ltable command 
within Stata version 14 (College Station, TX, USA) for months 0 to 2, months 3 to 5, and months 6 to 11 and 
converted to the monthly transition probabilities. Rates were derived separately for MDR/RR-TB and XDR-
TB and for HIV-negative and HIV-positive on ART for all three periods. Rates for HIV-positive not on ART 
were only derived for months 0 to 2, in accordance with treatment guidelines for fast-tracked initiation of 
ART. Culture conversion for MDR/RR-TB patients at 6 months(88%) was also extracted from the EDRweb 
cohort.  
Use of bedaquiline was modelled as increasing the proportion of patients who culture converted by the end 
of 6 months by a hazard ratio of 2.44 (95%CI: 1.57, 3.80) [30] for both MDR/RR-TB and XDR-TB patients. 
Similar to previous cost-effectiveness analyses [52–54], the model did not include the mortality imbalance 
found in the Phase 2b clinical trial as the deaths were not attributed to bedaquiline [30]. Mortality from all 
other causes was calculated from standardized life tables for South Africa 2013 [200], starting from age 35, 
the median age of the cohort. 
2.5 Costs, disability adjustments and model inputs 
Ingredients costs were collected from a provider perspective, in this case the SA NTP within the public 
health sector (Table 6-3). All costs were collected in ZAR. Average monthly exchange rate for 2016, 14.74 
ZAR/USD was applied to ZAR costs.[27] Costs were inflated to 2016 ZAR if applicable using the consumer 
price index for medical services [28].  
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Costs for laboratory services [201] and TB and HIV drugs were accessed from the public sector price lists for 
these cost components [202]. For ART, first-line treatment regimens were assumed, with drug substitutions 
as per guidelines in the case of drug-drug interactions [17,19]. Chest x-ray, pure tone audiometry, and elec-
trocardiogram (ECG) testing were categorized as other investigations required for monitoring treatment or 
screening for adverse drug reactions. Costs of these ambulatory procedures were extracted from the public 
sector uniform schedule of patient fees for unsubsidized patients [203], including both facility and health 
professional costs. Monthly resource utilization for laboratory services, medications, and other investiga-
tions were based upon SA NTP MDR/RR-TB-TB guidelines updated Jan 2013 for standard of care regimen 
for the adult weight band 55-70 kg [17]. Bedaquiline guidelines version June 2015 was used for bedaquiline 
containing regimen laboratory services, medications, and other investigations [19]. At the time of the study, 
the full 6 months of bedaquiline was dispensed for individual patients and therefore the full ZAR 9,950 was 
modelled for all initiating patients.   
The proportion of patients hospitalized at treatment initiation [26,128] was extracted from South African 
studies and applied to both bedaquiline and standard MDR/RR-TB regimens. For the 2nd month of treat-
ment, the proportion hospitalized was reduced by the proportion expected to culture convert, with fewer 
patients expected to be hospitalized in the 2nd month if on bedaquiline.  
Costs for either a medical officer or nurse-supported drug collection visits at a primary health care centre 
were also extracted from a South African study [26]. Based on this study and the treatment guidelines, it 
was assumed that for both standard of care and bedaquiline regimens there was a medical consultation at 
initiation, two weeks, and monthly thereafter. Injection regimens (standard of care) were assumed to re-
quire a drug collection visit daily during intensive phase; continuation phase treatment and bedaquiline 
regimens were assumed to require a weekly drug collection visit. Costs for an inpatient hospital stay at a 
sub-acute facility and a specialized M/XDR-TB hospital were extracted from the same study [26,49] and av-
eraged with the national per hospital day equivalent expenditure reported for South Africa [204]. US dollar 
costs from literature were converted to ZAR using the exchange rate provided by the study authors [26,49], 
and then inflated to 2016 values using the medical consumer price inflation index [28]. 
The effectiveness of treatment was evaluated in disability adjusted life years (DALYs). Disability weights (  
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Table 6-4) were extracted from the Global Burden of Disease (GBD) 2010 study [74]. The GBD 2010 was a 
large-scale, multi-country assessment of the pairwise ranking by the ‘general public’ (rather than medical 
experts) of the impact on health for different conditions such as infectious diseases, non-communicable 
disease, and injuries [74]. . Future costs and effectiveness were discounted at 3% as per international 
standards [205] and a time horizon of 10 years was assumed. Results were multiplied by a cohort of 12,527 
patients (the number who initiated MDR/RR-TB treatment in South Africa in 2015 [58]). 
 
2.6 Sensitivity analysis 
For parameters extracted from literature, i.e. bedaquiline effectiveness and the disability weights, associ-
ated confidence intervals from literature were used in one-way sensitivity analysis. For transition probabili-
ties and initial population distributions estimated from the SA NTP, a percentage adjustment of +25% and -
25% was used rather than calculated confidence intervals in order to introduce more uncertainty in the pa-
rameters than was reported for analysed cohort. Similarly, for costs, point estimates were collected from 
the South African public-sector price lists and therefore a percentage adjustment of +25% and -25% was 
considered to understand the impact of possible future changes in costs rather than observed variation. 
One-way sensitivity analysis is presented as a tornado diagram. The resulting expected values were multi-
plied by the number of patients for the 2015 cohort of MDR/RR-TB patients to estimate the total budgetary 
impact for the SA NTP of the different treatment strategies.   
Results 
3.1 Base case results 
At 24 months, the standard cohort reporting period for long-course MDR/RR-TB, the modelled standard 
regimen was associated with 28.0% mortality and 56.3% successful treatment outcome. Adding bedaquiline 
for MDR/RR-TB patients who failed treatment and needed to access individualized XDR-TB treatment did 
not change the treatment success rate at 24 months as XDR-TB treatment was still continuing. Providing 
bedaquiline for all MDR/RR-TB patients from initiation was associated with an improved  treatment success 
rate of 60.6% and reduced mortality of 26.2%.  
For non-bedaquiline regimens, the total expected cost over the 10-year time horizon for a MDR/RR-TB pa-
tient was US$4,439 and average disability-adjusted survival of 5.1 years. Compared to no treatment, 
MDR/RR-TB treatment without bedaquiline averted 3.7 DALYs. Replacing capreomycin with bedaquiline for 
patients who failed MDR/RR-TB treatment and required XDR-TB treatment resulted in cost savings 
(US$4,356, 1.8% less) and similar effectiveness with 0.02 DALYs averted (Table 6-5). As a result, the no be-
daquiline (standard) regimen for all was dominated (less effective and more expensive). Replacing kanamy-
cin with bedaquiline so that all MDR/RR-TB patients access bedaquiline cost US$4,647 (4.3% more) and 
averted 0.17 DALYs compared to the no bedaquiline regimen. The incremental cost of providing bedaqui-
line for all MDR/RR-TB (an increase of US$209) was less than the cost of bedaquiline at US$675 for the full 
6-month course of treatment, as the cost savings from an all-oral therapy offset the higher drug costs. The 
incremental cost effectiveness ratio (ICER) of bedaquiline for all MDR/RR-TB was US$1,242 per additional 
DALY averted compared to the standard regimen.  
In 2015, 12,527 patients initiated MDR/RR-TB treatment in South Africa [58]. The total estimated cost of 
the cohort for the standard regimen was US$55.6 million over the 10-year horizon of the analysis (Table 4). 
Providing bedaquiline for all MDR/RR-TB was estimated to cost US$58.2 million, or an incremental cost of 
US$2.6 million (4.7% increase), in order to avoid 2,109 DALYs (3.3%) over the 10 years. The incremental 
cost is less than the estimated cost of US$8.5 million to procure the recommended 6-month course of be-
daquiline for the entire annual cohort. 
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3.2 Sensitivity analysis 
Robustness of the findings was explored in one-way sensitivity analysis. The estimated ICERs of bedaquiline 
for all MDR/RR-TB compared to the non-bedaquiline standard regimen were calculated and plotted using a 
tornado diagram (Figure 6-8). Variables tested which resulted in a variance of less than ±5% from the ex-
pected value (±US$62.02/DALY averted; 2/3 of all variables tested) are not shown in Figure 2. Overall, the 
analysis was most sensitive to the proportion of patients who culture convert on the standard regimen: a 
25% increase culture conversion on standard regimens led to a 2.3-fold increase in the ICER for bedaquiline 
for all (US$3,908/DALY averted). Results were also sensitive to a 25% increase in the cost of bedaquiline, 
which led to a 90% increase in the ICER (US$2,242/DALY).  
Discussion 
In March 2017 [32], the WHO updated its 2013 conditional recommendations [31] for the use of bedaqui-
line for the treatment of MDR/RR-TB. Encouraging results from the compassionate use program [34] and 
the public sector roll-out of bedaquiline in South Africa was among the evidence considered by the guide-
lines development group in revising the recommendations [32]. Yet, in high-burden, limited resource set-
tings like South Africa, the uncertainty around the affordability of providing bedaquiline to all MDR/RR-TB 
patients rather than just those with no other option has delayed wider implementation. Using a Markov 
model for ambulatory treatment of MDR/RR-TB in a high-HIV prevalence setting, parameterized using evi-
dence from the SA NTP, we estimate that the incremental total cost of a long-course MDR/RR-TB regimen 
where bedaquiline replaces kanamycin for a cohort of patients to be US$2.6 million over 10 years. The in-
cremental cost effectiveness ratio of US$1,242 per additional DALY averted is below the 2015 per capita 
GDP for South Africa of US$5,718 (data.worldbank.org). This amount also represents less than 1% of the 
total SA NTP budget estimated at US$425 million for 2015 [58] and is less than the annual cost of procure-
ment for bedaquiline of US$8.5 million because of cost savings from an all-oral therapy compared to an in-
jection-based regimen. Additionally, with fewer bedaquiline patients failing MDR/RR-TB treatment and 
therefore requiring XDR-TB treatment, the SA NTP could potentially avert 2,109 DALYs when this one co-
hort is followed over 10 years.  
The results of this incremental cost-effectiveness analysis are consistent with previous analyses of bedaqui-
line regimens [52,54,197], despite significant differences in the model structure derived from the standard 
treatment regimens for MDR/RR-TB in South Africa compared to other contexts. A previously published 
cost-effectiveness analysis established that bedaquiline could actually be cost saving compared to the 
standard regimens when patients who are sputum culture positive are hospitalized until sputum negative 
[53]. However, South Africa adopted ambulatory, outpatient care for MDR/RR-TB in 2011 and therefore 
was unlikely to realize this cost saving. Similarly, like the adaptation of the model for Italy, surgery for 
MDR/RR-TB patients who have failed treatment is very rare in South Africa and the use of bedaquiline 
could not avert surgical costs [56]. The Markov model initially built for analysing the use of bedaquiline in 
the United Kingdom was also used to estimate the cost-effectiveness of bedaquiline in multiple low and 
middle-income countries, including South Africa. South Africa does benefit from a very discounted price to 
access bedaquiline, at ZAR 9,950 (US$675) for a complete course of treatment. Bedaquiline was projected 
to be cost effective, even at costs for bedaquiline 30- to 70-times what it is priced at for South Africa [55].  
However, this finding was driven by a very low treatment success rate for the standard regimens and there-
fore a large reduction in the number of patients requiring XDR-TB treatment once regimens included be-
daquiline [55]. Additionally, while the rates of HIV/TB co-infection in South Africa are among the highest in 
the world [58] the model did not account for the higher mortality of MDR/RR-TB patients with HIV co-infec-
tion [13] or the on-going costs of ART after MDR/RR-TB treatment completion.  
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The average cost for standard regimens modelled here (US$3,863 at 24 months and US$4,439 across the 10 
years) are similar to costs previously estimated for the SA NTP when adjusted to 2016 USD ($4,925 [26] and 
US$3,894 [25]). Costs have dropped since 2011 as a result of increasing decentralization and deinstitution-
alization of the SA NTP as well as devaluation of the local currency. Additionally, the cohort was limited to 
patients who did not have resistance to either fluoroquinolones or second-line injectable medicines at the 
initiation of treatment. SA NTP guidelines still recommend hospital-based initiation of treatment and indi-
vidualized regimens for patients with second-line drug resistance in South Africa, inclusion of patients with 
additional resistance would have increased the average costs of the cohort. Previous costing studies for 
MDR/RR-TB in South Africa have limited the time horizon to the 2 years, in line with the guidelines for re-
porting cohort outcomes. The 10-year horizon in the model established here may be more appropriate as it 
captured extended treatment for patients who failed MDR/RR-TB treatment initially as well as treatment 
interruptions when patients were lost from care but then returned. Additionally, the longer time horizon 
captures the costs of chronic care for HIV-positive patients who successfully complete MDR/RR-TB treat-
ment within the 2 years but then need to continue lifelong ART.  
4.1 Study limitations 
Similar to other cost-effectiveness analyses that have been published for bedaquiline [53–56], we did not 
use findings from the Phase 2b clinical trial with regards to mortality. The Phase 2b trial showed a statisti-
cally significant imbalance in mortality in the two treatment arms with more deaths occurring in the pa-
tients exposed to bedaquiline (10/79, 12.7%) than in the placebo arm (2/81, 2.5%) [30]. However, none of 
the deaths in the bedaquiline arm were attributed to bedaquiline by the clinical trial investigators. Prior to 
the roll-out of bedaquiline for patients with XDR-TB in South Africa, more than 40% of patients died before 
completing treatment [13,58,206]. The 19.8% mortality for patients with second-line resistance receiving 
bedaquiline through compassionate use access [34] reported in the revised WHO recommendations for be-
daquiline is therefore encouraging [32]. Additionally, the revised recommendations included observational 
reporting from the EDRweb where the mortality rates on bedaquiline were lower than for the patients not 
on bedaquiline [32]. If the observational data described in the WHO systematic review is confirmed, the 
analysis presented here with the same mortality for standard and bedaquiline regimens would underesti-
mate the DALYs that could be averted by adoption of bedaquiline for all MDR/RR-TB patients.  
This incremental cost-effectiveness analysis also did not include a measure of on-going transmission. TB, 
including RR-TB, is an infectious disease. RR-TB treatment costs and complexity increases with the degree 
of resistance, and treatment with a ‘failing’ regimen can lead to increased resistance. Therefore, successful 
MDR/RR-TB treatment can avert future costs of treating XDR-TB. These (averted) costs of transmission and 
development of further drug resistance are excluded from this analysis as transmission modelling is outside 
the scope of this study. However, this may result in an underestimate of the benefits of a more effective 
regimen. 
Finally, the direct provider costs estimated here, while a significant component of health care costs, do not 
reflect the cost to society. Direct and indirect costs incurred by patients to access MDR/RR-TB treatment 
while on treatment are excluded from this analysis and therefore the costs presented here will be an un-
derestimate of the societal costs of MDR/RR-TB treatment. In this analysis, it was assumed that injections 
were provided at a health care facility and not by an injection team travelling to visit a patient in his or her 
home. Patients on an injection-based regimen (e.g. kanamycin) are likely to incur higher out-of-pocket ex-
penses for the increased frequency of clinic visits required for injections.  
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Conclusions 
Markov modelling indicates providing bedaquiline for all MDR/RR-TB patients could increase the treatment 
success rate in South Africa for MDR/RR-TB patients without additional second-line drug resistance from 
56.3% on a non-bedaquiline regimen to 60.6%, at an incremental cost US$2.6 million over a 10-year hori-
zon. This amount is far less than US$8.5 million to procure bedaquiline for the initiating treatment cohort 
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Tables 
Table 6-2. Markov model monthly transition probabilities  
RR-TB diagnosis HIV, ART status Phase  
Mortality during treat-
ment 
  Transition probabilitya 
MDR/RR-TB HIV-negative Initiation 0.0184 
  Intensive 0.0101 
  Continuation 0.0061 
 HIV-positive, on ART Initiation 0.0325 
  Intensive 0.0167 
  Continuation 0.0086 
 HIV-positive, no ART Initiation 0.0547 
XDR-TB HIV-negative Intensive 0.0220 
  Continuation 0.0215 
 HIV-positive, on ART Intensive 0.0368 
  Continuation 0.0261 
Loss from treatment   Transition probabilitya 
MDR/RR-TB HIV-negative Initiation 0.0103 
  Intensive 0.0159 
  Continuation 0.0155 
 HIV-positive, on ART Initiation 0.0087 
  Intensive 0.0159 
  Continuation 0.0129 
 HIV-positive, no ART Initiation 0.0157 
XDR-TB HIV-negative Intensive 0.0103 
  Continuation 0.0107 
 HIV-positive, on ART Intensive 0.0045 
  Continuation 0.0078 
All RR-TB Return after loss Month 3-12 of loss .05b 
Mortality after treatment   Transition probability 
All RR-TB All HIV status  0.0005 to 0.0010 [200] 
Culture conversion   Proportion 
MDR/RR-TB All HIV status Intensive 88.4%a 
XDR-TB All HIV status Intensive 76.8% [30,34] 
Hospitalization    
MDR/RR-TB All HIV status Initiation 20.6% [128] 
Initial distribution   Proportiona 
 HIV-negative Initiation 28.3% 
 HIV-positive Initiation 71.7% 
 HIV-positive, no ART Initiation 
Assumption 40% HIV+ not on 
ART  [128,198] 
Bedaquiline effectiveness   Hazard ratios 
All RR-TB All HIV status Culture conversion 2.44 (95%CI: 1.57, 3.80) [30] 
MDR/RR-TB: Multi-drug resistant or rifampicin-resistant tuberculosis; XDR-TB: extensively drug resistant TB; 
HIV: human immunodeficiency virus; ART: anti-retroviral therapy 
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a Initial patient distribution and transition probabilities generated from South African EDRweb cohort 2012-
2014 
b Calibrated assumption 
Note: Patients that do not culture convert at 6 months (end of intensive phase) are considered as treat-
ment failures and, in the model, transition to intensive phase of XDR-TB treatment.   
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Table 6-3. Monthly unit costs in 2016 USD  
Diagnosis Phase Regimen Monthly costa Source 
Drugs b     
MDR/RR-TB Intensive standard of care  $ 100.96  [202] 
 Intensive bedaquiline c  $ 93.40  [202] 
 Continuation All  $ 83.79  [202] 
XDR-TB Intensive standard of care  $ 520.77  [202] 
 Intensive bedaquiline c $ 451.67 [202] 
 Continuation All $ 301.67 [202] 
HIV ART Intensive standard of care $ 11.92 [202] 
 Intensive bedaquiline c $ 10.92 [202] 
 Continuation All $ 9.88 [202] 
All RR-TB Intensive (full 6 months) bedaquiline c $ 675.23 SA NTP 
Laboratory testing b     
All RR-TB Initiation standard of care $ 54.40 [201] 
 Initiation bedaquiline c $ 52.50 [201] 
 Intensive standard of care $ 14.12 [201] 
 Intensive bedaquiline c $ 10.32 [201] 
 Continuation All $ 12.53 [201] 
HIV ART ART initiation (CD4) All $ 3.90 [201] 
 ART monitoring (Viral load) All $19.92 [201] 
Other investigations b     
All RR-TB Initiation standard of care $ 19.60 [203] 
 Initiation bedaquiline c $ 19.34 [203] 
 Intensive standard of care $ 10.56 [203] 
 Intensive bedaquiline c $ 10.30 [203] 
 Continuation All Not required  
Care b     
All RR-TB Hospitalized All $ 2,882.52 [26,49,2
04] 
 Initiation standard of care $ 98.12 [49] 
 Initiation bedaquiline $ 31.35 [49] 
 Intensive standard of care $ 89.86 [49] 
 Intensive bedaquiline $ 23.09 [49] 
 Continuation All $ 23.09 [49] 
MDR/RR-TB: Multi-drug resistant or rifampicin-resistant tuberculosis; XDR-TB: extensively drug resistant TB; 
HIV: human immunodeficiency virus; ART: anti-retroviral therapy; SA NTP: South African National TB Pro-
gramme 
a All costs: All costs collected in ZAR. Average monthly exchange rate for 2016, 14.74 ZAR/US$ was applied 
to ZAR costs [27].  
b Assumed resource utilization as per guidelines for each month patient in care. 
c Bedaquiline guidelines version June 2015 used for bedaquiline containing regimen laboratory and investi-
gations clinical monitoring requirements [19].  
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Note 1: bedaquiline costs are in addition to other MDR/RR-TB or XDR-TB treatment drugs, i.e. the total cost 
for MDR/RR-TB treatment per month in the intensive phase for someone completing the full 6 months of 
treatment would be $93.40 + $675.23/6 = $205.94, nearly twice as expensive as the kanamycin-based regi-
men cost of $100.96 / month. 
Note 2: Monthly ART costs differ according to whether bedaquiline or SOC regimen as per Sirturo prescrib-
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Table 6-4. Disability weights, extracted from the Global Burden of Disease 2010 study [74] 
HIV status Value (confidence interval) Applicable model states 
HIV-negative   
 Tuberculosis: without HIV infection 
0.331 (95%CI: 0.222– 0.450)  
Initiation, Intensive phase, Continuation 
phase, Lost from treatment, Palliative 
care 




 Tuberculosis: with HIV infection 
0.399 (95%CI: 0.267–0.547) 
Initiation, Intensive phase, Continuation 
phase, Palliative care 
 HIV/AIDS: receiving antiretroviral treatment 
0.053 (95%CI: 0.034–0.079) 
Cure 
HIV-positive, 
not on ART 
  
 Calculateda from product of two co-morbid-
itiesas 
0.697 (95%CI: 0.470 – 0.843) 
Initiation, Lost from treatment 
HIV: human immunodeficiency virus; ART: anti-retroviral therapy; AIDS: acquired immune deficiency syn-
drome 
aA multiplicative model for computing co-morbid conditions was used [80]. Scores (1 - disability weight) of 
two co-morbid conditions. AIDS: not receiving ART, 0.547 (95%CI: 0.382–0.715)  and TB: without HIV infec-
tion 0.331 (95%CI: 0.222– 0.450) were multiplied to create a disability weight for patients not on HIV or TB 
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Table 6-5. Sensitivity analysis, incremental cost effectiveness ratio of adding bedaquiline, 10-year horizon 

















Average  $ 4,439  5.12  Reference Reference Reference 
Total  $ 55.60 million  64,128 Reference Reference Reference 
MDR/RR-TB stand-




Average  $ 4,356  5.14 - $ 82.42  0.02  
Total $54.57  million       64,499  - $ 1.03 million        271  - $ 3,804  
MDR/RR-TB be-
daquiline for allc 
 
Average  $ 4,648  5.29  $ 208.99   0.17  
 
Total  $ 58.22 million        66,237   $ 2.62 million         2,109   $ 1,242  
MDR/RR-TB: Multi-drug resistant or rifampicin-resistant tuberculosis; XDR-TB: extensively drug resistant TB; 
HIV: human immunodeficiency virus; ART: anti-retroviral therapy 
a  MDR/RR-TB patients access standard regimen of kanamycin (injectable, 6 months), moxifloxacin, ter-
izidone, ethionamide, and pyrazinamide for 18 months. If fail MDR/RR-TB treatment, treated with XDR-TB 
regimen consisting of capreomycin (injectable, 6 months), linezolid, moxifloxacin, terizidone, ethionamide, 
clofazimine, para-aminosacylic acid, and pyrazinamide for 24 months 
b MDR/RR-TB patients access standard regimen of kanamycin (injectable, 6 months), moxifloxacin, ter-
izidone, ethionamide, and pyrazinamide for 18 months. If fail MDR/RR-TB treatment, treated with XDR-TB 
regimen consisting of bedaquiline (oral, 6 months), linezolid, levofloxacin, terizidone, ethionamide, clo-
fazimine, para-aminosacylic acid, and pyrazinamide for 24 months. 
c MDR/RR-TB patients access bedaquiline regimen of bedaquiline (oral 6 months), levofloxacin, terizidone, 
ethionamide, and pyrazinamide for 18 months. If fail MDR/RR-TB treatment, treated with XDR-TB regimen 
consisting of bedaquiline (oral, 6 months), linezolid, levofloxacin, terizidone, ethionamide, clofazimine, 
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Figures 
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Figure 6-8. Tornado analysis of the incremental cost-effectiveness ratio of bedaquiline for all MDR/RR-TB 
patients compared to standard regimen 
 
Note: Proportion culture converting refers to the baseline rate of culture conversion on the SOC regimen. A 
higher proportion of SOC patients converting (and therefore not experiencing treatment failure and requir-
ing individualized treatment regimens) would lower the incremental effect of bedaquiline and therefore 
increase the ICER/DALY averted, as while bedaquiline improves the rate of culture conversion, the propor-
tion of patients who have culture converted cannot exceed 100%.   
  
0 500 1000 1500 2000 2500 3000 3500 4000 4500
Cost ART, intensive, on bedaquiline
Cost ART, intensive
Cost drugs, continuation
Cost laboratory on bedaquiline, intensive
Cost investigations, intensive
Cost investigations on bedaquiline, intensive




Cost outpatient care, intensive
Cost laboratory, intensive
Proportion HIV-positive
Cost XDR TB drugs, continuation
Cost XDR TB drugs, intensive
Proportion culture convert, on bedaquiline




ICER, $ / DALY averted; expected value = $1,242
HIGH_VALUE LOW_VALUE
 
Page | 120 
7 RESULTS: PROVIDER COSTS OF ADR MANAGEMENT 
7.1 SYNOPSIS  
Formal citation: Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Direct costs of managing 
adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. International 
Journal of Tuberculosis and Lung Disease. In press. 
Supplemental materials appended (Annex - Supplemental materials ADR cost model) 
This chapter was written to achieve the second overall objective of the thesis research; namely, to evaluate 
the provider cost of management of ADRs incurred during RR-TB treatment, including drugs, hospitaliza-
tion, laboratory monitoring, and clinic visits for the most frequently occurring moderate to severe ADR as-
sociated with the current standard of care MDR/RR-TB treatment regimen in the SA public health sector. 
Resource use was extracted from clinical guidelines for MDR/RR-TB treatment in the public sector. Ingredi-
ent costs collected from the same public sector sources as for Chapter 6 were multiplied by the expected 
resource use in a cost worksheet (attached as supplemental materials, Annex - Supplemental materials ADR 
cost model). Weighted average costs for moderate ADR and for severe and serious ADR were multiplied by 
the expected frequency of each of the different events, as extracted from literature identified during the 
systematic review Chapter 5. Based upon the analysis presented inChapter 4, where the competing risk of 
mortality can affect the observed prevalence of the ADR, the Markov model for MDR/RR-TB treatment in-
troduced in Chapter 6 was used to evaluate the expected costs of ADR management. Distributions were 
added for all model parameters, so that instead of one-way sensitivity analysis, probabilistic sensitivity 
analysis could be used. For an average cohort of MDR/RR-TB patients such as the 12,527 who initiated 
treatment in the SA NTP in 2015, including ADR management costs increased the estimated cost of 
MDR/RR-TB treatment in South Africa from $57.55 million over 10 years to $62.31 million.  
Contribution to the thesis and novelty 
Cost-effectiveness analyses of MDR/RR-TB treatment have sometimes applied an average cost for ADR 
management to all patients, but have not specified the type, frequency, cause, or specific management for 
the ADR in the details. This analysis was a guidelines-based cost for the management of all common ADR 
included in the SA MDR/RR-TB treatment guidelines. A frequency for each of the ADR was estimated from 
literature review (as presented inChapter 5) and multiplied by the cost of managing the ADR estimated 
from the bottom-up ingredients approach. The costing workbook indicates the suspected drugs for each of 
the included ADR, and thus also can be used to estimate the costs of ADR for different regimens (as it was 
for Chapter 8).  
Role of the candidate 
The candidate worked with the clinicians to interpret the guidelines for treatment of ADR during MDR/RR-
TB treatment and to identify and quantify the resources required for management of ADR. She then ex-
tracted unit costs from public sector databases and consulted with the clinicians in ensuring that the costs 
were appropriately matched to the required resources. She built an Excel-based cost worksheet for the 
most frequently occurring serious or severe ADR and the most frequent mild, moderate and severe ADR as 
reported in M3. The candidate wrote the first draft of the manuscript and revised in response to inputs 
from co-authors. She made revisions based on comments from reviewers. All authors approved the final 
manuscript.   
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7.2 TREE STRUCTURE ADR COSTING 
The model described above was modified in order to include the costs of ADR and to estimate the expected 
costs per MDR/RR-TB patient. In order to account for additional uncertainty with regards to the frequency 
and timing of the ADR, probabilistic sensitivity analysis method was adopted. This meant that all parame-
ters (costs, transition probabilities, and initial patient distributions) had to be sampled from appropriate 
distributions rather than using point estimates and one-way variance.  
Figure 7-1 Decision tree: Modifications for ADR 
 
In the above diagram, unlike the initial Markov model, trackers have been added to be able to count the 
ADR or SAE experienced. Since some patients experience none and other patients experience more than 
one ADR, the tracker counts are important to estimate the cost for an ‘average’ patient.  
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Figure 7-2 Decision tree: Tree explorer for ADR model 
 
In the above diagram, unlike the initial Markov model, additional health states have been added during the 
intensive phase of MDR/RR-TB and XDR-TB treatment. Patients in the model can transition from initiation 
to one of three health states for intensive treatment (Tx_cult+): treatment (Tx), treatment and experiencing 
a moderate ADR (Tx + mod ADR), or treatment and experiencing a serious ADR (Tx + serious ADR).   
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Summary 
Word count: 190 
Objective 
To estimate the provider costs of managing adverse drug reactions (ADR) to standard long-course treat-
ment for multi-drug and rifampicin-resistant tuberculosis (MDR/RR-TB) according to South African guide-
lines. 
Methods 
We parameterized a previously published Markov health state model for MDR/RR-TB with guidelines-
based, bottom-up public-sector provider costing of ADR management. Frequency of ADR was extracted 
from literature. Costs were estimated over 10 years, discounted 3% annually, and tested using probabilistic 
sensitivity analysis.    
Results 
On average, the guidelines-based costing of moderate ADRs weighted by frequency of occurrence was 
US$135.76 (standard deviation (sd): US$17.18) and the cost of serious ADRs was US$521.29 (sd: US$55.99) 
per patient. We estimated the incremental costs of ADR management are $380.17 per patient initiating 
MDR/RR-TB treatment annually. The incremental costs of ADR management for the public health sector in 
South Africa was US$4.76 million; 8.3% of the estimated cohort costs of MDR/RR-TB treatment ($57.55 mil-
lion) for the 2015 cohort of 12,527 patients.  
Conclusions 
Management of multiple ADR and serious ADR, common during the first 6 months of standard, long-course 
MDR/RR-TB treatment, substantially increases provider treatment costs. These results add to need to ac-
count for the cost of adverse events in comparing regimen costs and the urgency for identifying drug regi-
mens with improved safety profiles. 
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Introduction 
Patients resistant to the core first-line drug for treatment of tuberculosis (TB), rifampicin, alone or in combi-
nation with any other first-line or second-line drugs require second-line TB treatment. The World Health 
Organization (WHO) estimates that globally in 2015 there were 580,000 new rifampicin-resistant (RR-) TB 
cases. In South Africa, there were 19,613 laboratory-confirmed diagnoses and 12,527 MDR/RR-TB cases ini-
tiated treatment, with an estimated HIV co-infection rate of 57%.[58]The average cost of treating a 
MDR/RR-TB patient in South Africa, assuming implementation of guidelines for ambulatory, outpatient 
standardized long-course treatment, is estimated at US$3,863 to US$4,926 per patient (converted to 2016 
USD).[25,26,207] Not only are the drugs expensive; many of the second-line TB drugs have known toxici-
ties. According to a meta-analysis of cohorts where at least 20% of the patients were known to be HIV-posi-
tive, 83% (95% confidence interval (CI): 82%,84%) of all patients experienced at least one adverse event 
(AE) during treatment and 24% (95%CI: 21%, 27%) experienced a severe or serious AE during MDR/RR-TB 
treatment.[208] On average, each patient experiences 3 to 8 AE during the course of MDR/RR-TB treat-
ment.[122,123,194] Although there is much evidence that many of the AE are related to drugs, i.e. are ad-
verse drug reactions (ADR), specification of the costs of ADR management has not been a focus of the 
MDR/RR-TB cost analyses.  
To improve planning, budgeting, and policy decision making, we collected the costs of provider (payer) 
costs of managing ADR during MDR/RR-TB treatment in South Africa and used a previously established 
Markov model [207] to estimate the incremental cost of ADR management.   
Methods 
Setting 
All MDR/RR-TB patients in South Africa receive treatment free of charge at public sector (government) facil-
ities. Treatment for MDR/RR-TB was both de-institutionalized and decentralized in 2011; most patients do 
not receive facility-based directly observed treatment. As of 2015, most patients without second-line drug 
resistance initiate treatment on an out-patient basis at a nearby hospital or community health centre and 
receive daily injections during the initial phase at a primary health clinic. Through the end of 2016, South 
African National TB Programme (SA NTP) guidelines recommended a long-course (18-24 month), standard-
ized regimen, including an injectable aminoglycoside (kanamycin) during the first 6 months 4 oral drugs: a 
fluoroquinolone (moxifloxacin), terizidone, ethionamide and pyrazinamide).[17] MDR/RR-TB patients in 
whom treatment fails are able to access individualized regimens similar to those for extensively drug-re-
sistant (XDR-) TB, which in South Africa prior to the introduction of bedaquiline in 2015 included capreomy-
cin, moxifloxacin, linezolid, clofazimine, ethionamide, para-aminosalicylic acid, terizidone, and pyra-
zinamide.  
Guidelines-based costing of ADR management 
An ingredients costing approach was built from the estimated resources use for guidelines-based manage-
ment of ADR and serious ADR included in the SA NTP guidelines [17] or WHO guidelines for the standard 
regimen.[209] The costing work book and details are attached as supplemental materials. Resource use for 
ADR management, e.g. quantity and duration of required medications, laboratory tests, investigations, flu-
ids, additional clinic visits, or hospitalization, was based on indications in the MDR/RR-TB SA NTP guidelines, 
or WHO or SA primary health care guidelines where there was insufficient details.[17,209,210] Costs for 
each ADR was then multiplied by the expected frequency of each ADR during MDR/RR-TB 
[108,123,179,194,211] and extensively drug resistant (XDR-) TB  [148,168] treatment which was extracted 
from literature [108,115,123,148,168,179,194] in order to create weighted average costs. Prevention and 
screening for early AE detection, e.g. screening for symptoms or monitoring for laboratory abnormalities, 
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are applicable to all patients who initiate treatment, included in guidelines-based costing of MDR/RR-TB 
treatment [25,26,207] and therefore are excluded here. 
All unit costs were collected from the perspective of the public sector in South Africa in the local currency 
(ZAR) using public sector databases and price lists.[202,212–214] If needed, costs were inflated to 2016 ZAR 
using the medical component of the consumer price index (CPI) and converted to USD at the average ex-
change rate for 2016, 14.74 ZAR to USD.[27,28] Capital investment in infrastructure, pre-service education, 
vehicles or medical equipment was not separately estimated as assumed to be considered in the listed 
prices. No patient costs were included in this analysis. Patient transport, including emergency transport to 
hospital, was also not included in the analysis. 
Cost per treatment episode and budget impact 
Having calculated a weighted average cost per ADR and serious ADR, the total cost of ADR management per 
MDR/RR-TB treatment episode was modelled using a previously published Markov model for ambulatory, 
long-course standard MDR/RR-TB treatment parameterized for South Africa.[207] Only patients without 
second-line resistance at the initiation of MDR/RR-TB treatment are included in the analysis. The health 
state model (Figure 7-3) was built in TreeAge Pro 2015 (TreeAge Software, Williamstown, MA). Patients are 
initially distributed in the model according to whether HIV-negative (28.3%) or HIV-infected (71.7%); HIV-
infected patients are differentiated as to whether already on anti-retroviral therapy (ART, 60.0%) or ART 
naïve at initiation of MDR/RR-TB (40.0%).[207] Patients progress through monthly steps from initiation of 
treatment, intensive phase (first six months), continuation (following 12-18 months) phase of treatment, to 
treatment completion (cure). Patients may be hospitalized at initiation of MDR/RR-TB treatment 
(20.6%).[11]  From any treatment state, patients could be lost from treatment or die. Patients failing to spu-
tum culture convert by 6 months transition in the model to XDR-TB treatment; patients failing to sputum 
culture convert after 6 months of XDR-TB treatment transition to palliative care. Transition probabilities for 
loss from care, treatment failure, and death for HIV-negative and HIV-infected patients with either 
MDR/RR-TB or XDR-TB were as reported in the original model analysis [207] derived from the SA drug-re-
sistant TB case register (January 2012 - April 2014 cohort).[199] Provider costs for ART, MDR/RR-TB treat-
ment, prevention of and monitoring for ADR were already included in the model and not adjusted for this 
analysis.[207]  
Based on the frequency of ADR reported in literature, it was assumed that during months 1 to 5, a patient 
could experience either a moderate ADR (mean transition probability 0.183)[208] or a serious ADR (mean 
transition probability 0.052).[194] ADRs were not included in the first month of treatment (month 0) or af-
ter intensive phase (months 6 to 18). Patients who failed MDR/RR-TB treatment and needed to initiate 
XDR-TB treatment regimen were modelled as possibly experiencing ADR or serious ADR in months 1 to 5 of 
XDR-TB treatment. Patients can experience one, none, or multiple ADR or serious ADR. HIV-infected pa-
tients naïve to ART at MDR/RR-TB initiation experienced a relative increase in risk of ADR and serious ADR 
(sub-hazard ratio: 3.07 relative to HIV-negative patients).[194]  
Frequency and costs of ADR and serious ADR for MDR/RR-TB and XDR-TB health states, initial population 
distributions of HIV-infected and HIV-infected on ART, and the relative risk of ADR if ART naïve, were varied 
using probabilistic sensitivity analysis through Monte Carlo simulation. ADR costs were sampled from a 
gamma distribution with variances as estimated; transition probabilities and HIV proportions were sampled 
from a beta distribution with variance of 25%. A time horizon of 10 years was assumed and future costs 
were discounted 3% annually as per international standards.[18] Potential impact on the SA health budget 
was summed from the 12,527 trials, based upon the 2015 SA initiating cohort.  
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Ethics and reporting 
No patient-level data or information was collected, reviewed, or analysed for this study. Description of 
methods and reporting of results is in alignment with the Consolidated Health Economic Evaluation Report-
ing Standards (CHEERS) statement.[195] 
Results 
Management of ADR 
The costs, frequency, and weighted costs of management of the most frequently occurring ADR during 
MDR/RR-TB treatment are presented in Table 7-1(cost components and XDR-TB frequencies are presented 
in supplemental materials). The weighted average for moderate ADR was US$135.76. The costs ranged 
US$2.51 for diarrhoea (ancillary medicine provided during regular MDR/RR-TB visit) to US$208.23 for tem-
porary drug-induced hypothyroidism, which requires ancillary treatment from onset to completion of 
MDR/RR-TB treatment. Hypothyroidism was also the most frequent moderate ADR at 36% [108] and there-
fore contributed the most to the weighted average. 
Nine of the 10 severe or serious ADR (Table 7-2) include hospitalization and the duration of hospitalization 
was the most significant cost component.  Severe systemic allergic reaction (e.g. Stevens–Johnson syn-
drome) require ICU care and, as a result, were the most expensive of all the ADR costed, at $5,461, alt-
hough it was also the most infrequent. The most frequently experienced severe ADR was permanent and 
profound hearing loss, at 40% of patients on the kanamycin-based regimen [115], which was estimated to 
cost the provider $50.76. The weighted average for serious ADR experienced during MDR/RR-TB treatment 
was US$521.29. 
Cost per MDR/RR-TB treatment episode 
In 2015, according to the WHO, 12,527 patients initiated MDR/RR-TB treatment in South Africa (63.9% of 
the 19,613 diagnosed).[58] On average, the standard, long-course regimen in South Africa was estimated to 
cost $4,594 (95%CI: 3,950 to 5,283) over the 10-year horizon of the model. Having adjusted the model to 
account for the costs of ADR management in the MDR/RR-TB and XDR-TB health states, including moderate 
(US$135.76 and $156.05, respectively) and serious ADR (US$521.29 and $1,039, respectively), increased 
the average cost to US$4,974 (95%CI: 4,280 to 5,714). The average cost of managing ADR was an additional 
US$381.17 per patient, an 8.3% increase. For the 2015 MDR/RR-TB cohort, ADR management increased the 
costs of MDR/RR-TB treatment from US$57.55 million to US$62.31 million, an additional $4.76 million per 
year (95%CI: 4.13 to 5.40 million).  
Discussion 
For South Africa, a high-burden TB/HIV and high-burden MDR/RR-TB country, the incremental costs of each 
ADR and serious ADR are estimated to add up to US$4.76 million annually. These substantial cost estimates 
highlight that ADR represent not only a burden on the patient experiencing the event(s), but also a measur-
able cost to the public health system. While the standard deviations presented here indicate uncertainty in 
an average cost based upon the nature, frequency and severity of the ADR that occur during the standard-
ized, long-course MDR/RR-TB treatment, nearly all patients experience at least one ADR. We added the av-
erage calculated weighted cost of managing ADR to a Markov health state model in order to estimate an 
expected cost per MDR/RR-TB patients sampling from the wide distribution of possible outcomes. Thus, 
until a better tolerated regimen is available, even an uncertain estimate of the costs is important for plan-
ning, budgeting, and analysis of MDR/RR-TB treatment regimens.  
 
Page | 128 
The 2016 SA NTP budget, as reported to the WHO, was $425 million for 2016 including $68 million for drug-
resistant TB, including patients with MDR/RR-TB and XDR-TB.[58] The budget is built from expected patient 
cohorts, multiplied by the drug costs per patient and expected days of hospitalization as per treatment 
guidelines [58] and excludes the costs of management of moderate to serious ADR. ADR management costs 
estimated here exceed previously reported estimates from South Africa ($190 [25]), at least in part because 
of longer duration of hospitalization(s) associated with serious ADR. Neither the SA NTP budget nor this 
analysis included the increased costs for individualized regimens (drug substitution) for patients after ADR, 
and thus is still a conservative estimate. Adding the incremental costs of ADR management estimated here 
as well would increase the estimated resources required for MDR/RR-TB treatment. Similar analysis should 
be done for those patients initiating as XDR-TB; the costing of the ADRs included here can serve as a start-
ing point.  
While the resources used and unit costs presented here were calculated for South Africa, the frequency of 
the ADR during MDR/RR-TB treatment are common across multiple settings [208] and the relative incre-
mental resource requirement (8.3% increase for ADR management) could improve estimation. Similarly, 
this analysis drew on evidence from the SA NTP prior to the 2017 roll-out of short-course (9 to 12 month) 
regimens for MDR/RR-TB, however, the methods and costing reported here are useful for the short-course 
as well, as most ADR during MDR/RR-TB treatment occur in the first 6 months [26] and the long and short-
course regimens are based on the same core and additional drugs.[14] Although treatment regimens and 
guidelines are changing; these results remain relevant as they are indicative of the need for taking into ac-
count the costs of medication as well as managing adverse events when comparing regimens. 
Limitations 
The provider perspective for costs excludes patient direct and opportunity costs and, therefore, underesti-
mates the societal burden of the ADR experienced. Hospitalization often results in increased transportation 
costs for patients and family members, as well as patient and caregiver loss of income. On average, a 
month of hospitalization for MDR/RR-TB cost SA patients US$211 (converted to USD 2016), mostly from 
lost productivity.[44] For patients experiencing profound hearing loss, the use of a provider-payer perspec-
tive, especially in a context where rehabilitative surgery (cochlear implants) is rare, greatly underestimates 
the societal costs for this treatment. Yet, ototoxicity (ranging from mild to severe) is one of the most fre-
quent ADR experienced by MDR/RR-TB patients.[115] Similarly, the most serious ADR may result in death, 
the burden of which is not considered in an analysis limited to provider costs.  
We also did not measure the non-monetary effects of ADR including increased stress and distress for pa-
tients experiencing these events. Patients who experience an ADR may be reluctant to continue treatment 
that they associate with the adverse reactions resulting in poor adherence, loss from care and sub-optimal 
outcomes.[215,216]  Patient-perceived toxicity may also not be aligned to the culprit drug and patients may 
associate ADR with a drug that was unlikely to have caused the ADR. If patients interrupt or reduce pre-
scribed dosing, they could be at risk of increased resistance and transmission of a highly resistant strain of 
TB. A study of MDR/RR-TB patients found that risk of acquired resistance increased by 20% for each month 
where less than 80% of the prescribed doses were taken.[217]  
Finally, this guidelines-based costing assumed that only the guideline-indicated minimum treatment was 
used; this may underestimate clinical care received. In cases where a patient experiences multiple ADR con-
currently, additional drug/drug interactions and contraindications may be experienced which require more 
complex or higher cost treatments. Conversely, guidelines-based costing may also overestimate the costs if, 
for any reason, treatment is not completed, laboratory tests not done, or medication not prescribed. The 
appropriate management of patients after ADR is limited by the availability of alternatives, when clinicians 
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have to weigh the risks of the ADR with the risks of untreated or undertreated disease.[192,218,219]  Addi-
tionally, this analysis did not consider the costs of on-going transmission of MDR/RR-TB, including transmis-
sion while hospitalized for ADR, or acquired resistance as a result of ADR.  
Conclusions 
Each year, management of multiple moderate to severe adverse drug reactions during the standardized, 
long-course MDR/RR-TB treatment requires US$4.76 million in additional medications, laboratory tests, 
procedures, and clinic and hospital utilisation – compared to the budgeted estimates of US$57.55 million 
which exclude ADR management. This represents a measurable and substantial cost to the South African 
public health system, underlines the need to account for the cost of adverse events in comparing regimen 
costs, and adds to the urgency of identifying a better tolerated regimen for the treatment of MDR/RR-TB, 
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Tables 
Table 7-1 South African public sector guidelines-based provider costs [17,209,210] of managing the 
most commonly experienced moderate ADR during MDR/RR-TB treatment (2016 USD) 
Moderate adverse 
events 
Description, severity Total cost, 2016 
USD 
Frequency MDR/RR-







tion  $                  208.23  36% [108]  $                   74.96  
Hepatitis, liver dys-
function 
e.g. elevated ALT < 5 x up-
per limit of normal  $                  155.01  7% [108]  $                   10.85  
Hearing loss 
Permanent, high frequency 
hearing loss  $                    50.76  18% [115]  $                     9.14  
Psychiatric disorder e.g. depression, confusion  $                    43.20  10% [108]  $                    4.32  
Sleep disturbance, 
insomnia   $                    31.57  10% [179]  $                     3.16  
Peripheral neuropa-
thy   $                    28.89  18% [123]  $                     5.20  
Visual disturbance   $                    23.73  Not associated   $                           -    
Tinnitus without hearing loss  $                    23.68  12% [123]  $                     2.84  
Dizziness, vertigo   $                    19.49  8% [123]  $                     1.56  
Hypersensitivity, al-
lergic reaction 
Rash, dermatologic reaction 
(moderate)  $                    15.97  16% [123]  $                     2.56  
Nausea, vomiting 
Vomiting or nausea limiting 
oral intake  $                    15.72  18% [123]  $                     2.83  
Joint pain, arthralgia   $                    11.09  12% [123]  $                     1.33  
Tendonitis   $                      3.06  0.5%, Assumption  $0.02  
Headache   $                      2.52  3% [123]  $0.08  
Diarrhoea    $                      2.51  15% [108]  $0.38  
 Average cost  $                     42.36  Weighted average 
$119.22 (sd: 
18.81) 
Description of laboratory tests, medications, investigations, and specialist consultations and the frequencies 
and averages for XDR-TB is included in each unit cost is provided the ADR cost workbook, attached as supple-
mental materials.  
^ An MDR/RR-TB patient may experience none, one or multiple ADR during treatment.  
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Table 7-2. South African public sector guidelines-based provider costs [17,209,210] of managing most 
commonly experienced serious adverse drug reactions during MDR/RR-TB treatment (2016 USD) 
Severe or seri-
ous adverse 










e.g. Stevens-Johnson Syndrome 
and Toxic epidermal necrolysis   $      5,461.05  0.5% [194]  $                    27.31  
Hepatitis, liver 
dysfunction 
e.g. ALT > 5 x the upper limit of 
normal  $      2,703.45  6% [194]  $                  162.21  
Anemia 
Thrombocytopenia, <50,000 
cells/mm3  $      1,943.75     $                           -    
Psychiatric disor-
der 
e.g. suicidal or pyschosis (harm 
to self or others)  $      1,824.41  8% [194]  $                  145.95  
Renal dysfunc-
tion 
Globular filtration rate < 30 
ml/min    $      1,807.88  2% [194]  $                    36.16  
Seizures New onset, severe  $      1,120.21  3% [194]  $                    33.61  




e.g. Magnesium 0.6 to < 0.9 
mEq/L or Potassium 2.0 to < 2.5 
mEq/L  $          891.99  2% [194]  $                    17.84  
Nausea, vomit-
ing 
Persistent vomitting or nausea 
resulting in minimal oral intake  $          847.65  7% [194]  $                    59.34  
Renal dysfunc-
tion 
Glomerular filtration rate < 60 
to 30 ml/min    $          100.65  8% [194]  $                      8.05  
Anemia 
Hemoglobin <11 g/dL and >8 




e.g. Magnesium 0.9 to < 1.2 
mEq/L or Potassium 2.5 to < 3.0 
mEq/L  $            70.75  12%  [108]  $                      8.49  
Hearing loss 
Permanent, profound deafness 
(with or without tinnitus)  $            50.76  40% [115]  $                    20.31  
 Average cost $1,371.99 Weighted average $561.46 (sd: 50.51) 
Description of laboratory tests, medications, investigations, and specialist consultations and the frequencies 
and averages for XDR-TB is included in each unit cost is provided the ADR cost workbook, attached as supple-
mental materials.  




Page | 132 
Figures 
Figure 7-3 Markov health state model of ambulatory standard long-course MDR/RR-TB treatment, 
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8 RESULTS: COST-EFFECTIVENESS ANALYSIS ADJUSTED FOR TOXICITY 
8.1 SYNOPSIS 
Formal citation: Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E. Impact of adverse drug reac-
tions on the incremental cost effectiveness of bedaquiline for drug-resistant tuberculosis. The Inter-
national Journal of Tuberculosis and Lung Disease, 2018. In press. 
In this manuscript, the decision-analysis model established under Objective 3 was adjusted in order 
to adjust the incremental cost effectiveness of bedaquiline RR-TB treatment regimen compared to 
the SOC RR-TB treatment regimen, including the costs and burden of ADR. Bedaquiline for all 
MDR/RR-TB compared to bedaquiline reserved for treatment failure after injection-based regimen 
was found to have a mean ICER of $567 per DALY averted using the standard Markov model. Costs 
for both regimens increased and effectiveness decreased for the injection-based regimen once the 
model was adjusted for the toxicity. The resulting ICER of a bedaquiline for all was cost saving ($96 / 
patient) and more effective (0.96 DALYs averted).   
 
Contribution to the thesis and novelty 
This final results chapter pulls together findings presented in earlier chapters, including timing of 
mortality during MDR/RR-TB treatment by HIV and ART status Chapter 3, proportion of persons ex-
periencing ADR and serious ADR in HIV settings Chapter 5, and the increased relative risk of ADR for 
HIV-infected patients newly initiating ART Chapter 4. Ingredients costs first used in the Markov 
model established in Chapter 6 and average costs for ADR management as estimated in Chapter 7 
are also used. Disability weights for hearing loss (Table 2-11) are added to the model. As identified in 
Chapter 2, indicated management of drug-induced QT prolongation, which is associated with bedaq-
uiline use, is interruption of treatment and therefore does not have a cost for management beyond 
the clinic visit already incorporated in the cost of treatment. The result is a cost-effectiveness analy-
sis that is based upon real-world implementation of an injection-free regimen in South Africa and 
that quantifies the provider costs and disability of permanent, profound hearing loss from the 
MDR/RR-TB injection-based regimens.  
Role of the candidate 
The candidate conceived the initial research question, and revised the Markov health state model 
according to findings from the objectives of the thesis (i.e. differential transition probabilities by 
time on treatment and HIV and ART status, differential risk of ADR for HIV-infected newly initiating 
on ART, and differential costs of ADR management during MDR/RR-TB or XDR-TB). All model revi-
sions, including use of trackers for counts of ADRs and months on ART, were built in TreeAge. She 
ran different versions to balance the availability of data, the complexity of the model, and the rea-
sonableness of the outputs for the base case outputs. The candidate wrote the first draft of the 
manuscript and revised in response to inputs from co-authors. She revised the article based upon 
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Summary 
Background 
Adverse drug reactions (ADR) are frequent during standard, long-course treatment for multi-drug 
and rifampicin-resistant tuberculosis (MDR/RR-TB). In particular, the second-line injectable agents 
(IA) are associated with permanent hearing loss, acute renal injury and electrolyte imbalance. We 
adapted an established Markov model for ambulatory treatment to estimate the impact of the tox-
icity profile on the incremental cost-effectiveness ratio (ICER) for a proposed MDR/RR-TB regimen 
replacing the IA with bedaquiline. 
Methods 
Treatment effectiveness was evaluated in disability adjusted life years (DALYs). Clinical outcomes 
and ingredient costs from a provider perspective were derived from the South African public-sector 
treatment programme or extracted from literature. Costs and effectiveness were discounted at 
3%/year over 10 years.  
Results 
A bedaquiline-based MDR/RR-TB regimen compared to the IA regimen had a mean ICER of $516 per 
DALY averted using the standard Markov model. Costs for both regimens increased and effective-
ness decreased for the IA regimen once adjusted for toxicity. The resulting ICER for bedaquiline-
based regimen was cost saving ($96/patient) and more effective (0.96 DALYs averted) after adjusting 
for ADR.   
Conclusion 
Decision analysis models of treatment for MDR/RR-TB, including new drug regimens, should con-
sider the costs of managing ADR and their sequalae.  
Key words: 
bedaquiline; cost-effectiveness; rifampicin-resistant TB; DALYs; Monte Carlo simulation 
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Introduction 
According to the World Health Organization’s (WHO), in 2016, there were 600,000 incident cases 
and 240,000 deaths from rifampicin-resistant (RR-) and multi-drug resistant (MDR-) tuberculosis 
(TB).[2] South Africa has the world’s largest epidemic of HIV, and one of the world’s largest epidem-
ics of TB, TB/HIV and MDR/RR-TB. In 2016, the South African National TB Programme (SA NTP) initi-
ated 11,192 MDR/RR-TB cases on treatment.[2] Through the end of 2016, the SA NTP implemented a 
standard, long-course regimen for MDR/RR-TB without additional second-line drug resistance (6 
months of kanamycin, moxifloxacin, ethionamide, terizidone and pyrazinamide followed by 12 
months excluding kanamycin).[19] In March 2015, the SA NTP approved bedaquiline as an additional 
drug to strengthen the existing regimens, where there was either resistance to or intolerance of 
fluoroquinolones and/or second-line injectable agents (IA).[19] 
Fluoroquinolones and IA are considered core drugs for constructing effective MDR/RR-TB regi-
mens.[14] Yet, even among MDR/RR-TB patients initiating recommended regimens, globally only 
54% to 60% patients are successfully treated [2,5]; for the South African 2014 cohort 54% were suc-
cessfully treated.[2] More recently registered drugs such as bedaquiline [30,32] have shown promise 
in terms of improved efficacy and there are hopes for an all-oral regimen where IA are replaced by 
more effective and safer drugs.[1] However, the costs of the newly developed drugs may pose a bar-
rier to adoption in resource-limited settings. A cost-effectiveness analysis for ambulatory treatment 
of MDR/RR-TB parameterized using SA NTP data estimated that IA-based long-course MDR/RR-TB 
regimens cost US$4,439 per patient over the 10-year horizon. Replacing IAs with bedaquiline cost 
US$4,647 and averted 0.17 disability adjusted life years (DALYs) for an incremental cost effective-
ness ratio (ICER) of US$1,242 per DALY averted.[207] 
The poor efficacy of current IA-based regimens is not the only concern: a meta-analysis of adverse 
drug reactions (ADR) during MDR/RR-TB treatment in high HIV prevalence settings reported 83% 
(95%CI: 82-84) of all patients experienced at least one event.[208] Second-line IAs are thought to be 
the cause of many of the known toxicities, including high rates of nephrotoxicity and electrolyte im-
balance (e.g. hypokalaemia).[1,130] Additionally, IAs are associated with high rates of ototoxicity in-
cluding tinnitus, vertigo, and hearing loss.[1,116,130,192] Hearing loss, which affects between 2.6 to 
61.5% of patients, ranges from loss of high frequency tones to profound deafness and can be perma-
nent.[116]  
To understand how the disability from hearing loss and the costs of managing other ADR impact the 
ICER calculations for an injection-free regimen based on bedaquiline, we adapted a previously estab-
lished Markov model[207,220] to include the toxicity profile of both regimens. 
 
Methods 
The model was parameterized with costs, transition probabilities, and initial populations distribu-
tions for the South African public health sector[207,220] and built in TreeAge Pro 2015  (TreeAge 
Software, Williamstown, MA). Although patients may incur costs for transport, food or lodging, all 
MDR/RR-TB treatment in South Africa is provided free of charge through the public-sector health fa-
cilities. A provider perspective, that of the SA public health sector, was assumed. Future costs and 
effectiveness were discounted at 3%.[205] A time horizon of 10 years was assumed to capture the 
full length of treatment for patients plus some impact of permanent disability. 
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Two MDR/RR-TB treatment strategies were modelled: 1) IA-based regimen for MDR/RR-TB (6 
months kanamycin, 18 months moxifloxacin, terizidone, ethionamide, and pyrazinamide) and 2) be-
daquiline-based regimen for all MDR/RR-TB, where bedaquiline replaces kanamycin. Patients with 
initial intolerance or additional second-line drug resistance including extensively drug resistant (XDR) 
TB at initiation were excluded in all scenarios. 
MDR/RR-TB Markov model 
Monthly transition probabilities (Table 8-1) for 11,192 HIV-negative and HIV-infected patients (the 
SA 2015 MDR/RR-TB initiating cohort[2]). for eachz health state were based upon the original model 
analysis[207] derived from the SA NTP drug-resistant TB case register[199] using Stata version 14 
(College Station, TX, USA). Markov health states (Figure 8-1) represent initiation of MDR/RR-TB treat-
ment (Month 0), intensive phase (Months 1-5), and culture negative continuation phase of treat-
ment (Months 6-18). In the model, patients failing to sputum culture convert after 6 months of 
MDR/RR-TB treatment transition to XDR-TB treatment; XDR-TB patients failing to culture convert af-
ter 6 months of treatment transition to palliative care. It was assumed that patient could experience 
either a moderate ADR or a severe or serious ADR during months 1 to 5.[122] HIV-infected patients 
naïve to ART at MDR/RR-TB initiation experienced a relative increase in risk of ADR and severe ADR 
(sub-hazard ratio: 3.07 relative to HIV-negative).[194] From any state, patients can be lost from 
treatment or die. After successful treatment completion, patients experience background mortality. 
HIV-infected patients continue to incur the costs of ART after completion of MDR/RR-TB treatment. 
In the model, it was assumed bedaquiline increased the proportion culture converting by a hazard 
ratio of 2.44 (95%CI: 1.57, 3.80).[30] Bedaquiline regimens were modelled to have 28% fewer mod-
erate and 60% fewer severe, or serious ADR than IA-based regimens[220]; the assumption was 
tested in sensitivity analysis. Based upon a South African study, IA-based MDR/RR-TB regimens were 
assumed to have 40% permanent profound hearing loss from month six.[192] 
Ingredients costing 
Provider costs (Table 8-2) for MDR/RR-TB treatment, derived from public-sector price lists for medi-
cines, laboratory tests, and procedures or from literature for clinic visits and hospitalization were 
also as reported in the original model.[207] Costs were collected in ZAR and converted to USD using 
the average monthly exchange rate for 2016, 14.74 ZAR/USD.[27] Costs were inflated to 2016 ZAR if 
applicable using the consumer price index for medical services.[28] The full 6 months’ course of be-
daquiline at US$675 was modelled for all bedaquiline-initiating patients. The distribution of ADR 
management costs during IA regimens was extracted from a separate study.[220] For the bedaqui-
line-based regimen, the costs of IA-associated ADR were excluded from the weighted average.  
 
Disability weighting 
Disability weights for TB (0.368, 95%CI: 0.260 to 0.430) were extracted from a South Africa study 
based on the Global Burden of Disease (GBD) methodology.[79] TB/HIV co-infection (0.408, 95%CI: 
0.274 to 0.549), AIDS with no ART (0.582, 95%CI: 0.406 to 0.743), and HIV-infected on ART (0.078, 
95%CI: 0.052 to 0.111) were extracted from the 2013 GBD study.[75] For hearing loss, effectiveness 
was adjusted using the disability weighting for moderate hearing loss estimated from the South Afri-
can survey (0.357, 95%CI: 0.240 to 0.437).[79] To avoid double counting, disability from all other 
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ADR, e.g. anaemia, peripheral neuropathy, kidney or liver injury that overlapped completely with 
MDR/RR-TB treatment, was not included in the model. Disability from co-morbidity, e.g. profoundly 
deaf and HIV-infected on ART, was calculated using a multiplicative model.[80] DALYs were calcu-
lated as 1- the sum of time spent in each health state after weighting for disability. 
 
Sensitivity analysis 
Incorporation of the toxicity profile into the model increased the number of input parameters and 
increased the variability of outcomes for an individual patient in terms of what ADR would be experi-
enced, at what frequency and severity. In line with recommendations for managing parameter un-
certainty[221], the Markov model was adapted in order to use probabilistic uncertainty analysis 
where model parameters are sampled from distributions through running 100 Monte Carlo simula-
tions for the cohort.  
Results 
Without adjustments made for the toxicity profile, i.e. without including costs of ADR management 
and disability burden, the mean expected value of sampled trials for the IA regimen was a cost of 
US$4,614 (95%CI: 3,821-6,496) and resulted in 4.88 DALYs (95%CI: 4.18-5.61) over the 10-year hori-
zon (Table 8-3). The mean expected bedaquiline regimen cost was $4,739 (95%CI: 4,077-5,463) and 
resulted in 4.64 DALYs (95%CI: 3.96-5.36), for an ICER of US$516 per DALY averted. Incorporating the 
cost of ADR management increased the cost of the IA regimen by US$381 per patient and the bedaq-
uiline regimen by US$161 per patient, a reduction of $221 in the incremental cost of using bedaqui-
line. Incorporating permanent hearing loss resulted in 0.72 more DALYs for the IA regimen, for a to-
tal of 5.60 DALYs. As a result, the bedaquiline regimen absolutely dominated the IA regimen, saving 
$96 and averting 0.96 DALYs per patient over the modelled period.  
The resulting ICERs of the probabilistic uncertainty analysis were plotted on cost-effectiveness plane 
(Figure 8-2). The distribution of the incremental cost of bedaquiline regimens shifted right (more ef-
fective) and incremental costs shifted down (less costly) relative to the IA regimens once toxicity pro-
file was added. The toxicity profile also increased results dispersion. Figure 8-3 shows the cost-effec-
tiveness acceptability curves, 80% of the sampled distributions resulted in an ICER of <$2,100 per 
DALY averted when the ADR costs and disability were not considered. Once adjusted for toxicity, 
80% of the sampled distributions resulted in an ICER below $150 per DALY averted and 62% of the 
distributions resulted in an ICER that was cost saving (below $0) and more effective.   
 
Discussion 
The public sector roll-out of bedaquiline in South Africa was among the evidence considered by the 
WHO’s guidelines development group in issuing revised recommendations for bedaquiline in 
2017.[32] No update was provided for the cost-effectiveness analysis initially done for the 2013 in-
terim recommendations.[32] Cost-effectiveness studies published since the initial exploratory analy-
sis have focused on savings achieved from the high rates of culture conversion using bedaquiline and 
therefore shorter duration of hospitalization lead it to be cost-effective or even cost saving com-
pared to the standard regimen.[52,53,55,56] The high rate of ADR during MDR/RR-TB treatment is 
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well established [1,14,208], yet cost-effectiveness analyses of new treatment regimens have not ex-
plicitly modelled the costs or disability associated with toxicity profiles.[52,53,55,56]  
Previous cost-effectiveness analyses also did not explicitly model bedaquiline replacing the IA. With 
growing evidence that bedaquiline is both effective and safe, including in the WHO guidelines review 
[32], a 15-country multi-centre study[138], clinical researchers[196], policy makers[46] and advo-
cates[1] are considering whether bedaquiline or delamanid should replace second-line IA as core 
MDR/RR-TB drugs. As of 2015 in South Africa, patients with either second-line drug resistance or  
demonstrated toxicity to the standard MDR/RR-TB injection-based treatment are eligible for bedaq-
uiline regimens.[19] The analysis presented here demonstrates that toxicity profile of the IAs can sig-
nificantly impact the calculation of the ICER for new regimens. Once the toxicity profile was included 
in the analysis, a bedaquiline regimen is both cost saving ($96 per patient) and more effective 
(averted 0.96 DALYs). For the sake of understanding, this model simplified into distinct regimens 
what has become a more fluid and incremental choice. Within the SA NTP, bedaquiline can be initi-
ated once either resistance or intolerance, such as ototoxicity, is detected. For ototoxicity, however, 
this change may be too late as hearing loss can progress even after the IA is withdrawn.[1,192] Thus, 
the more conservative use of bedaquiline only after other options have been exhausted may not re-
alize the cost savings or DALYs averted estimated here. 
This analysis built upon a previously established Markov model, where the ICER for a bedaquiline for 
all approaches was reported as $1,242 per DALY averted[207], more than twice the ICER of $516 re-
ported here. The major difference for the base models (i.e. not adjusted for ADR) was the use of 
probabilistic uncertainty analysis, which resulted in a smaller incremental cost and more DALYs 
averted.[207] The inclusion of ADR management, where the frequency, severity, and costs of ADR 
experienced are not easily measured or included in an analysis increased the model uncertainty fur-
ther. WHO-recommended standard long- and short-course regimens for MDR/RR-TB were not estab-
lished via prospective, randomized clinical trial but rather rely on observational studies.[1,14] Re-
porting of adverse events and ADR in observational and retrospective studies may reflect a reporting 
bias, where only serious or severe events are noted or only events associated with a particular drug 
of interest. Meta-analysis of the observational studies is further limited by a lack of common termi-
nology and definitions to determine whether variability was due to differences in measurement and 
study design or differences in regimen or patient characteristics.[5,130,199]  In the prospective 
Phase 2b trial where bedaquiline was added to the standard IA regimen the bedaquiline and placebo 
arms had statistically similar rates of adverse events (99% and 98%, respectively) and similar rates of 
ADR (70% and 69%), which suggests that bedaquiline did not add to the already high ADR bur-
den.[30]  
The higher relative effectiveness for an all oral regimen estimated in this analysis is because IAs are 
associated with the high levels of ototoxicity.[1,115,130] Permanent and profound hearing loss re-
duces the overall effectiveness of the IA treatments when disability weightings are applied beyond 
the completion of the MDR/RR-TB treatment. The profound hearing loss disability weighting used 
here was from a South African survey; the weighting was nearly twice as high as the global 
study.[75,79] The preference or value of a health state such as hearing loss may differ across con-
texts (e.g. South Africa compared to Europe), particularly for resource-limited contexts where coping 
mechanisms may be less available. Both the potential underestimation of effects of hearing loss on 
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quality of life and the inclusion of only guidelines-based provider costs suggest that the ICER for a 
safer, more tolerated treatment regimen for MDR/RR-TB presented here is a conservative estimate. 
 
Study limitations 
Similar to other cost-effectiveness analyses that have been published for bedaquiline[52,53,55,56], 
we used the same mortality rates for bedaquiline regimens as for IA regimens even though the 
Phase 2b trial showed a statistically significant imbalance in mortality with more deaths occurring in 
the patients on bedaquiline compared to placebo (12.7% and 2.5%, respectively).[30]  The revised 
2017 WHO bedaquiline guidance indicated the Phase 2b findings had potentially very serious bias for 
imprecision from the small patient numbers and also serious bias for indirectness; none of the 
deaths in the bedaquiline arm were attributed to bedaquiline.[32] The revised WHO guidance also 
reported on promising observational results from South Africa (the same cohort used for this analy-
sis) indicating that use of bedaquiline may result in reduced, rather than increased, mortality.[32] 
However, until completion of the phase 3 study for bedaquiline, the uncertainty of the mortality is a 
limitation of this and other cost-effectiveness analyses for bedaquiline. Other limitations are com-
mon to the initially established model: we did not include a measure of either on-going transmission 
or increased resistance profile due to ADR and excluded patient direct and opportunity costs.[207]      
Finally, in order to use data from implementation and roll-out, the analysis presented here is com-
parison of the long-course (18 to 24 months) IA regimen and the bedaquiline regimen used in South 
Africa prior to the end of 2016. SA NTP MDR/RR-TB patients without second-line resistance are now 
eligible for the short-course regimen, which was recommended by the WHO in 2016.[14] While wait-
ing for the results of studies using short-course bedaquiline and delamanid regimens[1], the results 
of this cost-effectiveness analysis adds more weight to the urgency to re-evaluate the use of IA in 
the treatment of MDR/RR-TB.       
Conclusion 
Current injection-based long-course standard treatment for MDR/RR-TB is associated with high rates 
of adverse drug reactions, including the possibility of permanent hearing loss. Based on this model-
ling of bedaquiline regimens in South Africa, new drugs that can allow for an all oral MDR/RR-TB 
treatment regimen may be cost saving and more effective than current injection-based regimens, if 
cost-effectiveness analyses incorporate the costs and burden of the expected adverse drug reac-
tions.   
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Tables 
Table 8-1. Markov model monthly transition probabilities and proportions 
Model inputs Patients Mean values 
Mortality  Transition probabilitya 
 MDR/RR-TB, HIV-negative 0.006 to 0.018c  
 MDR/RR-TB, HIV-infected, on ART 0.009 to 0.033 c  
 MDR/RR-TB, HIV- infected, no ART 0.055  
 XDR-TBd, HIV-negative 0.022 to 0.022 c  
 XDR-TBd, HIV- infected, on ART 0.026 to 0.037 c  
After treatment All patients 0.0005 to 0.001[200] 
Loss from treatment  Transition probabilitya 
 MDR/RR-TB, HIV-negative 0.010 to 0.016  
 MDR/RR-TB, HIV- infected, on ART 0.009 to 0.016 c  
 MDR/RR-TB, HIV- infected, no ART 0.016  
 XDR-TBd, HIV-negative 0.010 to 0.011c  
 XDR-TBd, HIV- infected, on ART 0.005 to 0.008 c  
Return after loss Month 3-12 .05 b 
Culture conversion  Proportion 
Cumulative at 6 months MDR/RR-TB, All HIV status 88.4%  
Cumulative at 6 months XDR-TBd, All HIV status 76.8% [30,34] 
Relative effectiveness Bedaquiline regimens 2.44 (95%CI: 1.57, 3.80) [30] 
Initial distribution  Proportiona 
HIV status HIV-negative 28.3%  
 HIV-positive 71.7%  
 HIV-positive, no ART 40% of the 71.7% 
Hospitalization All RR-TB, All HIV status 20.6% [128] 
Adverse drug reactions  Transition probability 
Any moderate to severe All RR-TB 0.183, excluding severe [208] 
Any severe or serious  All RR-TB 0.052 [208]  
Relative risk of ADR  
All RR-TB, if HIV+, newly on ART (<6 
months)  
Sub-hazard ratio: 3.07 (95%CI: 
1.46,6.46) relative to HIV-nega-
tive patients [194] 
Reduction of ADR if no 
kanamycin/amikacin 
MDR/RR-TB, All HIV status 
28%, assumption based on rela-
tive frequency ADR attributed to 
second-line injectables [220] 
Profound hearing loss All RR-TB, All HIV status 40% [192] 
MDR/RR-TB: Multi-drug resistant or rifampicin-resistant tuberculosis; XDR-TB: extensively drug resistant TB; 
HIV: human immunodeficiency virus; ART: anti-retroviral therapy; 95%CI: 95% confidence interval 
a Initial patient distribution and transition probabilities generated from South African EDRweb cohort 2012-
2014. Initial patient distribution and transition probabilities are the same as previously published model.[207] 
b Calibrated assumption 
c Value dependent on treatment phase 
d All XDR-TB in model is among patients in whom MDR/RR-TB treatment failed; patients diagnosed with XDR-
TB from onset are excluded from the model. 
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Table 8-2. Monthly unit costs in 2016 USD provider (payer) perspective and sampled distribution 
 Treatment strategy Patients Mean monthly cost a Distribution 
TB components  
Medications (anti-TB, antiretroviral therapy, and pyridoxine)  
 Injection-basedb MDR/RR-TB, HIV-negative $83.79 to $100.96d Normal, +/- 25% 
  MDR/RR-TB, HIV-infected, on ART $93.67 to $112.88d Normal, +/- 25% 
  XDR-TB, HIV-negative $301.67 to $520.77d Normal, +/- 25% 
  XDR-TB, HIV-infected, on ART $311.55 to $532.69d Normal, +/- 25% 
 Bedaquiline-basedc MDR/RR-TB, HIV-negative $83.79 to $205.94d Normal, +/- 25% 
  MDR/RR-TB, HIV-infected, on ART $93.67 to $216.86d Normal, +/- 25% 
  XDR-TB, HIV-negative $301.67 to $564.21d Normal, +/- 25% 
  XDR-TB, HIV-infected, on ART $311.55 to $575.13d Normal, +/- 25% 
TB monitoring (sputum smear microscopy, sputum culture, resistance testing, and chest x-ray)  
 All strategies All RR-TB, all HIV status $9.76 to $36.82d Normal, +/- 25% 
Clinic visits and hospital inpatient days  
 Injection-basedb Hospitalized, all RR-TB, all HIV status $ 2,882.52 Normal, +/- 25% 
  All RR-TB, all HIV status $23.09 to $98.12d Normal, +/- 25% 
 Bedaquiline-basedc Hospitalized, all RR-TB, all HIV status $ 2,882.52 Normal, +/- 25% 
  All RR-TB, all HIV status $23.09 to $31.35d Normal, +/- 25% 
ADR components  
ADR monitoring (guidelines-based laboratory screening, audiology, and electrocardiograms)  
 Injection-basedb All RR-TB, all HIV status $2.84 to $28.14d Normal, +/- 25% 
 Bedaquiline-basedc All RR-TB, all HIV status $2.84 to $25.99d Normal, +/- 25% 
Mean estimated costs of ADR management (ancillary medication for ADRs, clinic and hospitalization 
for ADR, laboratory tests and investigations required for managing and resolving ADR) 
 
 Injection-basedb MDR/RR-TB, moderate ADR $135.76 [220] Gamma, std dev 
  MDR/RR-TB, severe or serious ADR  $521.29 [220] Gamma, std dev 
  XDR-TB, moderate ADR $156.05  [220] Gamma, std dev 
  XDR-TB, severe or serious ADR  $1,039.06 [220] Gamma, std dev 
 Bedaquiline-basedc MDR/RR-TB, moderate ADR $105.68e [220]  Gamma, std dev 
  MDR/RR-TB, severe or serious ADR  $464.83e [220]  Gamma, std dev 
  XDR-TB, moderate ADR $130.42e  [220]  Gamma, std dev 
  XDR-TB, severe or serious ADR  $946.44e [220]  Gamma, std dev 
MDR/RR-TB: Multi-drug resistant or rifampicin-resistant tuberculosis; XDR-TB: extensively drug resistant TB; 
HIV: human immunodeficiency virus; ART: anti-retroviral therapy; SA NTP: South African National TB Pro-
gramme; std dev: standard deviation 
a Ingredient costs were collected in ZAR and converted to USD using the average monthly exchange rate for 
2016, 14.74 ZAR/USD.[27] Costs were inflated to 2016 ZAR if applicable using the consumer price index for 
medical services.[28] Drug costs from the Master Procurement Catalogue of the Essential Drug Programme, 
South African National Department of Health (2016). Laboratory test costs from the South African National 
Health Laboratory Service State Price List (2015). Procedures and investigation costs from the South African 
National Department of Health Uniform Patient Fee Schedule (2016). Ingredient costs were previously pub-
lished with the original model.[207]   
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b MDR/RR-TB patients access standard regimen of 6 months kanamycin, moxifloxacin, terizidone, ethionamide, 
and pyrazinamide and 12 months moxifloxacin, terizidone, ethionamide, and pyrazinamide. If fail MDR/RR-TB 
treatment, treated with XDR-TB regimen consisting of 6 months capreomycin, linezolid, moxifloxacin, ter-
izidone, ethionamide, clofazimine, para-aminosacylic acid, and pyrazinamide and 18 months linezolid, moxi-
floxacin, terizidone, ethionamide, clofazimine, para-aminosacylic acid, and pyrazinamide. 
c MDR/RR-TB patients access bedaquiline regimen consisting of 6 months bedaquiline, levofloxacin, terizidone, 
ethionamide, and pyrazinamide and 12 months moxifloxacin, terizidone, ethionamide, and pyrazinamide. If fail 
MDR/RR-TB treatment, treated with XDR-TB regimen consisting of 6 months bedaquiline, linezolid, levofloxa-
cin, terizidone, ethionamide, clofazimine, para-aminosacylic acid, and pyrazinamide and 18 months linezolid, 
moxifloxacin, terizidone, ethionamide, clofazimine, para-aminosacylic acid, and pyrazinamide. 
d Value dependent on treatment phase  
e Excluding ADR associated with injectables 
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Table 8-3. Impact of including toxicity profile in the incremental cost effectiveness ratio of replacing 











Cost per DALY 
averted 
No toxicity profile      
Injection-based  $4,614 
($435) Reference  4.88 (0.36)  Reference  
Bedaquiline-based   $4,738 
($358)   $124 ($267)   4.64 (0.36)   0.24 (0.12)   $516  
Adjusted for toxicity      
Injection-based $4,996 ($453) Reference  5.60 (0.34) Reference Dominated 
Bedaquiline-based  $4,899 
($365)   - $96 ($281)   4.64 (0.36)   0.96 (0.18)  
ADR: adverse drug reaction; XDR-TB: extensively drug resistant TB; sd (standard deviation) 
  
 
Page | 145 
Figures 
Figure 8-1. MDR/RR-TB state transition diagram of Markov health state model adjustments for tox-
icity profile 
 
ADR: adverse drug reaction; MDR/RR-TB: Multi-drug resistant or rifampicin-resistant tuberculosis; XDR-TB: ex-
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Figure 8-2. Cost-effectiveness plane, incremental cost effectiveness of bedaquiline-based regimen 
compared to injection-based regimen in DALYs averted, before and after adjusting for toxicity 
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Figure 8-3 Cost-effectiveness acceptability curve: probability that incremental cost effectiveness of 
bedaquiline-based regimen compared to injection-based regimen was below stated value, before and 
after adjusting for toxicity 
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9 DISCUSSION AND CONCLUSIONS 
9.1 DISCUSSION 
The aim of this thesis was to understand whether the inclusion of the costs and burden of ADR asso-
ciated with MDR/RR-TB treatment regimens would impact the incremental cost-effectiveness of a 
bedaquiline-based regimen compared to the injectable-agent based regimen. A bedaquiline-based 
regimen for all MDR/RR-TB patients compared to an IA-based regimen was found to have a mean 
ICER of $516 Chapter 8, using probabilistic sensitivity analysis) to $1,242 (Chapter 6), estimated at 
means) per DALY averted using the standard Markov model. This finding, set in the context of the SA 
NTP’s ambulatory model of care for MDR/RR-TB, expanded the body of evidence that bedaquiline-
based regimens are cost-effective beyond the previously described settings where MDR/RR-TB pa-
tients are hospitalized until culture conversion.[31,52–56] Costs for both regimens increased and ef-
fectiveness decreased for the injection-based regimen once the model was adjusted for toxicity. The 
resulting ICER of a bedaquiline-based regimen was cost saving ($96/patient) and more effective 
(0.96 DALYs averted) after adjusting for ADR, as described in Chapter 8. The analysis presented here 
demonstrates that toxicity profile of the IAs can significantly impact the calculation of the incremen-
tal cost-effectiveness ratio of adopting new MDR/RR-TB treatment regimens.  
The public sector roll-out of bedaquiline in South Africa was among the evidence considered by the 
WHO’s guidelines development group in issuing revised recommendations for bedaquiline in 
2017.[32] However, no update was provided for the cost-effectiveness analysis initially done for the 
2013 interim recommendations, even though the guidelines noted that the simplifying assumptions 
of how the cost-effectiveness analysis addressed the burden of ADR was a limitation.[31,32] The 
high rate of ADR during MDR/RR-TB treatment is well established [1,3,14,208] and was confirmed in 
this thesis research (Chapters 4 and 5), yet cost-effectiveness analyses of bedaquiline have not ex-
plicitly attempted to measure the incremental costs or effectiveness of the different toxicity pro-
files.[52–55,94] The pilot trial of an 8-week dose of bedaquiline versus placebo added onto the 
standard injection-based regimen to test the tolerability of bedaquiline found no statistically signifi-
cant differences in the frequency or severity of adverse events in the bedaquiline arm with the ex-
ception of mild to moderate nausea.[29] In the prospective Phase 2b trial where bedaquiline was 
added to the standard IA regimen the bedaquiline and placebo arms had statistically similar rates of 
adverse events (99% and 98%, respectively) and similar rates of ADR (70% and 69%), also suggesting 
that bedaquiline did not add to the already high ADR burden.[30] In the BCAP compassionate access 
programme implemented by the SA NTP from 2012 to 2015, severe adverse events reported were 
not attributed to bedaquiline.[34]  Rates of severe or serious adverse events in the BCAP cohort 
were noted to be similar to other compassionate treatment access programmes and in line with high 
rates known to be associated with the standard of care regimens.[34,105,222] There is growing evi-
dence that bedaquiline is both effective and safe, including in the WHO guidelines review [32] and a 
15-country multi-centre study [138]. With evidence of safety and effectiveness clinical researchers 
[196], policy makers [46,47] and advocates [1] are considering whether bedaquiline and delamanid 
should replace second-line IA as core MDR/RR-TB drugs. This advocacy for use of bedaquiline was 
despite the WHO finding that the cost-effectiveness of bedaquiline was “ambiguous in low-income 
settings” and possibly unaffordable beyond a donation program to low-income countries.[32] The 
finding that a bedaquiline-based regimen is both more effective and cost-saving therefore removes 
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an important barrier to further roll-out of an injection-free regimen for treatment of MDR/RR-TB, 
not just in South Africa.  
Discussion points and conclusions relevant to the results of each of the analyses were presented in 
the specific manuscripts which were presented in the results chapters (Chapters 3 to 8, Manuscript 1 
to 6, respectively). The following summary and discussion provides a cumulative summary of the 
thesis findings in respect to the objectives above as well as the unanswered questions from the liter-
ature review (Chapter 2, Literature Review). For each of the main findings, a discussion of the gener-
alizability of these findings to other contexts outside of South Africa or beyond the specific compari-
son of drug regimens is also included.  
Aims of the research 
Chapter 1, the Introduction and Overview, provided an introduction to the overall aims and objec-
tives of this research, based upon the approved proposal for the PhD research.  
As noted in Chapter 1.2 the objectives of this thesis were to:  
1. To describe the types, frequency, and severity of ADRs experienced during MDR/RR-TB 
treatment. 
2. To evaluate the provider cost of prevention, monitoring, and management of ADRs incurred 
during MDR/RR-TB treatment, including drugs, hospitalization, laboratory monitoring, and 
clinic visits. 
3. To estimate the ICER of bedaquiline treatment regimen compared to standard of care (SOC) 
MDR/RR-TB treatment regimen in SA. 
4. To estimate the ICER of bedaquiline compared to SOC regimen having included the cost and 
burden of ADR during MDR/RR-TB treatment.   
 
Each of the objectives builds on the previous, in that the estimated ICER of a bedaquiline-based regi-
men compared to an IA-based regimen for the treatment of MDR/RR-TB having adjusted for the tox-
icity of the regimens requires first to describe the expected toxicity and costs. Thus, if each of the 
objectives is achieved, the overall aim of the study would also be reached. The overall aim of the re-
search was to use the introduction of bedaquiline within the SA NTP as a case study to determine 
whether the inclusion of the cost and burden of ADR associated with MDR/RR-TB treatment affects 
the ICER of new treatment regimens.  
Literature review 
Chapter 2 presented a comprehensive literature review covering the basis for using cost-effective-
ness analysis for health policy decision making (Chapter 2.3), the state of the MDR/RR-TB epidemic 
in South Africa, including standard of care, long-course, IA-based MDR/RR-TB treatment guidelines 
and the introduction of bedaquiline (Chapter 2.4), measurements of effectiveness of MDR/RR-TB 
treatment (Chapter 2.5), and the burden of ADR during MDR/RR-TB treatment (Chapter 2.6). The 
chapter summarized current literature and presented unanswered questions that framed the PhD 
research.  
• Do ADR occur at similar frequency, duration, and severity when HIV-infected or when on 
HIV treatment? 
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• What is the cost of ADR management, as a function of the expected costs and the expected 
frequencies of ADR during MDR/RR-TB treatment? 
• What is the cost-effectiveness of a bedaquiline-based regimen rather than an injection-
based regimen?  
• What is the timing of outcomes that occur before 18-24 months? Do transition probabilities 
differ by HIV and ART status?  
• Does the inclusion of the cost and burden of ADR associated with MDR/RR-TB treatment 
affect the incremental cost-effectiveness of bedaquiline treatment regimen compared to 
the current kanamycin-based treatment? 
 
Timing of mortality during MDR/RR-TB treatment 
Chapter 3 described the timing of mortality during MDR/RR-TB treatment based upon analysis of the 
SA national electronic drug-resistant TB case register, the EDRweb. The timing and risk factors for 
mortality, including the differential risks of mortality for HIV-negative, HIV-infected patients on ART, 
and HIV-infected patients not on ART, were used for the development and parameterization of the 
Markov health state model used for the analysis in Chapters 6-8. This statistical analysis was pub-
lished in the International Journal of Tuberculosis and Lung Disease in October 2017 (doi: 
10.5588/ijtld.17.0202). The results of this analysis was presented as the first of the results chapters 
because of the unanswered questions identified through the literature review (Chapter 2). Addition-
ally, the reviewed literature left unanswered whether the risk of mortality over time would differ by 
HIV and ART status, or whether the increased risk of mortality for HIV-infected patients [13,186,223] 
was a proportional hazard. These questions needed to be resolved in order to build a Markov health 
state model that reflected the South African context of a high prevalence of HIV/TB co-infection.    
The statistical analysis, a retrospective review of routinely captured data in the South African na-
tional drug-resistant TB case register (EDRweb) and matched to the vital statistics register, found 
that mortality is highest during the first weeks of MDR/RR-TB treatment. Approximately 1 in every 5 
patients who starts MDR/RR-TB treatment in South Africa dies during treatment.[2,58] As reported 
in Manuscript 1, across the national cohort registered in the EDRweb, nearly half (44.2%) of the 
deaths occurred within the first 3 months of the 24 months of MDR/RR-TB treatment. The estimated 
incidence rate for all patients was 8.99 deaths per 1,000 person-weeks before week 12, 5-times the 
1.78 deaths per 1,000 person-weeks after week 24.  
The findings of this analysis of the EDRweb led to the structure of the Markov model built and re-
ported on in Chapters 6 to 8 reflecting three health states while on MDR/RR-TB treatment – initia-
tion, intensive phase, and continuation phase – with monthly time steps. The findings of this analysis 
also led to the a population distribution in the Markov model that reflected patients who are HIV-
negative, HIV-positive on ART at MDR/RR-TB initiation, and HIV-positive ART naïve at MDR/RR-TB 
initiation. Because the risks and timing of death during MDR/RR-TB treatment in South Africa differ 
by HIV status, inclusion of separate health states and transition probabilities for HIV-infected was 
important to be able to generate estimates for the context. 
Based upon this model structure, the cohort described in Chapter 3 was also used to create the 
monthly transition probabilities for each of the three sub-populations for each of the three treat-
ment phases. Although the manuscript reported only on the results of mortality over time, transition 
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probabilities were also extracted from this cohort for other health states of loss from treatment and 
treatment failure.   
Risk of severe ADR during MDR/RR-TB treatment 
Chapter 4 reports on the results of a ADR-focused clinical file review of two out-patient MDR/RR-TB 
clinic cohorts in Johannesburg, South Africa. Although a retrospective review, the clinical data cap-
tured provided more in-depth understanding of the ADR experienced. This analysis was designed to 
address the first objective of the overall research, namely: To describe the types, frequency, and se-
verity of ADRs experienced during MDR/RR-TB treatment. 
The statistical analysis presented in used competing risk analysis to separate out the sub-hazard ra-
tio of severe ADR after accounting for the very high early mortality of HIV-infected patients newly 
initiating ART (as described in chapter 3). This statistical analysis was published in BMC Infectious 
Diseases in October 2016 (doi: 10.1186/s12879-016-1933-0). Similarly to the national cohort de-
scribed in Chapter 3, for the Johannesburg MDR/RR-TB treatment cohorts analysed in Chapter 4, the 
risk of death was highest in the first 90 days, especially for HIV-positive patients not on ART at the 
initiation of MDR/RR-TB treatment. 
For these two Johannesburg-based out-patient (ambulatory) MDR/RR-TB cohorts described in Chap-
ter 4, 19.0% of patients had at least one severe adverse event. After accounting for the competing 
risk of high early mortality for HIV-positive patients not on ART at the start of MDR/RR-TB treatment, 
the analysis presented in Chapter 4 found that HIV-positive patients who initiated ART with 
MDR/RR-TB treatment were approximately 3 times more likely to experience a severe ADR (sHR: 
3.07, 95% CI:  1.46 to 6.46). 
Prevalence of moderate and severe ADR during MDR/RR-TB treatment 
Chapter 5 presents the results of a systematic review and meta-analysis on the types, frequency, and 
severity of ADR during MDR/RR-TB treatment in cohorts where at least 20% of the patients were 
HIV-infected. As found during the overarching literature review in Chapter 2, the prevalence of ADR 
during MDR/RR-TB treatment varies across different cohorts and settings. Additionally, it was un-
known whether patients co-infected with HIV were at a higher risk of ADR during MDR/RR-TB treat-
ment. The review was published in the Journal of Antimicrobial Chemotherapy in April 2017 (doi: 
10.1093/jac/dkx107). Similar to Chapter 4, this analysis was designed to address the first objective of 
the overall research, namely: To describe the types, frequency, and severity of ADRs experienced 
during MDR/RR-TB treatment. A meta-analysis approach was chosen in order to test the generaliza-
bility of the findings from the Johannesburg cohorts presented in Chapter 4 and to expand the analy-
sis to include moderate ADR, which were not routinely noted in the medical files reviewed for the 
analysis presented in Chapter 4. 
The systematic review and meta-analysis found that ADR are frequent during MDR/RR-TB treatment 
in high prevalence HIV settings, especially for HIV-infected patients who are newly initiating ART. In 
the systematic review presented as Chapter 5, of the 24 included studies, 10 counted the patients 
who experienced at least 1 ADR and could be included in the main meta-analysis; for these studies 
the pooled proportion of patients experiencing an ADR was 83% (95%CI: 82% to 84%). Among the 
studies which disaggregated reported ADR by severity, the pooled proportion of patients experienc-
ing at least one severe or worse ADR was 24% (95%CI: 21% to 27%). Similar to previously published 
meta-analyses on ADR during MDR/RR-TB treatment, the meta-analysis of the observational studies 
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was limited by a lack of common terminology and definitions to determine whether variability was 
due to differences in measurement and study design or differences in regimen or patient character-
istics.[3,5,130,208] Although the lack of consistency in reporting limited the meta-analysis of specific 
events to the two most commonly described in specific studies – ototoxicity and hypothyroidism – 
the systematic review process did identify studies with sufficient detail in reporting to be used for 
extracting the frequencies of events which were used in Chapter 7 to created weighted average 
costs. 
Cost-effectiveness of bedaquiline compared to injection-based regimen 
Chapter 6 is the first of three results chapters using a newly established Markov model for MDR/RR-
TB treatment. This model includes separate health states for initiation of MDR/RR-TB treatment, in-
tensive phase, continuation phase, and completion. The model was parameterized using the cohort 
analysed and described in Chapter 3, bottom up ingredients costing from the perspective of the pro-
vider – the SA NTP – and uses separate transition probabilities from all health based upon HIV and 
ART status. The Markov model and analysis presented in Chapter 6 was designed to meet the third 
objective of the overall thesis research, namely: To estimate the ICER of bedaquiline treatment regi-
men compared to standard of care (SOC) MDR/RR-TB treatment regimen in SA. 
In Chapter 6, the use of bedaquiline as a replacement for the injectable agents is found to be cost-
effective and affordable, but more expensive than the injection-based standard of care regimen and 
for a relatively modest gain in effectiveness. One-way sensitivity analysis indicated that the results 
were sensitive to a significant increase or reduction in the cost of bedaquiline or the assumption of 
the proportion of patients who culture convert on the standard regimen. Results of this cost-effec-
tiveness analysis were published in the journal Applied Health Economics and Health Policy in Octo-
ber 2017 (doi: 10.1007/s40258-017-0352-8). 
The incremental cost effectiveness ratio (ICER) of bedaquiline for all MDR/RR-TB was US$1,242 per 
additional DALY averted compared to the standard regimen. Markov modelling indicates providing 
bedaquiline for all MDR/RR-TB patients could increase the treatment success rate in South Africa for 
MDR/RR-TB patients without additional second-line drug resistance from 56.3% on a non-bedaqui-
line regimen to 60.6%, at a cost US$2.8 million over a 10-year horizon. This amount is far less than 
US$8.5 million to procure bedaquiline for the initiating treatment cohort due to cost savings from 
replacement of the injections.  
Direct provider costs of ADR management 
Chapter 7 describes the direct, provider costs of managing the most frequently occurring moderate 
to severe ADR associated with the current standard of care MDR/RR-TB treatment regimen in the SA 
public health sector. This analysis presented in this chapter was designed in order to achieve the sec-
ond objective of the overall thesis, namely: To evaluate the provider cost of prevention, monitoring, 
and management of ADRs incurred during MDR/RR-TB treatment, including drugs, hospitalization, 
laboratory monitoring, and clinic visits. 
While all patients should receive prophylaxis to prevent ADR – i.e. pyridoxine for peripheral neurop-
athy – and screening for the early detection of ADR – e.g. audiometry or ECG monitoring or kidney 
and liver function laboratory tests – only patients experiencing ADR incur the costs of ADR manage-
ment. Therefore, the Markov model for MDR/RR-TB treatment introduced in Chapter 6 was used to 
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evaluate the expected costs of ADR management when there is the competing risk of mortality. Us-
ing guidelines for the management of ADR, resource use was extracted and multiplied by ingredient 
unit costs from South Africa; the same ingredient costs were used to parameterize the cost-effec-
tiveness model in Chapter 6 and Chapter 8. The model used the frequencies of the ADR as calculated 
in the meta-analysis (Chapter 5) and the higher relative risk of ADR for HIV-infected patients newly 
initiated ART as presented in Chapter 3. Distributions were added for all model parameters, so that 
instead of one-way sensitivity analysis, probabilistic sensitivity analysis could be used. For an average 
cohort of MDR/RR-TB patients such as the 12,527 who initiated treatment in the SA NTP in 2015, in-
cluding ADR management costs increased the estimated cost by $4.76 million from $57.55 million 
total. The provider cost analysis was accepted at the International Journal of Tuberculosis and Lung 
Disease in December 2017 and is currently in press. 
The costs of managing the most frequently occurring ADR during MDR/RR-TB treatment are pre-
sented in Chapter 7. For moderate ADR with clinical management, the costs ranged US$2.51 for diar-
rhoea to US$208.23 for temporary drug-induced hypothyroidism. Severe systemic allergic reaction 
(e.g. Stevens–Johnson syndrome) require ICU care and, as a result, were the most expensive of all 
the ADR costed, at $5,461. Frequency of occurrence affected the weighted averages. The weighted 
average for moderate ADR was US$135.76, pulled up because the most expensive ADR (hypothyroid-
ism), was also the most frequent moderate ADR at 36%.[108] Conversely, the weighted average for 
severe or serious ADR was pulled down to US$521.29 per episode because the most frequently ex-
perienced severe ADR was permanent and profound hearing loss, which standard guidelines for the 
public sector in South Africa do not indicate hearing aids or cochlear implants. An estimated 40% of 
patients on the kanamycin-based regimen [115] experience this severe ADR, which was estimated to 
cost the provider $50.76. While the costs of ADR management were described for the standard of 
care regimen, the management of bedaquiline-based regimen could be derived from the same anal-
ysis (see Chapter 8). As indicated in Chapter 2, the indication for management of QT interval prolon-
gation once detected is to interrupt (if QT prolongation resolves) or stop bedaquiline, which does 
not add further to the costs of ADR management.[19] 
Management of ADR from MDR/RR-TB treatment was found to represent significant financial cost to 
the South African public-sector health services. For each patient treated for MDR/RR-TB the average 
cost of managing ADR was an additional US$381.17 per patient, an 8.3% increase. For the 2015 SA 
public sector MDR/RR-TB cohort, ADR management increased the costs of MDR/RR-TB treatment 
from US$57.55 million to US$62.31 million, an additional $4.76 million per year (95%CI: 4.13 to 5.40 
million). Similar to most of the TB treatment costs in South Africa, this additional cost is not incurred 
by the SA NTP or included in the HIV/TB conditional grant, rather, most of the cost is required for ad-
ditional primary health care services and hospital utilization.  
Cost-effectiveness of bedaquiline having adjusted for toxicity  
Chapter 8 builds upon the Markov model first presented in Chapter 6 and modified in Chapter 7 to 
include the disability weighting for patients who survive and complete MDR/RR-TB treatment but 
who experienced ototoxicity associated with the use of the second-line injectable agents. Disability 
weights, as reviewed in Chapter 2, are a means to discount years of life that are not lived at full 
health. Disability from having TB, TB/HIV on ART, TB/HIV not on ART, and HIV on ART (for persons 
who completed TB treatment) as reported in the Global Burden of Disease study in 2013 had been 
incorporated in initial version of the model. In Chapter 8, the disability weight discounting years of 
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life lived with profound deafness were used to discount the effectiveness of surviving the standard 
of care regimen, for an expected proportion of patients, as found through the systematic review 
(Chapter 5). The disability weight for hearing loss was extracted from a study implemented in South 
Africa using the Global Burden of Disease methodology; as described in the literature review (Chap-
ter 2) the South African respondents weighed hearing loss as a much more severe disability and loss 
of health than in other settings. Results of this incremental cost-effectiveness analysis were submit-
ted in December 2017 for peer review and publication.  
This final results chapter pulls together findings presented in each of the previous chapters, includ-
ing timing of mortality during MDR/RR-TB treatment by HIV and ART status Chapter 3, proportion of 
persons experiencing ADR and serious ADR in HIV settings Chapter 5, and the increased relative risk 
of ADR for HIV-infected patients newly initiating ART Chapter 4. Ingredients costs and the Markov 
model established in Chapter 6 and average costs for ADR management as estimated in Chapter 7 
are also used. Disability weights for hearing loss (Table 2-11) are added to the model. The result is a 
cost-effectiveness analysis that is based upon real-world implementation of an injection-free regi-
men in South Africa and that quantifies the provider costs and disability of permanent, profound 
hearing loss from the MDR/RR-TB injection-based regimens.   
With the probabilistic sensitivity analysis estimating a range of possible combinations of parameters, 
the relatively higher ADR management costs associated with the injection-based regimens, and the 
decreased effectiveness of the injection-based regimens once discounted for the hearing loss, a be-
daquiline-based MDR/RR-TB regimen dominated the standard of care regimen. Bedaquiline for all 
MDR/RR-TB, not just the patients with extensive drug-resistance, was more effective (DALYs 
averted) and cost saving.  
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9.2 GENERALIZABILITY OF FINDINGS 
Timing of mortality during MDR/RR-TB treatment 
The timing of MDR/RR-TB treatment outcomes was not previously described for the South African 
context, although the findings are consistent with previously published analyses of timing of mortal-
ity from initial sputum collection [224], as well as Kaplan-Meier and cumulative incidence function 
graphs from South African cohorts which showed sharp drops in survival in first weeks followed by a 
levelling off.[186,223–225] The South African context may be most generalizable to other contexts 
implementing a standardized, long-course regimen where there is a high prevalence of HIV/TB co-
infection. The early timing of mortality during treatment may be related to the time development of 
active disease to diagnsosis and to the time from diagnosis to initiation on treatment. Understanding 
of the natural history of the disease progression (i.e. in absence of medical interventions) is limited. 
Additionally, most studies, like this one, focus only on one part of the continuum from active disease 
to death from any cause. As a result, there is bias introduced in both the right censoring (e.g. starting 
at treatment initiation rather than sputum collection for diagnosis) and left censoring (e.g. stopping 
at 72 or 104 weeks rather than 120 weeks or longer) of the analysis period which limits generalizabil-
ity to analysis periods with different right or left censoring. 
Increased risk of ADR for MDR/RR-TB patients newly initiating ART 
The systematic review presented in Chapter 5 confirmed the novelty of the major finding from Chap-
ter 4, that patients newly initiating ART at the same time as initiating MDR/RR-TB treatment are at 
the highest relative risk of ADR. Although the experiences of the specific cohorts from Johannesburg 
may be a limitation of the study (see below, Chapter 0), the novelty of the finding is a strength of the 
specific data collection and analysis methods, rather than a limitation of the generalizability. As 
noted in the chapter, many other studies which described AE during MDR/RR-TB in high HIV preva-
lence settings did not differentiate the grade of AE [184], had insufficient numbers of patients on 
ART [109], or did not differentiate the time on ART [108]. Most commonly, when analysis was pre-
sented, it was a difference in proportions.[111,122] Other studies analysed difference in outcomes 
such as death, culture conversion, or treatment success by HIV and ART status, but did not provide 
the analysis for ADR by HIV and ART status.[183,188] For the current study, this differential risk for 
ADR was both statistically significant and clinically significant and, therefore, was used to parameter-
ize the Markov models used in Chapters 7 and 8. 
Applicability to the short-course regimen 
The use of robust statistical techniques to calculate pooled proportions across the observational 
studies strengthen the generalizability of these findings to similar standardized MDR/RR-TB long-
course treatment regimens. Further, because the newer short-course treatment regimens rely on 
the same drugs[14] and because the ADR typically occur during the initial months of treatment, the 
findings should be generalizable to the short-course regimens as well. The short-course regimen be-
ing implemented in South Africa since the end of 2016 is still based upon an intensive phase using 
kanamycin. Although the Bangladesh study that pioneered the short-course regimen reported hear-
ing loss of 7%, it is not clear that this low rate is a benefit of the short-course regimen as the meas-
urement of hearing loss is not described.[226] A subsequent report from the same centre of a larger 
cohort (n=515) did not report the proportion of patients who had hearing loss even in the section on 
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ADR and indicated that ADR “were not systematically recorded, and recording of most events (ex-
cept for glycosuria) was mostly based on spontaneous reporting by the patient”.[227] As discussed 
in Chapter 2.6, this could lead to under-reporting of ADR, especially hearing loss at high frequencies. 
A more recent study from Bangladesh designed to measure differences in hearing loss at baseline, 2, 
3, 6, and 8 months after treatment initiation reported 77.8% of the 36 MDR/RR-TB patients tested 
using pure tone audiometry acquired hearing loss, 1/3 of which occurred by 2 months.[228] Imple-
mentation of the short-course regimen in other settings has also led to high rates of permanent 
hearing loss, even though the duration of the intensive phase is shortened to 4 months. In Niger, 
20% of patients experienced hearing loss and in Cameron, 43% of patients had a documented deteri-
oration in their hearing during the short-course treatment that is now standard of care.[229,230] 
While waiting for the results of studies using short-course bedaquiline and delamanid regimens [1], 
the results of this cost-effectiveness analysis adds more weight to the urgency to re-evaluate the use 
of IA in the treatment of MDR/RR-TB. 
Inclusion of ADR in cost-effectiveness analysis of TB interventions 
While the specific dollar amounts estimated for South Africa are unlikely to be generalizable to other 
settings, the overall finding that the costs of ADR management should not be excluded from budget 
estimations is likely to hold true across all settings implementing MDR/RR-TB treatment. Particularly 
in contexts where treatment guidelines for managing hearing loss indicate expensive rehabilitation 
such as cochlear implants, unlike in the SA NTP, exclusion of ADR management costs could result in 
under-estimation of required resources. This finding is important beyond cost-effectiveness analyses 
of MDR/RR-TB treatment, for example, prevention of TB transmission and acquired drug-resistance 
also needs to have an accurate estimation of the costs of MDR/RR-TB treatment. 
Disability weighting of permanent profound hearing loss 
The increased effectiveness for an all oral regimen estimated in this analysis is because IAs are asso-
ciated with the high levels of ototoxicity.[1,115,130] Permanent and profound hearing loss reduces 
the overall effectiveness of the IA treatments when disability weightings are applied beyond the 
completion of the MDR/RR-TB treatment. The profound hearing loss disability weighting used here 
was from a South African survey; the weighting was nearly twice as high as the global study.[75,79] 
The commonality of the value or preference for different health states across contexts (e.g. South 
Africa compared to Europe) [33] continues to be questioned, particularly for resource-limited con-
texts where coping mechanisms may be less available.[34–37] While the disability may be less in 
higher-income settings, the costs may be higher. In countries with more coping mechanisms, the 
costs to providers or patients for accessing rehabilitative services or devices such as hearing aids and 
cochlear implants, would be much higher than the South African context. Although the disability 
weighting may not be generalizable across different contexts, again, the significance of considering 
the burden of ADR even after MDR/RR-TB treatment is appropriate for any settings implementing 
the IA-based drug-resistant TB drug regimens. 
South African health care costs 
As was noted in Chapter 2, generalizing cost-effectiveness analyses to other settings in part depends 
on whether the cost structures and relative prices and costs are common across settings.[40] The 
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major ingredients of the service delivery cost of MDR/RR-TB treatment are clinical care (hospitaliza-
tion or primary health care visits), anti-TB drugs, laboratory tests, and procedures. Of these, clinical 
care and procedures are not internationally traded; they are costs of services built from the underly-
ing wages of health care workers in South Africa. In this analysis, a detailed original costing study of 
hospital stays, clinic visits, or procedures was not done. The published, unsubsidized charges that are 
applied to foreigners or persons of high income were used in absence of more detailed information. 
The SA Department of Health’s Uniform Patient Fee Schedule (Revised April 2016)[3], which is based 
on the Reference Price List for medical services, was used as a proxy for estimating the costs of in-
vestigations, procedures, consultations, facility utilization, phlebotomy, and pharmacy dispensing. 
These charges include assumptions about allocation of shared and overhead expenses, capitalization 
and annuitization of buildings and equipment, staffing levels, and utilization rates. Where the analy-
sis used to generate the patient fee schedule is out of date, too simplistic or not granular, or simply 
where assumptions and actual experience differ, the charges and actual costs will differ. Further 
studies are needed to understand the cost to charge ratio in South Africa. Further, health care costs, 
whether actual costs or based on charges are affected greatly by utilization rates. South Africa has 
one of the world’s largest MDR/RR-TB treatment cohorts and is ranked even higher in terms of the 
treatment cohort size relative to its population.[2] Specialized doctors, nurses, and facilities may 
therefore have a lower cost per patient because of the patient volumes than would be applicable to 
other settings.  
The large treatment cohort also has an impact on internationally traded goods such as anti-TB drugs 
and laboratory cartridges, reagents, and equipment. For example, South Africa has been able to ne-
goitiate discounted rates for ARVs, Xpert MTB/RIF, and bedaquiline because it is a significant portion 
of the market. Because of its market size, South Africa does not participate in the Global Drug Facility 
(GDF) (http://www.stoptb.org/gdf/) a procurement system of the Stop TB partnership which pools 
orders from smaller programs to WHO-recommended anti-TB drugs. There is uncertainty as to how 
long South Africa will be able to procure bedaquiline at the $675 for a 6 month supply. In 2014, 
Janssen announced a partnership with the GDF where bedaquiline prices would be tiered: 
$30,000/treatment course for high-income countries, $3,000 for middle-income countries, and $900 
for low-income countries. Although South Africa is not a low-income country, Janssen supplied be-
daquiline to the SA public health sector at the $900/per treatment course. The $675 used in this 
analysis was not separately negotiated, it was the result of the procurement being set in ZAR and de-
flation in the value of the ZAR to the USD that occurred subsequent to procurement agreements. If 
the prices are below market value, they may be only temporary in nature, and the findings of this 
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9.3 STUDY LIMITATIONS 
The study design applied and analysis presented have limitations which were noted in the presenta-
tion of the results Chapters (3 to 8). Major limitations are further examined here. 
ADR experienced during MDR/RR-TB treatment 
Two different methods were combined to estimate the types, frequency, and severity of ADR experi-
enced by MDR/RR-TB patients. A retrospective, de-identified analysis of a clinical file review was 
used to describe the frequency, duration, and severity of ADR experienced during MDR/RR-TB treat-
ment at two sites in Johannesburg, South Africa; results are presented in Chapter 4. As noted above 
(Chapter 9.1), one of the major limitations of the data may be the generalizability of two public-sec-
tor clinics located within Academic Hospitals in Johannesburg to other contexts. Further, while the 
data extraction forms for the clinical file review were designed to capture details for clinical factors 
determined, a priori, to be relevant to the study, the study itself was a retrospective review of rou-
tinely captured data. Symptoms or ADR that were not reported could not be analysed.   
To improve the generalizability of the findings from the Johannesburg MDR/RR-TB treatment co-
horts, a systematic review and meta-analysis describing the frequency and severity of ADR during 
MDR/RR-TB treatment in the context of high HIV prevalence settings was presented as Chapter 5. 
The ‘true’ frequency of ADR during MDR/RR-TB treatment depends on many factors, from patient 
characteristics to health services and systems issues. The systematic review and meta-analysis re-
ported in Chapter 5 did not find any publications from randomized, clinical trials including where at 
least 20% of the treatment cohort was HIV-positive. The limitations of the observational data are 
worsened (generally) by inconsistency in definitions and reporting standards, as further described in 
Chapter 5.  
The limitations of observational data are more pronounced for the secondary analysis of routinely 
captured, implementation data such as the EDRweb. Transition probabilities for the modelling were 
based upon data as routinely documented in the SA NTP electronic case register, the EDRweb. As is 
elaborated on in Chapter 3, the large cohort size and real-world experience captured in EDRweb are 
strengths of this analysis, however, routinely collected data also has limitations in its completeness. 
Few indicators of physical condition or mortality risk factors are included in EDRweb, such as hospi-
talization, other comorbidities, body mass index, serum albumin, or haemoglobin. Fields that should 
be captured in EDRweb, including reporting of ADR or start date for ART and CD4 count if HIV-in-
fected were poorly completed and so not used in the analysis despite the importance of this infor-
mation. 
Provider cost of prevention, monitoring, and management of ADRs  
Limitations regarding the reporting of ADR were carried into the direct provider cost analysis (pre-
sented as Chapter 7, as the expected frequency of each ADR was used to create a weighted average. 
Additionally, the ADR management costs based on guidelines are limited by the use of a guidelines-
based approach. Where clinicians provide additional services, drugs, or procedures beyond those 
indicated or where clinicians are unable to provide all indicated resources, the actual costs would 
differ from the guidelines-based approach. 
All of the cost results – Chapter 6-8 – reported include the limitation of the provider cost perspec-
tive. Provider costs, while a significant component of health care costs in the South African public 
sector, do not reflect the cost to society. Direct and indirect costs incurred by patients to access 
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MDR/RR-TB treatment or to manage ADRs while on treatment were excluded and therefore the 
costs presented here are an underestimate of the societal costs. Further, this analysis effectively ig-
nored programme costs above the patient or service-delivery level. At least in the short-term as a 
bedaquiline-based regimen is rolled out in South Africa the costs of district, provincial or SA NTP 
training, coordination and management may be important costs to consider.[22,231] 
More broadly, and therefore not elaborated on in the results chapters, the focus of this thesis on the 
cost-effectiveness of bedaquiline-based MDR/RR-TB treatment regimens can be viewed as a limita-
tion. There are ethical and human rights reasons for adopting new treatments if more effective and 
more tolerated, even if more costly. A court in India ruled that the public health system had to allow 
for a girl with XDR-TB to receive bedaquiline, even though more costly and not available in her re-
gion of the country.[232] Recently, there have been high-profile editorials and reviews calling to end 
the use of IAs for children [233] and adults [1], even assuming a higher cost associated with new reg-
imens. However, this type of analysis also provides a systematic process for decision making that can 
help to balance the different competing needs in a society. There is risk in making commitments that 
a society cannot afford [37], even if there is a strong advocacy for a particular group in society and 
desire to protect life. The challenges of and need for multi-criteria decision making does not negate 
the value of cost-effectiveness analyses, but does emphasize that the finding that something is cost-
effective is not sufficient for decision makers.   
ICER of bedaquiline-based regimens 
For both of the results chapters presenting the ICER of bedaquiline-based regimens compared to IA-
based regimens, the most significant limitation is the uncertainty with regards to the mortality im-
balance reported in the Phase 2b trial.[30] As the WHO noted in both its 2013 and 2017 guidance on 
the use of bedaquiline, the evidence from the Phase 2b trial had potentially “very serious bias” for 
imprecision from the small patient numbers and also “serious bias” for indirectness; none of the 
deaths in the bedaquiline arm were attributed to bedaquiline.[31,32] Because of this potential for 
serious bias, similar to previously published cost-effectiveness analyses for bedaquiline [53–56], this 
thesis used the same mortality rates for bedaquiline regimens as for IA regimen. Data presented to 
the WHO during the guidelines review from the EDRweb cohort suggest that bedaquiline regimens 
have lower mortality than standard of care.[32] Thus, the uncertainty remains a limitation until 
Phase 3 clinical trial results are available.  
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9.4 SUMMARY OF THESIS CONTRIBUTIONS 
Detail on the contribution of this thesis to the field of study is included in the Synopsis section prior to 
each manuscript chapter (3-8). In summary:  
Chapter 3  
In this analysis, the EDRweb dataset was matched to the vital statistics register to validate the vital 
status of patients and to more precisely measure the timing of mortality. This matching had not 
been previously done for the national cohort. The finding that the mortality rates differ so substan-
tially over the period of treatment has implications for treatment policy and practice as well as budg-
eting and planning for the program, including whether there is sufficient clinical capacity to increase 
the intensiveness of clinical monitoring with the current patient volumes. 
Chapter 4 
As was confirmed through a systematic literature review and meta-analysis (Manuscript 3), previous 
observational studies and meta-analysis of ART during MDR/RR-TB treatment had not established 
whether patients on ART and second-line treatment were at higher risk for ADR, even with known 
overlapping toxicities. By using competing risk analysis to adjust the incidence of ADR for the com-
peting risk of mortality, this manuscript provided evidence that patients with the highest risk of mor-
tality (those who are HIV-positive and not stable on ART prior to MDR/RR-TB treatment initiation) 
also have the highest risk of ADR.      
Chapter 5 
This analysis was novel in using a relatively new statistical method for managing the variance of a 
meta-analysis, but relies on a binomial distribution, appropriate for binary questions such as 
whether a patient experienced an ADR or not. Using meta-analysis with pooled proportions provided 
more clarity as to the frequency of ADR during MDR/RR-TB treatment, as the literature was entirely 
from observational studies from varied settings. 
Chapter 6 
As of August 2017, the five studies identified that analysed the cost-effectiveness of bedaquiline 
[52–56], in addition to the original analysis included in the WHO recommendations [31] considered 
bedaquiline added on to the standard regimen rather than replacing the injection. This analysis was 
the first to use evidence from programmatic roll out to show what may happen using a new regimen 
where bedaquiline replaced the injection. Additionally, this was the first cost-effectiveness model for 
MDR/RR-TB with separate health states and transition probabilities for HIV co-infection.  
Chapter 7 
Previously published cost-effectiveness analyses of MDR/RR-TB treatment, if including the costs for 
ADR management, used an average which did not specify the type, frequency, cause, or specific 
management for the ADR in the details. Therefore, these analysis could not be used when the ex-
pected ADR differed by the comparison treatment regimens. The costing workbook indicates the 
suspected drugs for each of the included ADR, and thus also can be used to estimate the costs of 
ADR for different regimen than the standard of care injection-based regimen costed, as it was used 
for Chapter 8.  
Chapter 8 
Bringing together the estimated costs of ADR management Chapter 7and the burden of permanent 
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disability from hearing loss, this manuscript is the first to find that overall, a bedaquiline-based regi-
men is likely to be cost saving compared to an injection-based regimen, even in an low-resource set-
ting with ambulatory, decentralized treatment of MDR/RR-TB. The inclusion of the costs and disabil-
ity weighting of ADR for cost-effectiveness analysis of MDR/RR-TB treatment regimens is novel addi-
tion to the literature that is necessary to more closely  determine the cost of MDR care in analysis 
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9.5 FUTURE DIRECTIONS 
This thesis set out to evaluate whether the inclusion of the costs of adverse drug reaction manage-
ment and the disability burden affected the incremental cost-effectiveness ratio of a bedaquiline-
based MDR/RR-TB treatment regimen. Prior to adjusting for the toxicity of the standard of care regi-
men, the use of bedaquiline in the SA NTP was affordable, but more expensive for moderate gains in 
effectiveness. Compared with other health priorities or other societal priorities, expanded use of be-
daquiline did not dominate the standard of care injectable-agent based regimen. However, once the 
costs of managing ADR, including electrolyte imbalance and renal dysfunction and the permanent 
disability of profound hearing loss associated with the use of the second-line injectable drugs, the 
results changed. Bedaquiline-based treatment for MDR/RR-TB is cost-saving and more effective than 
regimens using the less expensive injections.  
Recommendations for future directions 
Beyond the importance of the findings of Chapter 3 for the analysis of the cost-effectiveness of be-
daquiline, the high rates of early mortality during MDR/RR-TB treatment presents an urgency to 
identify the associated risk factors. With more research into the clinical risk factors – e.g. low CD4 
count, poor HIV viral suppression, low BMI, pre-existing or incident anaemia, hepatitis, or kidney 
dysfunction – MDR/RR-TB treatment guidelines can be updated to allow for triaging of patients and 
differentiated care for those that are in greatest need. These clinical risk factors for poor treatment 
outcomes overlap with ADR common to MDR/RR-TB treatment and HIV treatment (as noted in 
Chapters 2, 5) and may also increase the risk for ADR during MDR/RR-TB or HIV treatment (Chapter 
4). Again, better understanding of the clinical markers during MDR/RR-TB treatment beyond sputum 
culture positivity will assist in more targeted monitoring for ADRs or treatment regimens individual-
ized to avoid toxicities. Further, the early mortality presents a compelling motivation for more re-
search into treatment guidelines that start from a perspective of assuming second-line resistance 
and reducing the number of active drugs over time, rather than starting with the standard regimen 
and adding active drugs after the initial regimen fails to lead to clinical improvement, if the burden 
of ADR from the additional drugs is does not outweight the benefits. 
The increased risk of ADR for HIV-positive, ART naïve patients described in Chapter 4 point to a need 
for additional or more frequent monitoring for AE for patients initiating both ART and RR-TB treat-
ment at the same time, beyond the current guidelines indications of monthly visits.[17] The cumula-
tive incidence function for mortality accounting for the competing risk of loss to treatment indicating 
that HIV-infected MDR/RR-TB patients who were ART naïve have the highest risk of mortality is con-
sistent with studies and guidelines that indicate early initiation of ART for patients with TB [169–171] 
and drug-resistant TB [16,136]. With the 2015 WHO recommendation that all persons living with HIV 
initiate ART, regardless of CD4 count, this differential risk for the HIV-positive, ART naïve MDR/RR-TB 
patient will hopefully become a less important factor over time as the population of HIV-infected pa-
tients not on ART declines. Until that time, routine monitoring such as that captured in the EDRweb, 
should capture information on CD4 count, duration of time on ART, and other clinical factors such as 
BMI, laboratory monitoring for ADR, and extent of damage to the lungs, none of which are currently 
routinely reported or monitored at a national level in South Africa.  
Given the findings of the systematic review and meta-analysis presented in Chapter 5, clinical guide-
lines should encourage active symptom screening and improved reporting of ADR during MDR/RR-TB 
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treatment. Patients whose clinical condition requires immediate initiation of ART and RR-TB treat-
ment may benefit from intensive monitoring  or even  inpatient treatment initially  to watch  for se-
vere AEs. This additional monitoring may require additional clinic capacity and resources and should 
be reflected in the SA NTP budget. The systematic review Chapter 5 highlighted that ADR are not al-
ways noted in patient files, and grading of severity and identification of suspected drugs is not even 
less frequency. Yet, if the symptoms go unnoticed by the clinicians, management of the symptoms or 
reaction, including changes to the treatment regimen, cannot be done. Active screening, by asking 
patients if they have had a set of symptoms using a standardized form for reporting, rather than pas-
sive screening by waiting for patients to report a complaint, could improve the evidence base for the 
effects of current or new treatment regimens. Further studies on the quality of life or the disability 
experienced during MDR/RR-TB treatment in high burden settings are also warranted, given the as-
sumptions and uncertainty in the estimates of disability weighting. The disability weights from the 
South African GBD study [79] were very different than the global weights [74,75,77,107], should the 
weights be re-evaluated with more input from the contexts with the highest burden? It may also be 
that the description of MDR/RR-TB (i.e. “has a persistent cough and fever, shortness of breath, night 
sweats, weakness and fatigue and severe weight loss” [107]) should be re-evaluated given new evi-
dence of the impact on patients, and that in doing so, the relative weight assigned to the disability, 
no matter what context is considering it, would differ.  
Finally, future MDR/RR-TB guidelines, policy considerations and recommendations should consider 
the differential impact of proposed treatment regimens on the costs of ADR prevention, monitoring, 
and management as well as any associated disability or morbidity that continues after treatment 
completion. Even while new trial results and guideline revisions are pending, MDR/RR-TB patients in 
South Africa should be given the opportunity to make an informed choice between an 18-month reg-
imen using bedaquiline for 6 months or a 12-month regimen using injectable agents for 4 months. 
Risks of both regimens, including success rates and expected ADR, should be discussed between the 
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9.6 CONCLUSION 
Bedaquiline-based treatment for MDR/RR TB is cost-saving and more effective than regimens using 
the less expensive injections. Based on these findings, it is important to modify policy guidelines to 
specifically recommend bedaquiline for all long-course MDR/RR-TB treatment from the start of 
treatment. Current guidelines still give preference for kanamycin before use of bedaquiline, for ex-
ample by waiting until a patient experiences hearing loss before switching.  
Additionally, the findings of this thesis suggest an urgent re-evaluation of the recommended short-
course regimen to determine whether bedaquiline can replace kanamycin for the short-course regi-
mens that also rely on IA. In order to use evidence from implementation and roll-out of bedaquiline, 
the analysis presented here is comparison of the long-course (18 to 24 months) IA regimen and the 
bedaquiline regimen used in South Africa prior to the end of 2016. SA NTP MDR/RR-TB patients with-
out second-line resistance are now eligible for the short-course regimen, which was recommended 
by the WHO in 2016. While waiting for the results of studies using short-course bedaquiline and 
delamanid regimens, the results of this cost-effectiveness analysis adds more weight to the urgency 
to re-evaluate the use of IA in the treatment of MDR/RR-TB. Until evidence is sufficient to adapt the 
regimen, patients should be given the opportunity to make an informed choice between an 18-
month regimen using bedaquiline for 6 months or a 12-month regimen using injectable agents for 4 
months. Risks of both regimens, including success rates and expected ADR, should be communicated 
to patients.   
Current injection-based long-course standard treatment for MDR/RR-TB is associated with high rates 
of adverse drug reactions, including permanent hearing loss. Based on this modelling of bedaquiline 
regimens in South Africa, new drugs that can allow for an all oral MDR/RR-TB treatment regimen 
may be cost saving and more effective than current injection-based regimens, if cost-effectiveness 
analyses incorporate the costs and burden of the expected adverse drug reactions.  
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11.1 ANNEX – SUPPLEMENTAL MATERIALS FOR META-ANALYSIS OF ADR IN HIV SETTINGS 
Supplemental Materials  
Adverse drug reactions during drug-resistant tuberculosis treatment in high HIV prevalence settings: 
a systematic review and meta-analysis 
Kathryn Schnippel, Cynthia Firnhaber, Rebecca Berhanu, Liesl Page-Shipp, and Edina Sinanovic 
 
Additional background: 
The duration of drug-resistant TB treatment is longer than for drug-sensitive TB (typically 9-24 
months) and standard regimens for MDR/RR-TB include 4 to 7 drugs with different[16] mechanisms 
of action, including oral bacteriostatic drugs such as cycloserine, terizidone, ethionamide; aminogly-
coside and cyclic peptide injectables; fluoroquinolones (e.g. moxifloxacin, ofloxacin, gatifloxacin, and 
levofloxacin); and newer agents such as bedaquiline (a diarylquinoline) and delamanid (a nitroimid-
azole).    
In some settings, particularly sub-Saharan Africa, TB and HIV are inextricably linked. Treatment of 
HIV and TB co-infection results in high pill burden and potentially increased toxicity. Effective ART 
regimens include three drugs, usually two nucleoside reverse transcriptase inhibitors (NRTIs) with 
either a non-nucleoside reverse transcriptase inhibitor or protease inhibitor (PI) in resource-limited 
countries. Toxicities can be overlapping, such as potential renal impairment from antiretrovirals in-
cluding tenofovir and anti-TB medications kanamycin/amikacin; peripheral neuropathy from stavu-
dine and zidovudine, ethionamide and linezolid; bone marrow suppression from zidovudine and line-
zolid; nausea and vomiting potentially from zidovudine and ethionamide and para-aminosalicylic 
acid; or psychiatric symptoms associated with efavirenz and cycloserine and terizidone.[16,136] HIV 
infection, even for the ART naïve, and particularly for those who have advance HIV disease or immu-
nosuppression may also pose its own risk for ADR. For example, thioacetazone was removed from TB 
treatment recommendations early in the HIV epidemic because of an increased risk of Stevens-John-
son syndrome in HIV-infected patients.[137]  
Within the last decade, there has been escalated progress for drug-resistant TB drug development; 
new treatments are being developed and multiple drugs are entering or in clinical trials.[167,173] In 
the Phase IIb randomized control trial for bedaquiline where bedaquiline or placebo was added to a 
standard background regimen, 99% of participants in the treatment arm and 98% of the participants 
in the placebo arm experienced one or more adverse events. Most of these events were categorized 
as being related to the treatment, 70% (bedaquiline) and 69% (placebo) for the two arms, respec-
tively.[30] Knowing whether the rates of ADR experienced in clinical trials for new drugs are of con-
cern requires a better understanding of the base case scenario. Additionally, in efforts to improve 
treatment outcomes existing drugs such as linezolid (an oxazolidinone) and clofazimine are being re-
purposed for drug-resistant TB treatment. Because the drugs have existing regulatory approval for 
other indications, randomized controlled trials are not required in many settings and available un-
derstanding of the potential side effects and optimal doses for the regimens are limited to observa-
tional cohorts.[98,174]  
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Table 11-1 Study inclusion and exclusion criteria 
Inclusion criteria: Exclusion criteria: 
Patients were diagnosed as at least rifampicin (RIF) resistant by any World Health 
Organization (WHO) approved method (e.g. Xpert MTB/RIF, phenotypic drug-sensi-
tivity testing, or line probe assay). 
Fewer than 20 RIF-resistant TB patients were included in the published cohort. 
At least 20% of the cohort was known to be HIV-infected.  Information on RIF-TB treatment regimen was not available. 
Results were available in English language. Information on HIV status of patients was not available. 
Patients described were on a second-line TB treatment regimen that was in align-
ment with the WHO 2011 Programmatic guidelines2 or subsequent updated rec-
ommendations in 2013 and 2014 for bedaquiline14 and delamanid15, respectively.  
Information on adverse drug reaction (ADR) or adverse event (AE) suspected to be 
related or known to be associated with second-line TB treatment experienced by 
cohort not reported.  
Alignment was defined as meaning treatment for 18-24 months with 4-6 drugs 
from the WHO recommendations:  
● Second-line injectable agent: kanamycin, amikacin, or capreomycin 
● Fluoroquinolones: levofloxacin, moxifloxacin, gatifloxacin, ofloxacin 
● Oral bacteriostatic: ethionamide, prothionamide, cycloserine, terizidone, 
para-aminosalicylic acid 
● Additional drugs (previously known as ‘Group 5 drugs’): clofazimine, line-
zolid, amoxicillin/clavulanate, thioacetazone, clarithromycin, imipenem 
● New agents: bedaquiline, delamanid 
Reports of a trial of a non-WHO recommended treatment regimen or method as of 
2015, i.e. short course, surgery, herbal treatments, or immunotherapy. 
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Table 11-2 Included articles, reporting on multiple ADR and suspected drugs 
First author Year Citation Country All patients HIV+ patients % HIV Year start Year finish Notes 
All ADR          
Brust 2013 [108] South Africa 91 74 81.3% 2008 2011  
Charles 2014 [178] Haiti 110 27 24.5% 2010 2013  
Isaakidis 2012 [114] India 67 67 100% 2007 2011  
Jacobs 2012 [179] South Africa 350 254 72.6% 2010 2011  
Kelly 2016 [123] South Africa 121 90 74.4% 2014 2014  
Meressa 2015 [124] Ethiopia 612 133 21.7% 2009 2014  
O'Donnell 2013 [180] South Africa 114 82 71.9% 2006 2007 XDR TB only 
Sagwa 2014 [181] Namibia 59 31 52.5% 2008 2010  
Seddon 2013 [182] South Africa 142 32 22.5% 2009 2011  
Shean 2013 [168] South Africa 115 48 41.7% 2002 2008 XDR TB only 
Thee 2014 [183] South Africa 23 6 26.1% 2012 2014  
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Table 11-3 Included articles, reporting on only severe ADR, one type of ADR, or one suspected drug 
First author Year Citation Country All patients HIV+ patients % HIV Year start Year finish Notes 
Severe ADR          
Burgos 2005 [185] United States 48 11 22.9% 1982 2000 Severe only 
Kvasnovsky 2011 [186] South Africa 206 108 52.4% 2006 2008 XDR TB; Severe only 
Ndjeka 2015 [34] South Africa 91 54 59.3% 2013 2014 Severe only 
Seung 2009 [187] Lesotho 76 56 73.7% 2007 2008 Severe only 
Serious ADR          
Van der Walt 2013 [109] South Africa 1,390 544 39.1% 2000 2004 Serious only 
ADR specific          
Andries 2013 [113] India 69 69 100% 2006 2013 Hypothyroidism 
Conradie 2014 [190] South Africa 246 199 80.9% 2009 2011 Peripheral neuropathy 
Harris 2012 [192] South Africa 151 86 57.0%   Hearing loss 
Modongo 2012 [112] Botswana 213 135 63.4% 2007 2011 Hypothyroidism 
Modongo 2014 [189] Botswana 437 288 65.9% 2007 2012 Hearing loss 
Satti 2012 [111] Lesotho 186 125 67.6% 2007 2009 Hypothyroidism 
Drug specific          
Padayatchi 2014 [188] South Africa 85 73 85.9% 2009 2011 XDR TB; Clofazamine 
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Figure 11-1 Forest plot of estimate of proportion of patients experiencing hearing loss (ototoxicity)^ 
 
 
^Excluding Meressa as noted in study that no hearing screening or tests performed. 
Metaprop was used as it is based on binomial distribution appropriate for analysing proportions and is less 
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11.2 ANNEX - SUPPLEMENTAL MATERIALS ADR COST MODEL 
Table 11-4 Definitions and methodology for calculating unit costs 
Unit costs 
All unit costs were collected from the perspective of the public sector in South Africa in the local currency (ZAR) us-
ing public sector databases. Costs were either collected in 2016 ZAR or inflated to 2016 using the medical compo-
nent of the consumer price index (CPI).[1] Costs were converted to USD at the average exchange rate for 2016, 
14.74 ZAR to USD.[2] 
 
Uniform patient fee schedule 
The SA Department of Health’s Uniform Patient Fee Schedule (Revised April 2016)[3], which is based on the Refer-
ence Price List for medical services, was used as a proxy for estimating the costs of investigations, procedures, con-
sultations, facility utilization, phlebotomy, and pharmacy dispensing. The Schedule includes a detailed list of differ-
ent procedures and investigations for patients and indicates costs groupings. 
Based on the cost grouping, a facility fee plus a general medical officer or specialist fee was extracted. The highest 
(unsubsidized, full cost) fee was assumed to be representative of the full cost of the health facility utilization for the 
provider.   
The Schedule for South Africa also includes a standard fee for 12 hours in either a general medical ward or an inten-
sive care unit. 
Additionally, the standard fee for an outpatient consultation was used for outpatient monitoring of mild to moder-
ate ADR or follow-up after hospital discharge for serious ADR. 
The standard pharmacy dispensing fee was added to all ADR with prescribed medications or IV fluids. 
The standard fee for a blood draw was added to all ADR with laboratory tests requiring phlebotomy. The charge 
was only added once per set of tests on the same day. 
 
National Health Laboratory Services state price list 
Indicated laboratory tests were matched to items on the 2015/16 state (public sector) price list from the National 
Health Laboratory Services [4] and inflated to 2016 ZAR. 
 
Essential medicines procurement 
The Master Procurement Catalogue March 2016 [5] was downloaded from the National Department of Health web-
site and public sector prices for medications at the indicated doses and quantities were extracted. 
 
National blood service state price list 
Costs for blood products and related services were extracted from the state price list of the South African National 
Blood Service for 2016.[6] 
 
Excluded costs 
Costs of antiretroviral therapy (ART) for HIV, the standard MDR/RR-TB regimen, and monitoring for TB sputum con-
version were excluded from the analysis as these are included in the costs of HIV and/or MDR/RR-TB treatment. 
Capital investment in infrastructure, pre-service education, vehicles or medical equipment was not separately esti-
mated.  No patient costs were included in this analysis. 
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Table 11-5 Resource estimation notes and methodology 
Resource use estimation 
Overall note 
Resource use was extracted from guidelines for the purposes of costing only; clinical screening or activities without 
an identified additional cost were excluded. Minimum or essential standard treatment was assumed for a conserva-
tive provider costing perspective. Resource use described below is not meant to be or replace clinical guidelines or 
to be interpreted as recommended practice. Also see limitations section in main article. 
 
Management of ADR 
Management of ADR and their sequalae may include additional clinic consultations, investigations, laboratory tests, 
medications, and/or hospitalization. Resource utilization for each of the most frequently experienced ADR and seri-
ous ADR were extracted from the SA guidelines for primary healthcare treatment [2] or the SA guidelines for the 
treatment of MDR/RR-TB [1] if described, and compared for consistency against guidelines for the management of 
ADR in the WHO companion handbook, chapter 11 [3]. 
Additional clinical consultations were assumed for each month (4 weeks) duration of the ADR episode if moderate 
and requiring either prescription medication, laboratory follow-up or specialist referral.  
1 week of hospitalization was assumed for serious ADR unless guidelines indicated additional duration of stay.   
All hospitalization was assumed to be in the general medical ward except ICU for Stevens-Johnsons Syndrome. 
Clinical follow-up was assumed for all hospitalized ADR episodes, at least at level required for moderate episode or 
1 x visit. 
Severity or details listed are extracted from the DAIDS grading tables [4], but are used only to be descriptive and 




1. Directorate Drug-Resistant TB. Management of Drug-Resistant TB: Policy Guidelines. Pretoria: National Depart-
ment of Health; 2013.  
2. The South African National Department of Health. Standard Treatment Guidelines and Essential Medicines List 
for South Africa: Primary Health Care Level; 2014. 
3. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of 
drug-resistant tuberculosis; 2014. 
4. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0; 2014. 
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Table 11-6 Costed ingredients of SAE 
 
  
Costed ingredients of (S)AE, 2016 USD, by component category and % of total cost
Adverse events Description, severity
 Hospitalization 
costs  % 
 Additional clinic 
visit costs  %  Laboratory costs  % 
 Investigations and 
procedures costs  % 
 Medication and 
fluids costs  % 
 Total cost per patient 
experiencing 
Severe or serious AE
Hypersensitivity, allergic 
reaction
e.g. Stevens-Johnson Syndrome and Toxic 
epidermal necrolysis 4,827.77$               88% 13.17$                    0% 101.16$                  2% 488.19$                  9% 30.76$                    1% 5,461.05$                          
Hepatitis, l iver dysfunction e.g. ALT > 5 x the upper limit of normal 2,438.35$               90% 39.50$                    1% 167.00$                  6% 46.42$                    2% 12.19$                    0% 2,703.45$                          
Thrombocytopenia <50,000 cells/mm3 812.78$                  42% 52.66$                    3% 63.49$                    3% 534.59$                  28% 480.23$                  25% 1,943.75$                          
Psychiatric disorder
e.g. suicidal or pyschosis (harm to self or 
others) 1,625.57$               89% 26.33$                    1% 87.77$                    5% 76.25$                    4% 8.50$                       0% 1,824.41$                          
Renal dysfunction Globular fi ltration rate < 30 ml/min  1,625.57$               90% 52.66$                    3% 111.05$                  6% -$                         0% 18.60$                    1% 1,807.88$                          
Seizures New onset, severe 812.78$                  73% 78.99$                    7% 48.56$                    4% 155.47$                  14% 24.40$                    2% 1,120.21$                          
Anemia Hemoglobin <8 g/dL 812.78$                  87% 52.66$                    6% 63.49$                    7% -$                         0% -$                         0% 928.93$                              
Hypokalemia, electrolyte 
imbalance
e.g. Magnesium < 0.9 mEq/L or Potassium  < 
2.5 mEq/L 812.78$                  91% 26.33$                    3% 23.80$                    3% -$                         0% 29.08$                    3% 891.99$                              
Nausea, vomiting
Persistent vomitting or nausea resulting in 
minimal oral intake 812.78$                  96% 13.17$                    2% 9.66$                       1% -$                         0% 12.04$                    1% 847.65$                              
Hearing loss
Permanent, profound deafness (with or 
without tinnitus) -$                         0% 13.17$                    26% -$                         0% 37.60$                    74% -$                         0% 50.76$                                
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Notes: hospital Notes: clinic visits Notes: laboratory tests
1 week ICU, 1 week medical 
ward x 1 follow-up 4 x full  blood count; 4x l iver function panel; 4 x kidney panel
3 weeks medical ward Monthly x 3
4 x l iver function panel; full  blood count; kidney function panel; hepatitis B surface antigen; hepatitis C serology; 
hepatitis A serology; and follow-up tests as per moderate (below)
1 week medical ward Monthly x 4 
Full blood count; ferritin; PT/INR, reticulocyte count; iron; thyroid stimulating hormone; and follow-up tests as per 
moderate (below)
2 weeks medical ward Monthly x 2 
Full blood count; kidney function panel; thyroid stimulating hormone; cryptococcal antigen; serum magnesium, 
cerebral spinal fluid (CSF) culture, CSF gram stain, CSF cryptococcal antigen, CSF HSV PCR; CSF protein; CSF 
gluclose; and follow-up tests as per moderate (below)
2 weeks medical ward Monthly x 4 
Urinalysis, l iver function panel, full  blood count, creatinine; 7 x kidney function panel; and follow-up tests as per 
moderate (below)
1 week medical ward Monthly x 6 
Full blood count; kidney panel; thyroid stimulating hormone; cerebral spinal fluid (CSF) culture, CSF gram stain, 
CSF cryptococcal antigen, CSF HSV PCR; CSF protein; CSF gluclose ; l iver function panel 
1 week medical ward Monthly x 4 
Full blood count; ferritin; PT/INR, reticulocyte count; iron; thyroid stimulating hormone; and follow-up tests as per 
moderate (below)
1 week medical ward Monthly x 2  Serum magnesium; serum potassium; serum calcium 
1 week medical ward x 1 follow-up Full blood count; serum magnesium; serum potassium
None standard x 1 for referral None standard
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Notes: procedures and investigations Notes: medications and fluids
Dressings, debridement, specialized care 14 x l iter IV fluid; 1 x week prednilosone
Abdominal ultrasound 6 x l iter IV fluid
Transfusion 1 x unit platelets
Lumbar puncture; 1/3 of patients brain CT (non-contrast) 14 x tablets haloperdal; 30 x tablets risperdal; 2 x months fluoxetine
6 x l iters IV fluid; 3 x days metoclopromide; 4 x months enalapril; 
furosemide
CT brain (contrast); chest x-ray; lumbar puncture 6 x months valproate
None standard
6 x l iters IV fluid; spironolactone; 6 x months potassium, magnesium, 
and/or calcium supplement as applicable
None standard 5 x Metoclopromide IV; 10 x l iter IV fluid
Evaluation by audiologist; 1/3 of patients ear, nose, throat specialist 
evaluation;  1/10 patients  CT brain with contrast None standard
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Table 11-7 Costed ingredients of AE 
Adverse events Description, severity
 Hospitalization 
costs  % 
 Additional clinic 
visit costs  %  Laboratory costs  % 
 Investigations and 
procedures costs  % 
 Medication and 
fluids costs  % 
 Total cost per patient 
experiencing 
Moderate AE
Renal dysfunction Glomerular fi ltration rate < 60 to 30 ml/min  -$                         0% 52.66$                    52% 36.81$                    37% -$                         0% 11.18$                    11% 100.65$                              
Anemia Hemoglobin <11 g/dL and >8 g/dL -$                         0% 52.66$                    62% 31.75$                    38% -$                         0% -$                         0% 84.41$                                
Hypokalemia, electrolyte 
imbalance
e.g. Magnesium 0.9 to < 1.2 mEq/L or 
Potassium 2.5 to < 3.0 mEq/L -$                         0% 26.33$                    37% 15.86$                    22% -$                         0% 28.56$                    40% 70.75$                                
Thyroid dysfunction, 
hypothyroidism e.g. requiring supplementation -$                         0% 78.99$                    38% 89.16$                    43% -$                         0% 40.08$                    19% 208.23$                              
Hepatitis, l iver dysfunction e.g. elevated ALT < 5 x upper limit of normal -$                         0% 39.50$                    25% 69.10$                    45% 46.42$                    30% -$                         0% 155.01$                              
Hearing loss
Permanent, high frequency hearing loss 
(with or without tinnitus) -$                         0% 13.17$                    26% -$                         0% 37.60$                    74% -$                         0% 50.76$                                
Psychiatric disorder e.g. depression, confusion -$                         0% 26.33$                    61% 10.95$                    25% -$                         0% 5.92$                       14% 43.20$                                
Sleep disturbance, insomnia -$                         0% 26.33$                    83% -$                         0% -$                         0% 5.24$                       17% 31.57$                                
Peripheral neuropathy -$                         0% 13.17$                    46% -$                         0% -$                         0% 15.73$                    54% 28.89$                                
Visual disturbance -$                         0% 13.17$                    55% -$                         0% 10.56$                    45% -$                         0% 23.73$                                
Tinnitus without hearing loss -$                         0% 13.17$                    56% -$                         0% 10.52$                    44% -$                         0% 23.68$                                
Dizziness, vertigo -$                         0% 13.17$                    68% 3.37$                       17% -$                         0% 2.96$                       15% 19.49$                                
Hypersensitivity, allergic 
reaction Rash, dermatologic reaction (moderate) -$                         0% 13.17$                    82% -$                         0% -$                         0% 2.80$                       18% 15.97$                                
Nausea, vomiting Vomitting or nausea limiting oral intake -$                         0% 13.17$                    84% -$                         0% -$                         0% 2.56$                       16% 15.72$                                
Joint pain, arthralgia -$                         0% -$                         0% 8.03$                       72% -$                         0% 3.06$                       28% 11.09$                                
Tendonitis -$                         0% -$                         0% -$                         0% -$                         0% 3.06$                       100% 3.06$                                  
Headache -$                         0% -$                         0% -$                         0% -$                         0% 2.52$                       100% 2.52$                                  
Diarrhoea -$                         0% -$                         0% -$                         0% -$                         0% 2.51$                       100% 2.51$                                  
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Notes: hospital Notes: clinic visits Notes: laboratory tests
None standard Monthly x 4 4 x kidney function panel; 4 x urinalysis
None standard Monthly x 4 Full blood count; ferritin; PT/INR, reticulocyte count; iron; thyroid stimulating hormone
None standard Monthly x 2  Serum magnesium; serum potassium; serum calcium; and follow-up tests as per moderate (below) 
None standard Monthly x 6  4 x thryroid function panel  
None standard Monthly x 3 Liver function panel; 3 x hepatitis antigen tests; 4 x alanine aminotransferase; 4 x bil l irubin
None standard x 1 for referral None standard
None standard Monthly x 2 Thryoid stimulating hormone
None standard Monthly x 2  None standard 
None standard
x 1 to prescribe ancillary 
medications None standard
None standard x 1 for referral  None standard 
None standard x 1 for referral  None standard 
None standard
x 1 to prescribe ancillary 
medications  Hemoglobin 
None standard
x 1 to prescribe ancillary 
medications None standard
None standard
x 1 to prescribe ancillary 
medications None standard
None standard None standard  Serum magnesium; serum potassium; uric acid 
None standard None standard None standard
None standard None standard None standard
None standard None standard None standard
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Notes: procedures and investigations Notes: medications and fluids
None standard 4 x months enalapril; furosemide
None standard None standard
None standard
6 x months potassium, magnesium, and/or calcium supplement as 
applicable
None standard 14 x months thyroxine (from onset to completion of MDR/RR-TB treatment)
Abdominal ultrasound None standard
Evaluation by audiologist; 1/3 of patients ear, nose, throat specialist 
evaluation;  1/10 patients  CT brain with contrast None standard
None standard 2 x months fluoxetine
None standard 2 x months amitriptyline
None standard 6 x months amitriptyline
Referral to opthamologist None standard
Evaluation by audiologist None standard
None standard Promethazine
None standard Calamine lotion; cetirizine 
None standard Metoclopramide
None standard 4 x weeks ibuprofen; methyl salicylate ointment
None standard 4 x weeks ibuprofen; methyl salicylate ointment
None standard Paracetomol
None standard 24 hours x loperamide
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Table 11-8 Weighted average costs of SAE, 2016 USD 
  
Adverse events Description, severity
 Associated 
MDR/RR-TB drug 
 Associated XDR-TB 
drug 
 Frequency (% patients 




e.g. Stevens-Johnson Syndrome 
and Toxic epidermal necrolysis Any Any 0.5%  Schnippel et al 
Hepatitis, l iver dysfunction
e.g. ALT > 5 x the upper limit of 
normal pyrazinamide, ethionamidepyrazinamide, ethionamide 6%  Schnippel et al 
Thrombocytopenia
e.g. Platelets <50,000 
cells/mm3 linezolid
Not associated with current treatment 
regimen
Psychiatric disorder
e.g. suicidal or pyschosis (harm 
to self or others) terizidone terizidone 8%  Schnippel et al 
Renal dysfunction
Globular fi ltration rate < 30 
ml/min  kanamycin capreomycin 2%  Schnippel et al 
Seizures New onset, severe terizidone, moxifloxacinterizidone, moxifloxacin 3%  Schnippel et al 
Anemia Hemoglobin <8 g/dL linezolid 2%  Schnippel et al 
Hypokalemia, electrolyte 
imbalance
e.g. Magnesium  < 0.9 mEq/L or 
Potassium < 2.5 mEq/L kanamycin capreomycin 2%  Schnippel et al 
Nausea, vomiting
Persistent vomitting or nausea 
resulting in minimal oral intake ethionamide ethionamide, para-aminosacylic acid 7%  Schnippel et al 
Hearing loss
Permanent, profound deafness 
(with or without tinnitus) kanamycin capreomycin 40%  Harris et al 
Summary stats
Resulting SAEs / MDR/RR-TB 
patient                           0.71 
Resulting SAEs / 
XDR-TB patient                                      1.09 Average per patient
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 Frequency (% patients 
experiencing) XDR-TB  Source, notes 





 Weighted XDR-TB 
costs 
1%
 Assumption 2 x MDR/RR-TB because 
of number of drugs used 5,461.05$               27.31$                    54.61$                    
6%
 Assumption same as MDR/RR-TB as 
same drugs 2,703.45$               162.21$                  162.21$                  
12%  Sotgiu et al 1,943.75$               -$                         233.25$                  
8%
 Assumption same as MDR/RR-TB as 
same drugs 1,824.41$               145.95$                  145.95$                  
4%  Shean et al 1,807.88$               36.16$                    72.32$                    
3%
 Assumption same as MDR/RR-TB as 
same drugs 1,120.21$               33.61$                    33.61$                    
26%  Sotgiu et al 928.93$                  18.58$                    243.57$                  
2%  Shean et al 891.99$                  17.84$                    13.92$                    
7%  Shean et al 847.65$                  59.34$                    59.34$                    
40%
 Assumption similar profile to 
kanamycin 50.76$                    20.31$                    20.31$                    
 $                          1,758.01  Weighted average MDR/RR-TB  $                  521.29 
 Weighted average 
XDR-TB  $              1,039.06 
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Table 11-9 Weighted average costs of AE, 2016 USD  
   
Moderate AE
Renal dysfunction
Glomerular fi ltration rate < 60 
to 30 ml/min  kanamycin capreomycin 8%  Schnippel et al 
Anemia
Hemoglobin <11 g/dL and >8 
g/dL linezolid




e.g. Magnesium 0.9 to < 1.2 
mEq/L or Potassium 2.5 to < 3.0 
mEq/L kanamycin capreomycin 12% Brust et al, grade 3 or higher
Thyroid dysfunction, 
hypothyroidism e.g. requiring supplementation ethionamide ethionamide, para-aminosacylic acid 36% Brust et al
Hepatitis, l iver dysfunction
e.g. elevated ALT < 5 x upper 
limit of normal pyrazinamide, ethionamidepyrazinamide, ethionamide 7% Brust et al
Hearing loss
Permanent, high frequency 
hearing loss (with or without 
tinnitus) kanamycin capreomycin 18%  Harris et al 
Psychiatric disorder e.g. depression, confusion terizidone terizidone 10% Brust et al
Sleep disturbance, insomnia terizidone terizidone 10% Jacobs and Ross
Peripheral neuropathy terizidone terizidone, l inezolid 18% Kelly et al (provider reported)
Visual disturbance linezolid
Not associated with current treatment 
regimen
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Tinnitus without hearing loss kanamycin capreomycin 12% Kelly et al (provider reported)
Dizziness, vertigo kanamycin capreomycin 8% Kelly et al (provider reported)
Hypersensitivity, allergic 
reaction
Rash, dermatologic reaction 
(moderate) Any Any 16% Kelly et al (provider reported)
Nausea, vomiting
Vomitting or nausea limiting 
oral intake ethionamide ethionamide, para-aminosacylic acid 18% Kelly et al (provider reported)
Joint pain, arthralgia pyrazinamide pyrazinamide 12% Kelly et al (provider reported)
Tendonitis moxifloxacin moxifloxacin 0.5%
Assumption, not reported in cited 
studies but is l isted in guidelines
Headache terizidone terizidone 3% Kelly et al (provider reported)
Diarrhoea para-aminosacylic acid 15% Brust et al
Summary stats
Resulting AEs / MDR/RR-TB 
patient                           2.04 
Resulting AEs / 
XDR-TB patient                                      2.73 Average per patient
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3%  Shean et al 100.65$                  8.05$                       3.02$                       
12%  Sotgiu et al 84.41$                    -$                         9.94$                       
12%
 Assumption at least as high as 
MDR/RR-TB as capreomycin has 
worse profile than kanamycin 70.75$                    8.49$                       8.49$                       
36%
 Assumption at least as high as 
MDR/RR-TB 208.23$                  74.96$                    74.96$                    
7%
 Assumption same as MDR/RR-TB as 
same drugs 155.01$                  10.85$                    10.85$                    
18%
 Assumption similar profile to 
kanamycin 50.76$                    9.14$                       9.14$                       
10%
 Assumption same as MDR/RR-TB as 
same drugs 43.20$                    4.32$                       4.32$                       
10%
 Assumption same as MDR/RR-TB as 
same drugs 31.57$                    3.16$                       3.16$                       
58%  Sotgiu et al 28.89$                    5.20$                       16.76$                    
13%  Sotgiu et al 23.73$                    -$                         3.08$                       
 




 Assumption similar profile to 
kanamycin 23.68$                    2.84$                       2.84$                       
11%  Shean et al 19.49$                    1.56$                       2.14$                       
6%  Shean et al 15.97$                    2.56$                       0.96$                       
30%  Shean et al 15.72$                    2.83$                       4.72$                       
9%  Shean et al 11.09$                    1.33$                       1.00$                       
0.5%
 Assumption same as MDR/RR-TB as 
same drugs 3.06$                       0.02$                       0.02$                       
7%  Shean et al 2.52$                       0.08$                       0.18$                       
19%  Shean et al 2.51$                       0.38$                       0.48$                       
 $                                42.36  Weighted average MDR/RR-TB  $                  135.76 
 Weighted average 
XDR-TB  $                  156.05 
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Costed standard long-course regimen for South Africa MDR/RR-TB:  
6 months kanamycin, moxifloxacin, terizidone, ethionamide, and pyrazinamide and 12 months moxifloxacin, terizidone, ethionamide, and pyrazinamide.  
Costed indivdiualized regimen for South Africa XDR-TB, injection-based (pre-bedaquiline): 
6 months capreomycin, linezolid, moxifloxacin, terizidone, ethionamide, clofazimine, para-aminosacylic acid, and pyrazinamide and 18 months linezolid, moxifloxacin, 
terizidone, ethionamide, clofazimine, para-aminosacylic acid, and pyrazinamide. 
   
Associated ADR are those that were indicated (first listed or bolded as most likely drug) in:  
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis; 2014. 
Directorate Drug-Resistant TB. Management of Drug-Resistant TB: Policy Guidelines. Pretoria: National Department of Health; 2013.  
   
Frequencies of ADR during MDR/RR-TB treatment were sourced according to severity from South African studies using current regimen that reported patient counts: 
SAE (except hearing): 
Schnippel K, Berhanu RH, Black A, et al. Severe adverse events during second-line tuberculosis treatment in the context of high HIV 
Co-infection in South Africa: a retrospective cohort study. BMC Infect Dis 2016; 16: 593. 
Hearing: 
Harris T, Bardien S, Schaaf HS, et al. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuber-
culosis patients. South African Med J 2012; 102: 363–6. 
AE (if reported): 
Brust JCM, Shah NS, van der Merwe TL, et al. Adverse events in an integrated home-based treatment program for MDR-TB and HIV 
in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 2013; 62: 436–40. 
 
Kelly AM, Smith B, Luo Z, et al. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment. Iterna-
tional J Tuberc Lung Dis 2016; 20: 442–7. 
 
Jacobs TQ, Ross  A. Adverse effects profile of multidrug-resistant tuberculosis treatment in a South African outpatient clinic. South 
African Fam Pract 2012; 54: 531–9. 
Frequencies of ADR during XDR-TB treatment:  
AE associated with capreomycin 
or PAS: 
Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving 
treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One 2013; 8: e63057. 
AE associated with linezolid: 
Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-
TB: Systematic review and meta-analysis. Eur Respir J 2012; 40: 1430–42. 
 
